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ABSTRACT 
 
 
Recombinant antibody formats and therapeutic proteins have found increasing applications 
as therapeutics, e.g. for the treatment of cancer or inflammatory diseases. While whole 
antibodies have an exceptionally long half-life, small antibody formats and small molecular 
weight therapeutic proteins often suffer from rapid elimination from circulation.  Usually, this 
involves frequent administration and repeated infusions with the drug application intravenous 
or subcutaneously, using a slow adsorption into the blood stream. These limitations of small 
size protein drugs have led to the development and implementation of several half-life 
extension strategies to prolong circulation of these molecules and thus improve their 
administration, pharmacokinetic and pharmacodynamic properties. Over the recent years, 
plasma protein binding has been shown to be an effective approach to improve 
pharmacokinetic properties of short half-life molecules. Within this context, in order to 
improve the half-life of therapeutic proteins we have investigated new strategies based on 
protein fusions with two albumin-binding domains (ABDs) from streptococcal cell surface 
proteins. These two ABDs were the Zag and protein H (ProtH) derived from Streptococcus 
zooepidemicus and Streptococcus pyogenes, respectively. To validate our ABDs half-life 
strategy and as a proof-of-concept, the Zag and ProtH domains were fused with an anti-TNFα 
VHH single-domain antibody. Our results showed that Zag and ProtH ABDs alone and fused 
to the anti-TNFα VHH could be stably produced in vitro, present nanomolar binding to 
human, rat and mouse albumins, quantified by ELISA, and for VHH-Zag, using surface 
plasmon resonance (SPR). VHH, VHH-Zag and VHH-ProtH proteins presented high thermal 
properties, and human and mouse serum stabilities as well. Moreover, the fusion of the ABDs 
with the anti-TNFα VHH did not affect the efficacy of the therapeutic molecule against 
TNFα. Furthermore and importantly, fusion with Zag and ProtH domains strongly increases 
the half-life and stability of the anti-TNFα VHH. Comparing with the VHH (terminal half-life 
of 47 min), VHH-Zag (terminal half-life of ~31 h) and VHH-ProtH (terminal half-life of ~21 
h) presented prolonged circulation times of 39-fold and 26-fold, respectively. Therefore, after 
injection, the residence in mouse serum presented higher time extensions until 72 h for VHH-
Zag and 48 h for VHH-ProtH (versus 2 h exhibited by VHH). The biodistribution profile of 
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VHH-Zag was determined with technetium 99 m (99mTc) and gallium 67 (67Ga)-
radiolabelling. The prolonged circulation time with both radionuclides lead to a reduction of 
the 99mTc-VHH-Zag in kidneys and an increase of the presence of the fusion anti-TNFα VHH 
in blood and other organs, e.g. liver, intestine, muscle and lungs. The biodistribution profile of 
VHH-ProtH was evaluated with 99mTc, presenting a similar organ distribution that the 
observed for the nanobody alone. Accordingly, 99mTc-VHH-ProtH is retained in kidneys and 
showed a trend to accumulate within highly perfused organs like and intestine. 
Though, Zag and ProtH unmodified ABDs preserved the albumin-binding ability and 
thermal stability of the fusions with the recombinant antibody, these domains present very 
different amino acid sequences and unit organization. Whereas, Zag ABD presents one 
domain with 52 aa, ProtH ABD possess three C repeats (C1C2C3) that were tested in ELISA 
assays to evaluate the binding of each unit alone (C1, C2 and C3) or several combinations of 
these repeats (C1C2, C2C3 and C1C2C3), to human serum albumin. The results obtained 
showed that C1 repeat is a key unit for the albumin-binding, presenting the highest HSA 
binding with similar values that those observed with the three repeats. The predicted in silico 
of the three-dimensional structure of ProtH showed an α-helical conformation. Nuclear 
magnetic resonance (NMR) assignments show that Zag domain presents a three-α-helix three-
dimensional structure. Circular dichroism (CD) measurements confirmed the α-helical 
conformation of these motifs and also indicate that the conformation of both ABDs is 
maintained in the presence of HSA. 
In summary, the results presented on this Thesis strongly demonstrate that Zag and ProtH 
ABDs are promising strategies to increase the half-life of therapeutic proteins. Both ABDs 
will be certainly an alternative to the recent most used PEGylation or N-glycosilation 
approaches to improve therapeutic applications of recombinant proteins. Furthermore, Zag 
and ProtH can be engineered and be used on therapeutic applications as protein scaffolds. 
 
Keywords: Albumin-binding domain (ABD), biodistribution, half-life, pharmacokinetics, 
streptococcal protein H, streptococcal protein ZAG, therapeutic proteins. 
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RESUMO 
 
 
Nos últimos anos, os formatos de anticorpos recombinantes e as proteínas terapêuticas têm 
sido desenvolvidos e utilizados para diversas aplicações terapêuticas, como por exemplo, para 
o tratamento de cancro e doenças inflamatórias, entre outras. Enquanto que os anticorpos no 
seu formato natural, ou imunoglobulinas, possuem um tempo de semi-vida excepcionalmente 
longo, os pequenos derivados de anticorpos e as proteínas terapêuticas são, geralmente, 
rapidamente eliminadas da circulação sanguínea. Para aplicações terapêuticas esta 
característica faz com que, frequentemente,  seja necessário recorrer-se a uma administração 
frequente e a infusões repetidas com uma aplicação intravenosa ou subcutânea, utilizando 
uma adsorção lenta destes medicamentos biológicos na corrente sanguínea. Estas limitações, 
inúmeras vezes relacionadas com o reduzido tamanho destas moléculas, têm resultado no 
desenvolvimento e implementação de diversas estratégias de extenção do tempo de semi-vida, 
para prolongar a sua presença na circulação sanguínea. Desta forma, é possível melhorar o seu 
modo de administração e as suas propriedades farmacocinéticas e farmacodinâmicas, sem 
afectar a sua eficácia terapêutica. 
 Actualmente, algumas das estratégias mais utilizadas pela indústria farmacêutica para 
aumentar o tempo de circulação deste tipo de moléculas terapêuticas, como a PEGilação e a 
glicosilação, apresentam várias desvantagens. Entre as mesmas encontram-se os elevados 
custos na produção, o facto de o processo de conjugação nem sempre produzir moléculas com 
iguais propriedades terapêuticas e de não serem métodos que permitam uma reprodutividade 
das características da molécula terapêutica, na sua produção. Para evitar estes problemas, 
existe uma necessidade de desenvolvimento de metodologias alternativas para o mesmo fim.  
Deste modo, neste projecto científico desenvolvemos novas estratégias para melhorar o 
tempo de semi-vida de proteínas terapêuticas, utilizando dois domínios de ligação à albumina, 
provenientes de proteínas da superfície celular de estreptococos (proteína ZAG e a proteína 
H). A proteína ZAG é uma proteína da superfície membranar de Streptococcus 
zooepidemicus, que apresenta um domínío de ligação à albumina (Zag) constituído por 52 
aminoácidos. Esta proteína também possuí uma região de ligação às imunoglobulinas. Assim 
como a proteína ZAG, a proteína H, proveniente da superfície celular de Streptococcos 
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pyogenes, também apresenta um domínio de ligação à albumina (ProtH), constituído por três 
unidades denominadas repetições C (C1C2C3) e uma região de ligação às imunoglobulinas. 
Pensa-se que estas proteínas possam ser factores de virulência bacterianos e que possam 
funcionar como mecanismo de escape das bactérias à vigilância do sistema imunitário, 
camuflando estes microorganismos com proteínas plasmáticas do hospedeiro. 
Uma vez que a albumina é das proteínas plasmáticas mais abundantes e apresenta um 
tempo de semi-vida muito elevado (~19 dias em humanos), o objectivo deste trabalho 
científico foi utilizar a capacidade natural de ligação à albumina destes domínios para, em 
fusão com um proteína terapêutica, melhorar o desempenho farmacocinético destas 
moléculas, aumentando assim o seu tempo de semi-vida em circulação. Deste modo, os 
domínios de ligação à albumina (ABDs, do inglês albumin-binding domains) Zag e ProtH 
foram testados utilizando, como prova-do-conceito, um anticorpo recombinante (VHH, 
designado também por nanobody) desenvolvido pela empresa de biotecnologia belga Ablynx 
contra o TNFα (factor de necrose tumoral alfa), para o tratamento da artrite reumatóide. Este 
nanobody foi desenvolvido para bloquear a interacção entre o TNFα e o seu receptor, 
prevenindo assim o desencadeamento da resposta inflamatória responsável pela formação das 
junções artritícas, nos doentes com artrite reumatóide. Este tipo de moléculas têm sido sido 
extensivamente estudadas ao longo dos últimos anos para o tratamento da artrite reumatóide e 
encontram-se em ensaios clínicos de fase II, com o nome de ATN-103 (actualmente 
Ozoralizumab). 
Os resultados obtidos mostraram que ambos os ABDs sozinhos ou em fusão com o VHH 
podem ser estavelmente produzidos em bactérias, preservando as suas propriedades naturais 
de ligação à albumina, com uma ligação às albuminas humana, de rato e de ratinho na ordem 
do nanomolar e apresentando também elevadas estabilidades térmica e no soro humano e de 
ratinho. Adicionalmente, a fusão destes domínios com o VHH não afectou a ligação ao TNFα 
nem a eficácia terapêutica do nanobody. A fusão dos domínios Zag e ProtH com a molécula 
terapêutica aumentaram eficazmente o tempo de semi-vida da mesma. Comparando com o 
anticorpo recombinante não-modificado (tempo de semi-vida terminal de 47 min), o VHH-
Zag (tempo de semi-vida terminal de ~31 h) e o VHH-ProtH (tempo de semi-vida terminal de 
~21 h) apresentaram aumentos de 39 e de 26 vezes, respectivamente, no tempo de circulação 
plasmática em murganhos. Após injecção, observou-se a presença no sangue de ratinho até às 
72 h para o VHH-Zag e até às 48 h para o VHH-ProtH, comparando com o curto tempo 
apresentado para o VHH de apenas 2 h.  
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 O perfil de biodistribuição do VHH-Zag foi avaliado utilizando a marcação com os 
radioisótopos tecnécio 99 m (99mTc) e gálio 67 (67Ga). Nos estudos feitos com os dois 
radioisótopos, verificou-se que a extensão do tempo de circulação do VHH-Zag também 
influenciou o perfil de biodistribuição, conduzindo a uma redução da presença do anticorpo 
nos rins e um aumento da quantidade de proteína no sangue e nos orgãos mais irrigados, 
como o fígado, intestino, músculos e pulmões. O perfil de biodistribuição do VHH-ProtH foi 
determinado, usando apenas a marcação com o radioisótopo 99mTc. Deste modo, o 99mTc-
VHH-ProtH mostrou um perfil de biodistribuição diferente do 99mTc-VHH-Zag, mas 
semelhante ao do 99mTc-VHH, ou seja,  com uma retenção mais acentuada nos rins e uma 
menor presença no sangue. O 99mTc-VHH-ProtH também mostrou uma tendência para se 
acumular em orgão altamente perfundidos, como o intestino. Contudo, embora o 99mTc-VHH-
Zag e o 99mTc-VHH-ProtH apresentem um perfil de biodistribuição diferente, ambos 
revelaram um elevado tempo de semi-vida, comparando com o nanobody não-modificado. 
Deste modo, o nosso objectivo de desenvolver estes domínios como estratégias para 
aumentar o tempo de semi-vida de proteínas foi alcançado. Após se determinar que os ABDs 
Zag e ProtH em fusão com o anticorpo mantinham a sua capacidade de ligação à albumina, 
fomos investigar se estes domínios não-modificados mantinham as mesmas propriedades. 
Para atingir este objectivo, as proteínas Zag e ProtH foram clonadas num vector de expressão 
bacteriano, expressas em E. coli e, posteriormente purificadas. Seguidamente, verificamos que 
os domínios de ligação à albumina Zag e ProtH não-modificados preservam as propriedades 
de ligação às albuminas humana, de rato e de ratinho observadas anteriormente, assim como 
também mantêm a estabilidade térmica observada quando se encontram em fusão com o 
VHH.  
Estas proteínas possuem uma sequência de aminoácidos e organização de domínios muito 
diferentes. Enquanto que o domínio Zag é composto por uma única unidade de 52 
aminoácidos, o domínio ProtH é constituído por três unidades, denominadas de sequências 
repetidas C ou repetições C (C1C2C3). Estas unidades apresentam, entre si uma elevada 
homologia entre as suas sequências aminoacídicas. Para avaliar a ligação que cada uma destas 
unidades à albumina, várias combinações destes domínios (C1, C2, C3, C1C2, C2C3, 
C1C2C3) foram expressas em bactéria e purificadas. De todas as combinações, a unidade C1 
tem uma elevada ligação à albumina humana semelhante à ligação observada com os três 
domínios juntos, mostrando assim que esta unidade apresenta um papel muito importante para 
a ligação à albumina de todo o domínio. De todas as repetições C, a C1 também é a que 
apresenta uma maior estabilidade térmica. A previsão in silico da estrutura tridimensional do 
xii 
 
ABD ProtH revelou uma possível conformação de alfa-hélix. Os resultados de resonância 
magnética nuclear (RMN) mostraram que o ABD Zag possui uma estrutura tridimensional de 
tri-α-hélix. Os dados de dicroismo circular confirmam os resultados referidos anteriormente e 
indicam que, em ambos os domínios, a ligação à albumina não altera a conformação de 
nenhuma destas proteínas, mantendo a sua conformação helical.  
Como perspectivas futuras, seria interessante determinar a estrutura tridimensional do 
domínio ProtH e investigar por RMN ou cristalografia de raio-X as interacções entre a 
albumina e estas proteínas. Assim será possível determinar o local de ligação à albumina de 
cada um destes domínios.  
Em conclusão, estes resultados demonstram que os domínios de ligação à albumina Zag e 
ProtH podem ser utilizados como estratégias promissoras, para o aumento do tempo de semi-
vida de proteínas terapêuticas, como alteranativa às metodologias mais utilizadas actualmente 
pela indústria farmacêutica. Outra potencial aplicação para estas proteínas será a seu 
desenvolvimento como scaffolds terapêuticos para o tratamento de inúmeras doenças, como 
por exemplo, a artrite reumatóide.  
 
 
Palavras-chave: Biodistribuição, domínio de ligação à albumina (ABD), farmacocinética, 
proteína H de estreptococos, proteínas terapêuticas, proteína ZAG de estreptococos, tempo de 
semi-vida. 
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I - Therapeutic Proteins 
At the end of 2011, approximately 200 biologics were approved for therapeutic 
applications and more than 600 are in different stages of clinical development as drug 
molecules (Walsh, 2010; Kontermann, 2011). 
Besides monoclonal antibodies (mAbs) and vaccines, which account for more than two-
thirds of these products, hormones, growth factors, cytokines, fusion proteins, coagulation 
factors, enzymes and other proteins are enumerated. With the exception of antibodies and Fc 
fusion proteins, many of these proteins possess a molecular mass below 50 kDa and for that 
reason, are rapidly cleared from circulation, presenting short terminal half-lives in the range 
of minutes to a few hours (Fig. 1). In order to maintain a therapeutically effective 
concentration over a prolonged period of time, infusions or frequent administrations are 
performed, or the drug is applied loco-regional or subcutaneously, using a slow adsorption 
into the blood stream. Half-life extension strategies have therefore become increasingly 
important to improve the pharmacokinetic (PK) and pharmacodynamic (PD) properties of 
therapeutic proteins, but also for reasons of compliance (Kontermann, 2012). 
Several half-life extension strategies are already used in approved drugs, including 
PEGylation, hyperglycosylation, binding to human serum albumin and fusion to an 
immunoglobulin G (IgG) 
Fc region. However, there 
is a strong need for new 
strategies, not only to 
further improve the 
pharmacokinetic properties 
of these molecules, but 
also to facilitate production 
and application of these 
half-life extended drugs. 
These strategies include 
those that increase the hydrodynamic radius of the drug, thus aiming at reducing the renal 
clearance and also strategies that implement recycling by neonatal Fc receptor (FcRn), which 
is responsible for the extraordinary long half-life of IgG molecules and serum albumin. In the 
past 5 to 10 years, half-life extension strategies experienced a rapid growth in the 
establishment of novel approaches, including the application of novel hydrophilic polymers, 
Fig. 1 - The molecular mass and half-life of plasma proteins. Proteins 
are allocated according to their function (Kontermann, 2012).     
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the generation of recombinant PEG mimic polypeptide chains and the development of several 
albumin-binding molecules. Furthermore, the half-life of IgG molecules was altered by 
engineering of the Fc region, which opens new opportunities for the development of next-
generation antibody and protein drugs (Kontermann, 2012). 
 
I.1 - Engineered antibody fragments and therapeutic proteins 
As one of the most important defences against disease, antibodies are produced by the 
immune system in response to substances (antigens) that appear to be foreign to the human 
body. In vertebrates, there are five different classes of antibodies known as IgD, IgA, IgM, 
IgE and IgG, which differ in their function from the immune system. IgGs are the most 
abundant immunoglobulins in the blood and the dominant format of therapeutic antibodies 
(Aires da Silva et al., 2008). These typical antibodies are usually ‘Y’ shaped molecules and 
are bivalent molecules composed of two identical heavy (H) and two light (L) chains with a 
molecular mass of approximately 150 kDa (Fig. 2). Monovalent derivates thereof include Fab 
fragments, which are linked via a flexible region (hinge) to a constant fragment (Fc) region, 
single-chain Fv (scFv) and single variable domains from human IgGs (domain antibodies, 
dAbs) or camelid (VHH) and shark (VNARs) single-domain antibodies (sdAbs) (Holliger and  
Hudson, 2005). These antibody formats are small in size (11-50kDa) and do not possess an Fc 
region, thus they are not capable of exerting Fc-mediated effector functions. The small size 
and less complex structure of these molecules compared with IgG facilitate production, e.g. in 
bacterial expression systems (Kontermann, 2009). In addition, small bivalent derivates (e.g. 
diabodies) have been generated with the lack of constant domains. Bivalent diabodies are 
composed of the VL and VH domain connected by a short linker of approximately 5 amino 
acid residues, leading to the formation of a homodimeric protein. Recombinant antibody 
fragments also include several bispecific formats, e.g. minibodies, Fab2, as well as multimeric 
formats (Fig. 2) (Holliger and Hudson, 2005). 
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In comparison with whole antibodies, small antibody fragments such as Fab or scFv 
exhibit better pharmacokinetics for tissue penetration and also provide full binding specificity 
because the antigen-binding surface is unaltered. Indeed, the first clinical trials of scFv 
fragments are likely to be as multivalent reagents, because they exhibit high functional 
affinity and have been very successful in preclinical studies (Holliger and Hudson, 2005; 
Hudson and Souriau, 2003). Small size antibody fragments are monovalent and often present 
fast off-rates and poor retention time on the target (Hudson and Souriau, 2003). Therefore, 
Fab and scFv fragments have been engineered into multimeric conjugates to increase 
functional affinity through the use of either chemical or genetic cross-links. Various methods 
have been devised to genetically encode multimeric scFvs, of which the most successful 
design was the simple reduction of scFv linker length to direct the formation of bivalent 
dimers (diabodies), triabodies or tetrabodies (Holliger and Hudson, 2005). In general, several 
multivalent antibody conjugates are generated to be monospecific. However, some strategies 
have also been applied to produce bispecific multimers. These bispecific antibodies have two 
different binding specificities fused together in a single molecule. Because of dual specificity, 
they can bind to two adjacent epitopes on a single antigen, thereby improving avidity. 
Antibody engineering has also been applied to the development of bifunctional antibodies. In 
contrast to bispecific antibody derivates, bifunctional molecules combine the antigen-binding 
site of an antibody with a biological function encoded by a linked or fused partner (Hudson 
and Souriau, 2003). These include radionuclides, cytokines, toxins, enzymes, peptides and 
proteins. Recently, ibritumomab or Zevalin® (Biogen Idec) (Vose et al., 2007), tositumomab 
or Bexxar® (GlaxoSmithKline) (Macklis, 2006), both applied to the treatment of Non-
   Fig. 2 - Schematic representation of different antibody formats. A variety of antibody fragments are 
depicted, including Fab, scFv, single-domain VH, VHH and VNAR and multimeric formats, such as 
minibodies, bis-scFv, diabodies, triabodies, tetrabodies and chemically conjugated Fab multimers (sizes 
given in kDa are approximate) (Holliger and Hudson, 2005).   
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Hodgkin lymphoma, and gemtuzumab or Mylotarg® (Wyeth) (Larson et al., 2002) with 
therapeutic use against acute myeloid leukemia, are three examples of FDA-approved 
bifunctional antibodies designed to specifically deliver cytotoxic drugs into cancer cells. 
To escape immunosurveillance, many pathogenic viruses have evolved narrow cavities 
(canyons) in their surface antigens, which bind their target receptors but are poorly accessible 
to intact antibodies and are thus largely immunosilent. This antibody response is caused by 
the limited diversity of complementarity-determining region (CDR) loop lengths, which 
constrains the displayed antigen-binding surfaces to mostly flat or concave topologies (Arndt 
et al., 2004). Interestingly, the camelids (camels and llamas) and cartilaginous fish 
(wobbegong and nurse sharks), have evolved high-affinity single V-domains mounted on an 
Fc-equivalent constant domain framework as an integral and crucial component of their 
immune system (Klooster et al., 2007; Stretsov and Nuttal, 2005). In addition to these 
conventional antibodies, camelids and sharks also produce unusual antibodies composed only 
of heavy chains. These peculiar heavy 
chain antibodies (hcAbs) lack light 
chains (and, in the case of camelid 
antibodies, also the CH1-domain). 
Therefore, the antigen binding site of 
hcAbs is formed only by a single 
domain that is linked directly via a 
hinge region to the Fc-domain. The 
variable domain is designed VHH for 
camelid and VNAR for shark single-
domain antibodies (Fig. 3). The CDR3 
region of these antibodies possesses the 
extraordinary capacity to form long 
finger-like extensions that can extend 
into cavities on antigen, e.g. the active 
site crevice of enzymes. The CDR3 can 
form convex extensions that occupy the 
cleft for the substrate and is often much 
longer than that of conventional VH 
domains. The extended CDR3 is usually 
stabilized by an additional disulfide bond connecting the CDR3 to the adjacent CDR1 loop 
Fig. 3 - Schematic diagram of the VHH domain of a 
camelid heavy chain antibody. a The three CDRs of the 
antigen-binding paratope are depicted as colored loops: 
CDR1 red, CDR2 green, and CDR3 blue. b The canonical 
disulphide bond connecting framework regions 1 and 3 
(FR1 and FR3) in the two β-sheets of the immunoglobulin 
domain is indicated in yellow. Many camelid antibodies 
contain an additional disulfide bond (S–S) connecting the 
CDR3 with the end of the CDR1 (camels) or the beginning 
of the CDR2 (llamas). h Hinge, M transmembrane domain 
of membrane isoform, G glycosylation site, S stop codon 
of secretory isoform  (Wesolowski et al., 2009).  
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(common in camel and shark sdAbs) or to the CDR2 loop (common in llama sdAbs). The 
interface of conventional VH and VL domains is stabilized by hydrophobic interactions, the 
corresponding residues in llama antibodies are replaced by hydrophilic residues. In shark 
sdAbs, the CDR2 loop is replaced by two shorter less variable loops (Wesolowski et al., 
2009). 
In general, camelid VHH and shark VNAR domains are soluble and can be produced as 
stable in vitro targeting reagents for sensitive diagnostic platforms and nanosensors. 
Compared to monoclonal antibodies, VHH domains have also demonstrated improved 
penetration against cryptic (immuno-evasive) target antigens (Holliger and Hudson, 2005). 
However, for in vivo administration, humanization (or deimmunization) may be crucial to 
reduce immunogenicity, although llama VHH domains have been claimed to be only 
minimally immunogenic (Cortez-Retamozo et al., 2004). As it is frequently observed with 
display technologies, favourable properties (such as good expression, stability and solubility) 
are co-selected with binding activity of VHH molecules (Holliger and Hudson, 2005). 
 
I.2 - Scaffolds 
Antibody size dependence of epitope accessibility can be highly non-linear and some 
protein surface-exposed structures can be completely obstructed for full size antibodies (Chen 
et al., 2010; Chen et al., 2009).  Therefore, a large amount of work has been aimed at 
developing novel scaffolds of much smaller size. The term “scaffold” reflects the use of a 
protein framework that can carry altered amino acids or insertions giving protein variants with 
entirely novel functions, typically new binding specificities. Such scaffolds are stable, soluble 
and easy to format, manufacture and express in microbial cell cultures. High stability 
independent of disulfide bonds is a clear advantage, facilitating high yields in bacterial 
expression and enabling intracellular applications. There are presently approximately 50 
suggested protein scaffolds reported and these have intensely reviewed over the last years 
(Dimitrov, 2009; Dimitrov and Marks, 2009; Chen et al., 2008; Honegger, 2008; Kolmar and 
Skerra, 2008; Saerens et al., 2008; Skerra, 2007). Examples of several non-immunoglobulin 
scaffolds are illustrated in Fig. 4 and Table 1. 
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Table 1: Non-immunoglobulin scaffolds for generation of new affinity ligands (adapted from 
Grönwall and Ståhl, 2009). 
 
Affibodies are small antibody mimetics (~6 kDa), robust 3-helix proteins, designed based 
on the Z domain of staphylococcal protein A that were developed for targeted therapy of 
several diseases, e.g. cancer and inflammatory diseases (Jonsson et al., 2009; Tolmachev et 
al., 2007). Affibody® molecules can also be used for protein purification (Nord et al., 2001), 
enzyme inhibition (“Phusion Hot Start High-Fidelity DNA Polymerase", Finnzymes),  
research reagents for protein capture and detection (Lundberg et al., 2007; Renberg et al., 
2007) and diagnostic imaging (Orlova et al., 2006).  
An ABD-fused tumor-targeting construct was derived from a HER2-specific Affibody 
molecule, which belongs to a class of small protein A-derived antibody mimetics, originally 
developed for imaging purposes. The original affibody presented a rapid kinetics ideal for 
imaging, but the uptake in kidneys was very high, which was incompatible with radionuclide 
therapy that would be a logical extension of the successful tumour targeting obtained. 
Therefore, Nilsson and co-workers decided to convert the imaging tracer to a candidate for 
targeted radiotherapy by fusion to ABD (Tolmachev et al., 2007). The albumin association 
did not compromise the tumour targeting properties. Compared with the non-fused Affibody 
molecule, kidney uptake was decreased 25-fold and the tumour uptake increased three to five- 
fold. This combined with retained high specificity for the tumour, allowed for successful 
radioimmunotherapy using the beta-emitting nuclide 177Lu. Treatment of mice bearing HER2-
overexpressing microxenografts completely prevented tumour formation, in contrast to 
radioactivity coupled to an ABD-fused construct against an irrelevant antigen (Tolmachev et 
al., 2007). The HER2-specific Affibody ABY-025 is in clinical development for tumour 
diagnosis (Gebauer and Skerra, 2009; Baum et al., 2010). 
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I.3 - Pharmacokinetics of therapeutic proteins 
The basic paradigm of clinical pharmacology is the fact that drug effects, desired as well as 
undesired, are function of drug concentrations within different organs and tissues in the 
human body. Thus, drug concentrations are the driving force for the spectrum of drug 
responses observed in a drug-treated patient (Meibohm, 2012). Pharmacokinetics is the study 
and characterization of the time course of drug adsorption, distribution, metabolism and 
excretion (ADME), and provides a quantitative analysis of how living systems handle 
xenobiotics and biodrugs (Mahmood, 2009).  The pharmacokinetic properties, especially their 
distribution, metabolism and excretion, are influenced by several factors including size, shape, 
charge, hydrophilicity, interaction with other molecules and cells, and sensitivity to 
proteolytic degradation (Tang et al., 2004). Similar to conventional small molecule drugs, 
protein therapeutics is characterized by well-defined properties that form the basis for the 
design of therapeutic dosing regimens as well as drug delivery strategies. The distribution 
volume of proteins is determined largely by their molecular weight, physicochemical 
properties (e.g., charge, lipophilicity), protein binding, and their dependency on active 
Fig. 4 - Representative illustrations of a selection of scaffold proteins applied for generation of novel 
affinity proteins. (A) Adnectin, derived from 10th fibronectin type III domain (PDB ID: 1TTG). (B) 
Affibody, derived from Z-domain of protein A (PDB ID: 1Q2N). (C) Anticalin, derived from the bilin-
binding protein, here a digoxigenin binding anticalin is illustrated (PDB ID: 1LKE). (D) Avimer, designed 
from a consensus human A-domain here an A-domain is represented by the LDL receptor ligand-binding 
module 5 stabilized by a Ca2+ ion (PDB ID: 1AJJ). (E) Darpin, designed from a consensus ankyrin repeat 
domain, here a HER2-binding darpin with two repeat modules is illustrated (PDB ID: 2JAB). (F) Kunitz 
domain, derived from the protease inhibitor domain of the amyloid beta protein precursor (PDB ID: 1AJJ). 
Images were generated using PyMOL software (Grönwall and Ståhl, 2009).  
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transport processes (Meibohm, 2012). Since most therapeutic proteins have high molecular 
weight and are thus large in size, their apparent volume of distribution is usually small and 
limited the volume of the plasma or the extracellular space, predominantly because of their 
limited mobility secondary to impaired passage through biomembranes (Zito, 1997). In 
contrast, to small molecular drugs, protein transport from vascular space into the interstitial 
space of tissues is largely mediated by convection rather than diffusion, following the 
unidirectional fluid flux from the vascular space through paracellular pores into the interstitial 
tissue space. The subsequent removal from the tissues is accomplished by lymph drainage 
back into the systemic circulation (Flessner et al., 1997). Another, but much less prominent 
pathway for the movement of protein molecules from the vascular to the interstitial space is 
transcellular migration via endocytosis (Reddy et al., 2006).  
Engineering antibodies or proteins for therapy must generally exhibit high affinity, 
discriminating specificity, minimal immunogenicity and low cross-reactivity. Normally, these 
factors can be addressed by making relatively small changes to the primary protein structure 
of the molecule. In addition to this, a major consideration in protein engineering is developing 
one that exhibits optimal pharmacokinetics: appropriate dosing leading to optimal 
bioavailability, uptake, distribution and clearance in targeted and non-targeted tissues, which 
will lead to optimal pharmacodynamics (Constantinou et al., 2010; Beckman et al., 2007; 
Batra et al., 2002). Therapeutic administration requires a balance between prolonged retention 
at the target site and slow clearance, which can lead to liver accumulation and high radiation 
exposure of other tissues (Holliger and Hudson, 2005).  
Systematic in vivo studies have provided striking confirmation that size is an important 
parameter in pharmacokinetics and biodistribution of therapeutic proteins. Large IgG 
molecules specific for tumour surface molecules have been found to penetrate solid tumours 
only slowly, are non-uniform in their final distribution and have high serum levels and 
associated toxicities. Conversely, small scFv fragments (30 kDa) are cleared extremely 
rapidly and have poor tumour retention because of their monovalent binding properties. Some 
biodistribution studies (Kenanova et al., 2005; Robinson et al., 2005) have independently 
confirmed that diabodies, because of their small size, are rapidly eliminated through the 
kidneys, thereby limiting the exposure to the bone marrow, which is most often the dose-
limiting organ with intact radiolabeled mAbs.  
However, small size antibodies have to be administered by infusion or repeated 
intravenous bolus injections in order to maintain a therapeutically effective dose over a 
prolonged period of time, or are restricted to loco-regional treatment. Their rapid elimination 
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is mainly due to renal filtration and degradation, because the kidney generally filters out 
molecules below 50-60 kDa (Tang et al., 2004).  This has led to the development of half-life 
extension strategies to prolong circulation of these recombinant antibodies in the blood and 
thus improve administration and pharmacodynamic properties. With an increasing number of 
small antibody molecules and antibody mimetics developed for clinical applications, 
strategies to improve pharmacokinetics, especially half-life extension, have become 
increasingly important, not only with respect to therapeutic efficacy but also regarding the 
costs of therapy as well as convenience for patients, and compliance (Mahmood and Green, 
2005; van de Weert et al., 2005; Tang et al., 2004). 
 
II – Renal clearance and FcRn-mediated recycling 
As mentioned in the previous section, due to their small size, some protein therapeutics 
have to be administered as infusion or repeated intravenous (i.v.) or subcutaneous (s.c.) bolus 
injections in order to maintain a therapeutically effective dose over a long period of time, or 
are restricted to loco-regional treatment. A comparison of the half-lives of plasma proteins 
reveals the threshold for rapid excretion to be in the range of approximately 40-50 kDa, 
demonstrating that the size of the molecules is one of the determining factors (Fig. 1). The 
glomerular filtration barrier is formed by the fenestrated endothelium, the glomerular 
basement membrane (GBM) and the slit diaphragm located between the podocyte foot 
processes (Tryggvason and Wartiovaara, 2005). The fenestrae between the glomerular 
endothelial cells presents diameters between 50-100 nm, consequently, allowing free 
diffusion of molecules. It was suggested that the slit diaphragm represents the ultimate 
macromolecular barrier, forming an isoporous, zipper-like filter structure with numerous 
small, 4-5 nm diameter pores and a lower number of 8-10 nm diameter pores (Haraldsoon and 
Sörensson, 2004; Wartiovaara et al., 2004; Rodewald and Karnovsky, 1974). In addition to 
size, the charge of a protein contributes to renal filtration. It has been suggested that the 
proteoglycans of the endothelial cells and the GBM contribute to an anionic barrier, which 
partially prevents the passage of plasma macromolecules (Tryggvason and Wartiovaara, 
2005). Therefore, the size of a therapeutic protein, that is, its hydrodynamic radius, and also 
its physicochemical properties, that is, charge, represent starting points in order to improve 
half-life. Interestingly, of all the plasma proteins, two kinds of molecules, serum albumin and 
IgGs, exhibit an extraordinary long half-life in humans. Thus, human serum albumin (HSA) 
has a half-life of 19 days and immunoglobulins (IgG1, IgG2 and IgG4) have half-lives in the 
 12 
 
range of 3 to 4 weeks, exceeding those of the other plasma proteins (Lobo et al., 2004; Peters, 
1996). In humans, IgG molecules present half-lives in the range of 1 to 4 weeks depending on 
the subclass (IgG1, IgG2, IgG4 = 12–21 days, IgG3 = 7–8 days) and possibly also the 
allotype (Kontermann, 2009). The half-lives of the other Ig classes are shorter (IgM = 5–6 
days, IgA = 6 days, IgD = 3 days, IgE = 2 days). The half-lives of therapeutic IgGs can differ 
dramatically and differences can also be seen between different forms of antibodies. The 
approved fully human, humanized, and chimeric antibodies possess half-lives in the range of 
1–3 weeks. In contrast, murine IgGs are much more rapidly cleared from the circulation, with 
half-lives of approximately 2–3 days (Lobo et al., 2004; Ternant and Paintaud, 2005). These 
long half-lives, which clearly set albumin and IgG apart from the other plasma proteins (Fig. 
1) are caused by a recycling process mediated by the neonatal Fc receptor (Roopenian and 
Akilesh, 2007; Anderson et al., 2006; 
Lencer and Blumberg, 2005). FcRn, 
expressed, for example, by endothelial 
cells, is capable of binding albumin and 
IgGs in a pH-dependent manner. The 
kinetics of IgG and albumin recycling is 
illustrated in Fig. 5. Thus, after cellular 
uptake of plasma proteins through 
macropinocytosis, albumin and IgG will 
bind to FcRn in the acidic environment of 
the endosomes. This binding diverges from 
albumin and IgG from degradation in the 
lysosomal compartment and redirects them 
to the plasma membrane, where they are 
released back into the blood plasma 
because of the neutral pH (Section III.2). 
This offers additional opportunities to 
extend or modulate the half-life proteins, 
for example, through fusion to albumin or 
to Fc region of IgG (Kontermann, 2009).  
 
 
Fig. 5 - Effect of FcRn-mediated recycling on IgG 
and albumin turnover in humans expressed as 
fractional rates. Shown are homeostatic plasma 
concentrations (12.1 and 38.2 mg mL−1), fractional 
catabolic rates (7.4 and 10.9%/day), the FcRn-mediated 
fractional recycling rates (10.6 and 4.8%/day), and the 
fractional production rates (7.4 and 10.9%/day). The 
figure is to scale: areas for plasma amount and arrow 
widths for rates (Meibohm, 2012).  
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III – Half-life extension strategies 
With an increasing number of therapeutic proteins approved and developed, including 
various alternative antibody formats, many of them presenting a short plasma half-life, serum 
half-life extension of small therapeutic proteins has become an established method to increase 
potency and improve patient compliance by allowing for fewer administrations (Frejd, 2012).  
There is no strict correlation between molecular mass and half-life though, factors other than 
size also influences half-life. Studies of the half-lives of various recombinant antibody 
fragments in animals also revealed rapid elimination from the circulation (Holliger and 
Hudson, 2005). In mice, scFv fragments have a terminal half-life of approximately 10–30 
minutes, and molecules with a size similar to Fab fragments, such as diabodies, single-chain 
diabodies and tandem scFvs, have a half-life of 5–6 hours. In comparison, the half-life of 
IgGs in mice is in the range of 4–5 days. From these and other studies it is evident that small-
sized antibody molecules that also lack an Fc region are indeed rapidly cleared from the 
circulation. This is especially a concern for therapeutic applications such as cancer and 
chronic inflammatory diseases, where long-lasting activity is desirable (Kontermann, 2009).  
Strategies to extend the half-lives of recombinant antibodies and other proteins can be 
divided into those that (i) rely on 
increasing the size and thus the 
hydrodynamic volume; and (ii) in 
addition implement recycling by the 
FcRn, the receptor responsible for the 
long half-lives of IgGs and albumin 
(Fig. 6 and Table 2) (Kontermann, 
2009). These strategies comprise a 
variety of different approaches 
including chemical coupling of 
polymers and carbohydrates, post-
translational modifications such as N-glycosylation, and fusion to recombinant polymer 
mimetics. Additionally, conjugation, binding or fusion to an Fc region or serum albumin, 
respectively, results not only in an increase size but also incorporates FcRn-mediated 
recycling (Table 2). More recently, nanoparticulate formulations have also been developed to 
improve the half-life and biodistribution of therapeutic proteins, for example, through 
encapsulation into liposomes or polymeric capsules (Pisal et al., 2010). 
Fig. 6 - Strategies to improve half-lives of therapeutic 
proteins (Kontermann, 2009). 
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Table 2: Recombinant antibody and antibody/albumin complexes (adapted from Kontermann, 
2012). 
Strategy Modification 
Effect on 
hydrodynamic 
radius 
Effect on fcRn-mediated 
recycling Effect on half-life 
PEGylation 
Chemical conjugation 
methoxy polyethylene 
glycol (mPEG) 
Increased None 
Prolonged 
depending on PEG 
size and structure 
Polysialylation 
Chemical conjugation or 
attached by post-
translational modification 
of polysialic acid 
Increased (plus 
change in pI) None 
Prolonged 
depending on 
extent of 
polysialylation 
HESylation Chemical conjugation of hydroxyethyl starch (HES) Increased None 
Prolonged 
depending on HES 
size and structure 
Recombinant PEG 
mimetics 
Genetic fusion of flexible, 
hydrophilic amino acid 
chains 
Increased None 
Prolonged 
depending on size 
and composition 
N-glycosylation Post-translational attachment of N-glycans Increased None 
Moderately 
prolonged 
O-glycosylation Post-translational attachment of O-glycans Increased None 
Moderately 
prolonged 
Fc fusion Genetic fusion of IgG Fc region Increased Utilized Prolonged 
Engineering Fc 
Mutations introduced into 
the Fc region of IgGs or Fc 
fusion proteins 
Unaltered Utilized or diminished (depending on mutations) 
Prolonged or 
reduced 
IgG binding 
Genetic fusion or 
conjugation to IgG-binding 
moieties 
Increased upon 
binding to IgG 
Utilized or diminished 
(depending on binding site) Prolonged 
Albumin fusion Genetic fusion to serum albumin Increased Utilized Prolonged 
Albumin binding 
Genetic fusion or 
conjugation to albumin-
binding moieties (peptides, 
protein domains, antibody 
fragments, antibody 
mimetic scaffolds, small 
chemicals, fatty acids, etc.) 
Increased after 
binding to 
albumin 
Utilized Prolonged 
Albumin coupling Chemical conjugation to cysteine 34 Increased Utilized Prolonged 
Nanoparticles 
Encapsulation into or 
conjugation to 
nanoparticles (e.g., 
liposomes, polymeric 
capsules) 
Strongly 
increased by the 
size of the 
nanoparticles 
(50-200nm) 
None Prolonged (slow release) 
 
III.1 – Strategies to increase the hydrodynamic radius  
The primary approach in improving the half-life of a protein therapeutic is to reduce the 
renal clearance rate, for example, by increasing the size above the renal cut-off. This can be 
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achieved by several ways including chemical and post-translational modifications as well as 
genetic engineering (Table 2). 
These strategies comprise a variety of different methods, including di- or multimerization, 
chemical coupling of polymers or carbohydrates, post-translational modifications such as N-
glycosylation, and fusion to polymer mimetics. Another obvious approach to increase the size 
of therapeutic proteins is the fusion to another proteins moiety, for example, a plasma protein. 
Mainly, fusion to immunoglobulin Fc region or serum albumin has been used to extend the 
half-life of peptides and proteins (Schulte, 2009). Because albumin and Fc containing proteins 
utilize recycling by the FcRn, these strategies are described below (Section III.2).  
Another approach to increase the hydrodynamic volume of small molecular weight drugs is 
the incorporation or encapsulation of these molecules into liposomal carrier systems.  In 
addition to liposomes, various other nanoparticulate carrier systems have been used to 
improve pharmacokinetic and pharmacodynamics properties of proteins. The carrier systems 
combine several advantages. Because of their large size in the range of 50 to 200 nm, the half-
life is strongly increased (Hartung and Bendas, 2012; Landfester et al., 2012). Furthermore, 
nanoparticulate formulations influence biodistribution, for instance, accumulation in tumours 
through an enhanced permeability and retention in the tumour tissue (Peer et al., 2007). 
Additionally, they are also capable of protecting the protein drug from degradation, for 
example, through plasma proteases, and can act as a slow release formulation, namely, as a 
drug depot in the body  (Hartung and Bendas, 2012; Landfester et al, 2012). 
 Several studies showed that PEGylation and glycosylation are the most efficient and 
relevant strategies for therapeutic use of recombinant antibodies (Jevsevar et al., 2010; Solá 
and Griebenow, 2010; Kontermann, 2009). 
 
III.1.1 - PEGylation  
PEGylation, that is, the chemical conjugation of polyethylene glycol (PEG), mainly of its 
methoxy derivative, methoxy polyethylene glycol (mPEG), was established more than two 
decades  ago (Jevsevar et al., 2010). Conjugation of one or more PEG chains to a protein is an 
established and approved method to prolong the half-life of a protein, and various PEGylated 
molecules are in clinical use (Duncan, 2006; Harris and Chess, 2003). In 1990, the first 
PEGylated protein drug was approved by the FDA (Fishburn, 2008; Harris and Chess, 2003) 
and since then eight more PEGylated protein drugs have been approved, including enzymes, 
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interferon-α2b, G-CSF, hGH, erythropoietin and a Fab fragment (Gaberc-Porekar et al., 2008; 
Veronese and Mero, 2008). 
PEG molecules are amphiphilic, chemically inert polymers of ethylene oxide, composed 
by ethylene oxide units connected in a linear or branched configuration and a varying length. 
In the approved drugs, one or several PEG chains of 5 to 40 kDa are conjugated. The dipole 
nature of the oxygen atom makes PEG highly hydrophilic. A monomer unit can bind two to 
three water molecules, thus PEG can bind water up to its own molecular mass, occupying a 
large hydrodynamic volume. Therefore, the molecular mass of PEGylated proteins is 
drastically increased through the binding of water molecules, reflected by a strong increase of 
the hydrodynamic radius. Different coupling methods have been established, comprising 
random and site-directed approaches. The PEGylation strategy, that is, the site of PEGylation 
as well as the number and size of the attached PEG chains, has to be carefully chosen in order 
to avoid a reduction or abrogation of the activity of the therapeutic protein (Knop et al., 2010; 
Fishburn, 2008). Ideally, a single PEG chain is conjugated in a site-directed manner, for 
example, over the use of existing or genetically introduce cysteine residues. This is 
exemplified by Cimzia (certolizumab pegol), a bacterially produced anti-TNF Fab’ fragment, 
where a 40 kDa PEG chain is attached to the free cysteine at the C-terminus of the heavy 
chain, that is opposite the antigen-binding. Certolizumab pegol was the first PEGylated 
antibody fragment that was approved for clinical use. The antibody was approved to reduce 
signs and symptoms of Crohn’s disease and maintain clinical response in adult patients from 
moderately to severely active disease which have had an inadequate response to conventional 
therapy, and is also in development for the treatment of rheumatoid arthritis and psoriasis. 
The terminal half-life was determined to be approximately 14 days (Melmed et al., 2008; 
Rutgeerts et al, 2008). In general, this strategy is considered to be safe and well tolerated 
(Veronese and Mero, 2008). Although in animals, the occurrence of renal tubular 
vacuolization has been observed due to accumulation of the non-degradable PEG chains in the 
kidney.  
PEGylation also influences polarity, structure and surface properties leading to altered 
physicochemical properties (solubility, stability), immunogenicity, cellular uptake, 
elimination and tissue localization (Hamidi et al., 2006).  Thus, besides improved circulation 
half-lives, the advantages of PEGylation include reduced immunogenicity, improved 
solubility, enhanced proteolytic resistance, improved bioavailability, and reduced toxicity. 
PEGylation was successfully applied to prolong the half-lives of a variety of antibodies and 
antibody fragments including IgG and scFv molecules by coupling one or more PEG chains 
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with different sizes. However, several studies also showed that PEGylation can affect antigen 
binding and bioactivity (Veronese and Mero, 2008). 
Recently, alternative strategies to PEGylation have been established. For example, it was 
noted that the polypeptide backbone, resembles, at least in part, the structure of PEG. This has 
led to the generation of long polypeptide chains of hydrophilic and flexible structure, which 
can be genetically fused to recombinant proteins (Schellenberger et al., 2009; Schlapschy et 
al., 2007). Thus, chemical conjugation and additional purification steps are avoided. Besides, 
the fused polypeptide chains are biodegradable and have also been shown to be 
immunologically inert. In vivo studies established that this recombinant PEG mimetics behave 
in a similar manner to PEG that is they result in a drastic increase of the hydrodynamic radius 
and extension of the half-life (Kontermann, 2012). 
 
III.1.2 - N- and O-glycosylation  
As an alternative, carbohydrate chains can be attached to therapeutic proteins. Because this 
process takes place naturally, for example, by post-translational modifications in mammalian 
cells, therapeutic proteins have been genetically modified to contain additional N- or O-
glycosylation (Solá and Griebenow, 2010; Li and d’Anjou, 2009; Sinclair and Elliott, 2005). 
Human antibodies are glycoproteins with varying degrees of glycoslyation depending on the 
isotype. All IgG isotypes possess a single N-glycosylation site in the CH2 domain (amino acid 
Asn297). IgG3 was N-glycosylated at the CH3 domain. Often ignored is the observation that 
20–25% of the immunoglobulins also exhibit N-glycosylation of the variable domains, either 
of the variable heavy or light chains, or even both variable domains, which in some cases has 
been reported to be associated with a pathophysiological role of the antibodies (Batra et al., 
2002). IgG-Fc glycosylation has been shown to influence Fc-mediated effector functions of 
antibodies, especially antibody-dependent cell-mediated cytotoxicity (ADCC) and 
complement-dependent cytotoxicity (CDC), but as well as other properties such as thermal 
stability and pharmacokinetics. In addition to the modulation of the composition of existing 
glycans, the introduction of new N-glycans was applied to increase the hydrodynamic radius 
and thus the plasma half-life of recombinant proteins (Solá and Griebenow, 2010; Jefferis, 
2005). 
Several studies emphasize that the introduction of (additional) N-glycosylation sites into a 
protein leads to only a moderate increase in plasma half-lives. Nevertheless, it can improve 
administration and efficacy of therapeutic proteins. For example, Stork and co-workers 
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introduced 3–9 N-glycosylation sites in the linker regions as well as a C-terminal extension of 
a bispecific single-chain diabody (scDb) molecule. Expression in HEK293 cells resulted in 
heterogeneous populations of glycosylated molecules possessing an increased hydrodynamic 
radius. In mice, the circulation time was prolonged, resulting in an approximately 3-fold 
increased area under the plasma concentration-time curve from 0 to 24 hours (AUC24) 
compared with non-glycosylated scDb (Stork et al., 2008). 
 
III.1.3 – Polysialylation, HESylation and other strategies 
Carbohydrates have also been chemically conjugated to therapeutic proteins in a similar 
way to the PEGylation approach. For example, polysialic acid (PSA) has been investigated as 
an alternative to PEG (Gregoriadis et al., 2005; Gregoriadis et al., 2000). PSA is found on the 
surface of several cells including mammalian cells, thus is a biocompatible and biodegradable 
natural polymer. Colominic acid, a linear polymer of α-(2,8)- linked N-acetylneuraminic acid, 
was used for polysialylation of various proteins including asparaginase, insulin and antibody 
fragment and was shown to be capable of prolonging their half-lives (Constantinou et al., 
2008). 
Another carbohydrate structure, which has been established for half-life extension of 
therapeutic proteins, is hydroxyethyl starch (HES). HES is a modified, branched amylopectin, 
isolated from waxy maize starch, composed of glucose units linked by α-1,4- and α-1,6-
glycosidic bonds. HES is an approved plasma volume expander with a proven safety record. 
Because of its close similarity to glycogen, HES is not immunogenic (Agreda-Vásquez et al., 
2008; Brecher et al., 1997). The size and structure of HES and thereby its stability can be 
adjusted by acidic hydrolysis and by chemical hydroxyethylation at positions 2, 3, and 6 of 
the glucose unit. The HESylation technology was pioneered by the company Fresenius and 
Kabi to improve the pharmacokinetic and pharmacodynamic properties of therapeutic 
proteins. For example, it was successfully applied to produce improved derivatives of 
erythropoietin by chemical coupling of 60 kDa HES (Hey et al., 2012). 
Another interesting approach is the fusion of recombinant polypeptides in the strategy used 
by Schellenberger and colleagues to extend the half-life of peptides or proteins. Their work 
showed that genetic fusion of an unstructured recombinant polypeptide of 864 amino acids, 
called XTEN, to exenatide peptide, for treating type 2 diabetes, should increase exenatide 
half-life in humans from 2.4 h to a projected time to 139 h. XTEN lacks hydrophobic amino 
acid residues that often contribute to immunogenicity and complicate manufacture. Based on 
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XTEN fusions to exenatide, glucagon, GFP (Green Fluorescent Protein) and human growth 
hormone, XTEN can provide an effective means for extending half-life of therapeutic 
proteins, and the recombinant nature of XTEN provides several advantages over traditional 
PEGylation (Schellenberger et al., 2009). 
 
III.2 – Strategies implementing FcRn-mediated recycling 
IgG molecules and serum albumin 
possesses extraordinary long half-lives in 
humans. The half-life of IgG1 is in the 
range of 21-23 days and that of human 
serum albumin is 19 days (Kontermann, 
2009). No other soluble serum protein is 
known to exhibit these long half-lives. In 
both cases, pH-dependent binding to 
FcRn after endosomal uptake into 
endothelial cells is responsible for 
recycling into the bloodstream (Lencer 
and Blumberg, 2005). The neonatal Fc 
receptor also known as Brambell 
receptor, is an MHC class I-related 
receptor consisting of a heavy chain, 
which is non-covalently associated with 
β2-microglobulin (B2M) light chain. The 
domain III of albumin is responsible for FcRn binding and the long serum half-life. In vitro 
mutagenesis and binding studies showed that the conserved H166 residue of the human FcRn 
heavy chain, located opposite to the FcRn-IgG interaction site, plays a critical role in the pH-
dependent FcRn-albumin interaction (Andersen et al., 2006; Chaudhury et al., 2006) (Fig. 7).  
FcRn is also involved in transplacental transport of maternal IgG to the fetus and in antigen 
presentation (Roopenian and Akilesh, 2007).  The FcRn-mediated recycling mechanism of 
albumin is illustrated in Fig. 8. Briefly, following pinocytosis, plasma proteins move to acidic 
endosomal compartments where IgG and albumin bind FcRn with high affinity at distinct 
binding sites. When FcRn is saturated, unbound plasma proteins or excess ligands are 
destined for degradation in lysosomes, while bound complex is diverted to the cell membrane 
Fig. 7 - The crystal structure of FcRn and its ligands 
binding sites. The crystal structure of a truncated 
recombinant soluble FcRn with the HC (α1, α2 and α3) 
shown in cream and the β2m subunit in green. The amino 
acid residues essential for IgG binding (E115, E116, 
D130, W131, E133 and L135 of the FcRn HC and I1 of 
β2m) are highlighted by blue spheres while H166, which 
is crucial for albumin binding is indicated by red spheres 
(Sleep et al., 2013). 
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where IgG and albumin dissociate from FcRn at physiologic pH, providing longer survival to 
the two proteins. Unbound receptor is either recycled back to endosome for another round of 
recycling or degraded in the lysosome (Kim, 2012). Concerning binding stoichiometry, one or 
two molecules of FcRn can bind one IgG molecule. Under equilibrium conditions, two 
molecules of FcRn bind one IgG (2:1 stoichiometry), whereas alterations of the carbohydrate 
moieties on FcRn can result in 1:1 binding stoichiometry under nonequilibrium conditions 
(Sánchez et al., 1999). IgG and albumin bind to FcRn independently and noncooperatively. 
Unlike  FcRn-IgG binding, albumin binds FcRn with a 1:1 stoichiometry, and a large positive 
charge in entropy upon binding suggests a hydrophobic interaction (Chaudhury et al., 2006). 
 
Since the Fc region of IgG has been involved in pH-depending binding to FcRn (Martin et 
al., 2001), protein engineering of the Fc region can improve the half-life of therapeutic 
antibodies with enhanced binding of FcRn at acidic pH. Another approach is via fusion to the 
Fc region of IgG molecule to recombinant antibody fragments, and these fusion proteins 
exhibit affinities similar to whole antibodies, but because of their smaller size are able to 
penetrate more easily into tissues (Kontermann, 2009; Holliger and Hudson, 2005).  
 
 
Fig. 8 - FcRn mediated, pH-dependent, albumin recycling. Extracellular albumin (gold heart-shaped 
protein) with drug attached (green molecule) is pinocytosed along with a range of other plasma 
constituents at neutral pH (blue shading). Upon acidification of the vesicle (red shading) albumin binds 
to the integral FcRn membrane protein (purple molecule). Non-FcRn interacting proteins and plasma 
constituents are sorted to the lysosome for degradation while vesicles containing functional albumin–
FcRn complexes are recycled back to the plasma membrane cell surface where they are exposed to 
neutral pH of the plasma and the albumin is released back into the circulation (Sleep et al., 2013). 
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III.2.1 - Half-life extension by binding to albumin 
In contrast with antibodies, albumin is also present at high concentration in the interstitial 
compartment and has a larger volume of distribution. Proteins that take advantage of albumin 
to increase their half-life will therefore have a different tissue distribution profile than Fv-
fused proteins (Frejd, 2012).  However, some applications (e.g. of cytokines, growth factors, 
receptor-neutralizing antibodies, bispecific antibodies) may require monovalent interaction 
and the lack of Fc-mediated effector functions (ADCC, CDC) (Müller and Kontermann, 
2007). In these cases, fusion to albumin or albumin-binding domain (ABD) offers an 
alternative.  
The strategy of binding antibody fragments or peptides to albumin is meanwhile being 
extensively explored for the design of a new generation of albumin-binding antibodies and 
therapeutically active peptides. Three strategies can be distinguished: (i) bivalent antibodies 
that binds the desired antigen or peptide derivatives are constructed, which additionally 
comprise the heavy or light chains of antibodies as an albumin-binding domain; (ii) the fc 
region is substituted by albumin and two antigen-binding regions (Fab regions) are fused to 
albumin; (iii) an albumin-binding domain or peptide with high affinity in the nano to 
fentomolar range to albumin is bound to Fab regions, other antibody formats or therapeutic 
peptides (Elsadek and Kratz, 2012).  
 
III.2.1.1 - Human serum albumin 
Human serum albumin (HSA) provides colloidal osmotic pressure in plasma and buffering 
capacity in the blood, and serves as a transport and depot protein for numerous endogenous 
and exogenous compounds (Fanali et al., 2012; Fasano et al., 2005). The protein binding 
results in an increased solubility in plasma, decreased toxicity, and/or protection against 
oxidation or the bound compounds (Kragh-Hansen et al., 2002). HSA (~ 600 µM, 585 aa, 
MW ~67.000) is the most abundant plasma protein, with a normal concentration of 
approximately 34–54 g/L and with an average plasma volume of 2.5-3.0 L for a 70 kg person, 
the average intravascular albumin mass is 113-126 g (~120 g). Human albumin is one of the 
few non-glycosylated plasma proteins and it is synthesized predominantly in the liver. 
Hepatocytes do not contain a large pool of stored intracellular albumin, rather the protein is 
rapidly secreted from the cell resulting in approximately 13-14 g of albumin entering the 
intravascular space every day, equivalent to 3.7%/day of the total albumin  mass of 360 g for 
a 70 kg person (Sleep et al., 2013). Human serum albumin is a α-helical protein monomer 
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composed of three 
structurally 
homologous domains 
(I, II, III), each being 
further divided into 
two subdomains (A, 
B), connected by 
random coil (Fig. 9). 
Albumin is a major 
carrier protein for a 
variety of small 
molecules such as 
ions, fatty acids, 
hormones, bilirubins, 
and drugs (Fasano et 
al., 2005; Ghuman et 
al., 2005; Sugio et al., 1999). The modular structure organization of HSA provides a variety 
of ligand binding sites, illustrated in Fig. 9. Also, several sites with acyl chain binding activity 
have been identified in this molecule (Bhattacharya et al., 2000). In humans, albumin has a 
half-life of approximately 19-20 days, while in mice the half-life is approximately 1.07-1.6 
days and 1.9 days in rats (Schmidt et al., 2013; Peters, 1996; Stevens et al., 1992; Peters, 
1985; Beeken et al., 1962). 
HSA abundance makes it an important factor in the pharmacokinetic behaviour of many 
drugs, affecting their efficacy and rate of delivery (Fasano et al., 2005). Over the past 
decades, albumin has played an increased role as a drug carrier for therapeutic and diagnosis 
agents. Albumin also represents a valuable biomarker for several pathological conditions 
including cancer, rheumatoid arthritis, ischemia, post-menopausal obesity, severe acute graft-
versus-host disease, and diseases that need monitoring of the glycemic control (Fanali et al., 
2012). The first evidence demonstrating that tumours are able to trap plasma proteins and use 
their degradation products for proliferation appeared in the middle of the 20th century (Babson 
and Winnick, 1954). The high HSA turnover in tumours has been explained by the fact that 
albumin represents the main energy and nutrition source for the tumour growth, with liver 
having an active metabolic role (Kratz, 2008). In the later stages of disease, malnutrition and 
inflammation supress HSA synthesis (Yeun and Kaysen, 1998; Ballmer et al., 1994).  The 
Fig. 9 - Summary of the ligand binding capacity of HSA as defined by 
crystallographic studies. Ligands are depicted in space-filling representation; 
oxygen atoms are coloured red; all other atoms in fatty acids (myristic acid), 
other endogenous ligands (hemin, thyroxin) and drugs are coloured dark-grey, 
light grey and orange, respectively (Ghuman et al., 2005). 
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reduced HSA concentration in blood seems to be due to the production of cytokines, such as 
interleukin-6, which modulate the production of HSA by hepatocytes (Barber et al., 1999). 
Alternatively, the tumour necrosis factor α may increase the permeability of the 
microvasculature, thus allowing an increased transcapillary passage of HSA. The presence of 
micrometastatic tumour cells in the liver may indicate that the Kupfer cells produce a variety 
of cytokines, which may modulate HSA synthesis by hepatocytes (McMillan et al., 2001; 
Barber et al., 1999). As a consequence there is a slight or no hypoalbuminemia in the early 
stages of cancer, but as the disease progresses HSA levels drop significantly, serving as a 
good indicator of cancer prognosis (Gupta and Lis, 2010; Sun et al., 2009; McMillan et al., 
2001; Barber et al., 1999). 
Patients with active rheumatoid arthritis frequently develop hypoalbuminemia, primarily 
by high HSA uptake at sites of inflammation (Kratz, 2008; Niwa et al., 1990; Ballantyne et 
al., 1971; Wilkinson et al., 1965).  The metabolism of synovial cells is highly up-regulated, 
and the HSA uptake is probably a relevant source covering their high demand for nitrogen and 
energy. The permeability of the blood-joint barrier for HSA in rheumatoid arthritis patients is 
markedly increased (Kratz, 2008) Remarkably, using preclinical models it has been 
demonstrated that serum albumin accumulates in the arthritis paws of mice suffering from 
collagen-induced arthritis (Wunder et al., 2003). Since the anti-rheumatic drug methotrexate 
bound serum albumin has shown promising activity in the collagen-induced murine arthritis 
model, HSA may represent an attractive drug carrier to target drugs to inflamed joints of 
patients with rheumatoid arthritis (Kratz, 2008). 
 
III.2.1.2 - Fusion to albumin  
Direct fusion to the whole albumin has been applied to a variety of proteins, including 
interferons, interleukin 2 (IL-2), insulin, human growth hormone, and antibody fragments. 
Merrimack Pharmaceuticals, Inc. has developed an albumin fusion protein, using the scFv 
format for targeting HER2 and HER3. The bispecific format of MM-111 could be an optimal 
approach of inhibiting the enhancement of cell proliferation of HER3 in HER2-
overexpressing tumours. This molecule entered clinical development for PhaseI/II in June 
2009 and is currently in clinical trials with patients with tumours that over-express HER2 in a 
phase I study and restricted for breast cancer patients, in phase II (Elsadek and Kratz, 2012).  
Müller and co-workers generated bispecific anti-CD3 x anti-CEA antibody albumin fusion 
proteins by fusing either a bispecific single-chain diabody or a bispecific tandem scFv to the 
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N-terminus of HSA, or two different scFvs, one at the N-terminus and one at the C-terminus. 
All three constructs possessed a molecular mass of approximately 120 kDa, and showed 
similarly prolonged circulation after intravenous injection into mice, with terminal half-lives 
increased 4- to 5-fold compared with scDb and tandem scFv (taFv) molecules (MW ~55.000) 
and AUC24 values increased approximately 10-fold. However, differences were observed in 
the ability to activate peripheral blood mononuclear cells (PBMCs) in a target cell-dependent 
manner, where effector and targets have to come into close contact. Here the scDb-HSA 
fusion protein was superior to the taFv-HSA and the scFv-HSA-scFv fusion proteins, but was 
still less active than the parental scDb molecule (Müller et al., 2007). Reduced bioactivity was 
also observed for other albumin fusion proteins, e.g. albuferon alpha, albuferon beta, and 
albuleukin, presumably caused by fusing the large albumin moiety to a comparably small 
therapeutic protein component. Nevertheless, these proteins displayed improved therapeutic 
efficacy, demonstrating that fusion of a therapeutic protein to albumin improves both 
pharmacokinetics and pharmacodynamics (Kontermann, 2009). 
 
III.2.1.3 - Fusion to bacterial albumin-binding domains 
Depending on the nature of the therapeutic protein, its fusion or coupling to serum albumin 
can complicate the manufacturing process, especially if the protein as such is produced 
recombinantly in, for example, Escherichia coli. Pre-clinical development can also be 
affected by the fact that human serum albumin does not always cross-react with the neonatal 
receptor of other species, murine FcRn, for example, binds very weakly to HSA (Andersen et 
al., 2011).   
As an alternative to direct fusion to albumin, several molecules have been exploited as 
albumin-binding moieties, employing reversible, non-covalent interaction with serum 
albumin. These albumin-binding moieties comprise small synthetic chemicals, peptides, 
antibodies or antibody fragments, as well as naturally occurring albumin-binding domains, 
and several reports show that binding derivates of albumin-binding domain from streptococcal 
protein G can be used to increase the plasma half-life of a fusion protein partner (Fig. 10) 
(Kontermann, 2009).  
Pathogenic Gram-positive bacteria express cell wall-associated proteins that interact in 
several ways with the extracellular environment. These proteins are involved in host escape 
mechanisms of the bacteria, as virulence factors (Patti et al., 1994) and might become useful 
as components in vaccines against these bacteria (Ji et al., 1994; Mamo et al., 1994). 
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Curiously, some of these bacterial proteins present binding to plasma proteins as albumin, 
IgG or fibrinogen. Examples of these surface proteins are the streptococcal surface proteins G 
(Sjöbring et al., 1989) and G-related proteins MAG (Jonsson et al., 1994), MIG and ZAG 
(Jonsson et al.b, 1995), H (Ǻkesson et al., 1994; Frick et al., 1994; Nilsson et al, 2008) ,  M 
(M1, M5, M12) (Ǻkesson et al., 1994; Sandin et al., 2006;  Retnoningrum and Cleary, 1994), 
PAB (de Château et al., 1996; de Château and Björck, 1994) and FAI (Talay et al., 1996). 
This section will be focused in the well-studied streptococcal albumin-binding domains 
(ABDs) from proteins G and PAB, and the ABDs from ZAG (and ZAG-related MIG and 
MAG proteins), and finally the albumin-binding domain from Protein H. 
 
 
 
 
III.2.1.3.1 - Protein G 
Many streptococcal strains are known to bind the most abundant plasma proteins, namely, 
immunoglobulin G and albumin. Based on the specific albumin binding activity expressed on 
the cell surface, Widebäck et al. grouped the streptococcal albumin receptors into five 
different types (a-e) (Widebäck et al., 1983). The type a receptors are expressed on human 
group G strains, and the best studied bacterial albumin-binding domains are from protein G of 
strain G148. As shown in Fig. 11, protein G is a bi-functional receptor with different parts 
responsible for the IgG and albumin binding. More precisely, three Ig-binding domains and 
three serum albumin-binding domains (Sjölander et al., 1997; Sjöbring et al., 1991; Sjöbring 
et al., 1988; Åkerström et al., 1987; Björck et al., 1987).  
 
Fig. 10 - Historical outline of the development of using ABD for half-life extension (Frejd, 2012). 
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Pioneering approaches from the 1990s included fusion to larger albumin binding 
fragments, BA or BABA (BB), derived from SpG (Fig. 11). In 1991, Nygren and co-workers 
reported on the use of BB to extend the half-life of a soluble form of CD4 (Nygren et al., 
1991). CD4 is an important component of the infection mechanism of HIV being a target 
receptor for the virus envelope protein gp120. By providing an excess of half-life extended 
CD4, the authors reasoned that the infectious action of viral gp120 would be diluted or even 
blocked. A fusion construct containing an N-terminal BB followed by two domains of the 
extracellular part of CD4 (E1 and E2) followed by a C-terminal BB region was produced and 
shown to bind recombinant gp120. In a kinetics study in mice, the BB-stabilized CD4 was 
compared with an IgG1 Fc-stabilized CD4 or CD4 or BB alone. It turned out that the half-life 
of the BB-stabilized protein or BB alone (t1/2 15-24h) was similar or slightly better than the 
Fc-stabilized counterpart, and much longer than CD4 alone. The long half-life of BB was 
confirmed in monkeys, where it had a half-life of 16 days. As the SpG derivates are of 
bacterial origin, Nygren and co-workers suggested the use of a much smaller but still albumin 
binding part of the receptor (<6 kDa, denoted ABD) to minimize potential recognition by the 
immune system (Nygren et al., 1991). ABD was initially used as an affinity tag (Nilsson et 
al., 1997), and later used as an affinity handle fused to antibody fragments such as Fv or Fab, 
to facilitate capture in a sandwich ELISA format (König and Skerra, 1998). 
Fig. 11 - An overview of the streptococcal protein G (SpG). The IgG and albumin-binding parts are 
separated. Both parts consist of three homologous domains. Nomenclature according to Ståhl and Nygren 
(1999) (adapted from Linhult et al., 2002). 
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Nevertheless, protein G has the well-studied ABD used in fusion with therapeutic proteins 
for half-life extension and structural studies, including the resolution of its three-dimensional 
structure and mutagenesis studies to reveal residues involved in interaction with albumin from 
different species (Linhult et al., 2002; Kraulis et al., 1996). Protein G ABD is composed by 
46 amino acid residues, forming a left-handed three-helix bundle. The domain on its own is 
chemically and thermally stable and it is independent from disulfide bonds, crosslinks, bound 
ligands or metal ions. An affinity of approximately 1–4nM for human serum albumin was 
determined by various methods. Residues involved in binding were localized mainly in helix 
2 and 3 by mutational analysis and chemical shift perturbation (Johannson et al., 2002; 
Linhult et al., 2002). 
 Several in vivo studies, have demonstrated the applicability of fusion to the ABD from 
protein G to improve the plasma half-lives of small antibody molecules (e.g. Fab fragments, 
bispecific antibody derivatives) and various antibody mimetics. One application consisted of 
the fusion of the ABD to the C-terminus of the light chain of an anti-HER2 Fab increased the 
terminal half-life in mice from approximately 2 to 20.9 hours (Schlapschy et al., 2007). 
Similar results were described for a single-chain diabody-ABD fusion protein (scDb-ABD), 
which extended the half-life from 5.6 hours to 27.6 hours after a single intravenous injection 
into mice (Nilsson and Tolmachev, 2007). Stork and colleagues extended the plasma of a 
single-chain diabody against carcinoembryonic antigen (CEA) and CD3 capable of 
retargeting T cells to CEA-expressing tumour various strategies were applied including 
PEGylation, N-glycosilation and fusion to an albumin-binding domain from streptococcal 
protein G. Furthermore, prolonged circulation time results were shown in an increased 
accumulation in CEA+ tumours, which were most pronounced for scDb-ABD and PEGylated 
scDb. Interestingly, tumour accumulation of the scDb-ABD fusion protein was approximately 
2-fold higher compared to PEGylated scDb, although both molecules exhibit similar plasma 
half-lives and similar affinities for CEA. Comparing half-lives in FcRn wild-type and FcRn 
heavy chain knockout mice, the contribution of FcRn to the long plasma half-life of scDb-
ABD was confirmed, while no differences were observed for PEGylated scDb. Compared to 
scDb, a reduced cytotoxic activity was observed for scDb-ABD, which was further reduced in 
the presence of albumin (Stork et al., 2009). The protein G ABD was also applied to prolong 
the half-life of Affibody molecules, derived from the Z domain of protein A (Tolmachev et 
al., 2007) and to investigate the impact of a very high affinity binding to serum albumin, 
using an affinity maturated variant of ABD with femtomolar affinity binding to HSA (Jonsson 
et al., 2008). 
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As illustrated in Fig. 12, at least 16 protein G-related albumin-binding (GA) modules or 
domains with relatively high sequence identity have been identified in six proteins and four 
bacterial species (Johansson et al., 2002). The most well-conserved region in this sequences 
so far identified is the C-terminal part of the second helix and the flexible region between 
helices 2 and 3 (residues 32 to 39) (Johansson et al., 1997). 
 
 
 
III.2.1.3.2 - PAB streptococcal cell-surface protein  
Protein PAB, a surface molecule from the anaerobic human commensal and pathogen 
Peptostreptococcus magnus, was found containing a domain of 45 amino acid residues 
showing high affinity for HSA. The sequence analysis of this domain revealed homologies 
both to the HSA-binding domain of protein G and to the framework regions of protein L, 
suggesting that this mosaic protein has emerged as the result of interspecies exchange of an 
Fig. 12 – Peptide sequence alignment of 16 different GA modules from six proteins and four bacterial 
species. The consensus sequence is shown at the bottom. Conserved amino acids have been shaded. The 
GA module of protein PAB (de Château and Björck, 1994) under study in this work is at the top (ALB8-
GA) followed by the second HSA-binding domain (ALB8-uGA) of protein PAB (de Château et al., 1996). 
The conserved, mobile, and folded sequence originally defined as the GA module comprises 45 amino acid 
residues, whereas the material studied here contains eight additional residues (in italics). Preparation of this 
53 amino acid fragment (residues 213 to 265 of the intact protein), as well as preparation of NMR samples, 
has been described previously (de Château and Björck, 1994; Johansson et al., 1995). ALB1-GA is from 
another isolated of P. magnus expressing protein PAB (de Château and Björck, 1994) and ALB1B- uGA is 
from protein urPAB (de Château and Björck, 1996). L3316-GA1-4 originate from a protein L-like 
molecule (Murphy et al., 1994), G148-GA1-3 from streptococcal protein G (Guss et al., 1986),  DG12-
GA1-2 a bovine Streptococcus dysgalactiae isolate (Sjöbring, 1992), MAG-GA1-2 from protein MAG  of 
S. dysgalactiae (Jonsson et al., 1994) and finally, ZAG-GA from protein ZAG of Streptococcus 
zooepidemicus isolate (Jonsson et al.b, 1995) (adapted from Johansson et al., 1997). 
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HSA-binding protein module (de Château and Björck, 1994, de Château et al., 1996). This 
domain has been subject to module shuffling between bacterial species, and was subsequently 
named the GA module (de Château and Björck, 1994). Such shuffling of modules seems to be 
a persistent activity among this group of genes, and when a consensus sequence of 15 
nucleotides (called “recer” sequence) flanking the different modules in the P. magnus family 
of surface proteins was identified, a model for the shuffling was proposed (de Château and 
Björck, 1996). Recer sequences were also identified in Ig-binding domains, and promote 
interdomain in frame recombination and act as structureless flexibility-promoting spacer 
sequences in the corresponding protein (de Château et al., 1996). The albumin-binding protein 
G of group G streptococcal strain G148 carries three GA modules in the N-terminal part of 
the protein showing up to 60% identity to the shuffled module of protein PAB, indicating that 
protein G might be the source of the GA modules in protein PAB.  Analysis of gene encoding 
protein PAB revealed that the HSA binding domain had been transferred from the protein G 
gene by action of a conjugational plasmid from a third bacterial species, Enterococcus 
faecalis (de Château et al., 1996; de Château et al., 1994).  This protein contains two GA 
modules (Johansson et al., 1997; de Château et al., 1996), and nuclear magnetic resonance 
(NMR) and circular dichroism (CD) analyses to determine the stability, secondary structure, 
and global fold of this module, identify a 
three-helix-bundle structure with a left-
handed folding topology (Johansson et al., 
1995). The X-ray structures at 2.7 Å 
resolution and in the presence of fatty acid 
at 2.5 Å resolution, shows how GA 
module forms a complex with HSA 
(Lejon et al., 2004; Lejon et al., 2008). 
The GA module binds to HSA at a site in 
domain II of the albumin molecule close 
to a cleft bounded by helices 2 and 3 in 
domain IIA, helices 7 and 8 in domain 
IIB, and the loop region before helix 7 in 
IIB (Fig. 13). In the GA module, residues 
from the second helix and the two loops surrounding it are involved in binding. The GA 
helices pack outside the cleft at an angle of ~60º against HSA helix 3 in domain IIA. 
Although this arrangement is almost identical to the orientation reported for the all α-helical 
Fig. 13 - Structure of the complex formed by SpG 
ABD and HSA. The albumin-binding domains 
recognize a site located in domain II of HSA that does 
not overlap with the binding site for the FcRn, which 
plays an important role in albumin homeostasis. The 
picture was generated from PDB-file 1TF0 (Nilvebrant 
and Sober, 2013). 
 30 
 
affibody-ZSpA complex (Högbom et al., 2003), the respective binding sites on the Z domain 
and the GA module do not overlap. The three-helix bundle Z domain of protein A and the GA 
module share a striking similarity in their overall structure. Even so, it is helix 1 of the Z 
domain that packs against the affibody helices, not the second and third as in the HSA-GA 
case (Lejon et al., 2004). Residues Phe27, Tyr28 and Glu47 were confirmed as necessary 
residues for binding HSA and for conferring species specificity (Cramer et al., 2007; Lejon et 
al., 2004). The presence of fatty acid in the HSA-GA binding interface might influence 
complex formation. The binding of fatty acid causes the side chain of Lys212 to be pushed 
aside slightly into a position that allows it to form a hydrogen bond to GA (Lejon et al., 2004; 
Lejon et al., 2008). A previous study present the crystal structure at 1.4 Å resolution of GA 
module and compare it with crystal structure of the GA-albumin complex. The study of the 
interaction of this domain in various crystal forms indicates that no crystal would have been 
formed without making the relevant protein-protein interactions. The analysis of GA dimer 
interactions between chain A and chain B shows that there is one main interface involving 11 
residues from chain A and another 11 different residues in chain B. Cramer and co-workers 
show more than one protein-binding surface on the GA in solution and that there are three 
residues (Trp5, Val38, Asn42) participating in protein-protein interactions on the dimer 
interface between GA module (Cramer et al., 2007).   
 
III.2.1.3.3 - MAG and MIG streptococcal cell-surface proteins 
Jonsson and co-workers cloned and sequenced two genes encoding IgG-binding proteins 
from Streptococcus dysgalactiae strains isolated from cases of bovine mastitis. These 
proteins, called MIG and MAG, were highly homologous in their IgG-binding domains as 
well as to protein G from group G streptococci. Protein MIG contained five IgG-binding 
domains, while protein MAG only presents one such domain. Interestingly, both proteins 
MIG and MAG have one albumin-binding domain and also bound the proteinase-complexed 
form of the plasma proteinase inhibitor α2-macroglobulin (α2-M). These findings suggest that 
both proteins are tri-funtional with a similar structural organization (Jonsson et al., 1994; 
Jonsson and Müller, 1994). The protein MAG, a plasma protein receptor from S. dysgalactiae 
strain 8215, has an albumin-binding domain (50 amino acids) in the center of the molecule 
with homology to the albumin-binding domains of protein G. The IgG binding domain 
located in the C-terminal part of the molecule shows high homology to streptococcal type III 
Fc receptor. The alpha 2 M-binding domain is located in the N terminus of the molecule and 
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is composed of a unique amino acid sequence (Jonsson et al., 1994). In protein MAG the 
ABD is flanked by an upstream located region which binds α2M and a downstream located 
region that binds IgG (Fig. 14). The albumin receptors of S. dysgalactiea belong to albumin 
receptors of type c and present a broader binding profile than protein G. This is reflected for 
example by the binding of type c receptors to serum albumins from cow, goat and sheep, 
which are not reactive with protein G (Falkenberg et al., 1992).  
 
 
 
 
III.2.1.3.4 - ZAG streptococcal cell-surface protein 
Like other streptococcal species, Streptococcus zooepidemicus specifically binds through 
cell surface components, a number of host-derived proteins such as immunoglobulin G (IgG) 
(Myhre and Kronvall, 1980; Kronvall et al., 1979), serum albumin (Widebäck et al., 1983), 
fibronectin, collagen (Mamo et al., 1987) and α2-macroglobulin (α2M) (Müller et al., 1985). 
These host-parasite recognition components might be of importance as virulence factors by 
acting as adhesins, antiopsonins or host mimicry factors (Jonsson et al., 1995).  
The ability to bind IgG from several species and of different subclasses has led to the 
classification of bacterial IgG-binding proteins in six different Fc receptor types. According to 
this classification, the IgG receptors from S. zooepidemicus are distinct from the well-studied 
type I and type III Fc receptors, staphylococcal protein A and streptococcal protein G, 
respectively. The cloning and sequencing of the zag gene revealed that the protein ZAG from 
S. zooepidemicus Z5 has many similarities to the type III Fc receptors from group C and G 
streptococci. The IgG-binding domains from ZAG are homologous to the IgG-binding 
domains in protein G, as well to the corresponding domains in proteins MIG and MAG from 
S. dysgalactiae (Jonsson et al., 1995).  
Protein ZAG shows an albumin-binding profile similar to those of protein G (Nygren et al., 
1990; Nygren et al., 1988) and the albumin-binding DG12 protein from a bovine group G 
streptococcus (Sjöbring, 1992). Protein ZAG and MAG also present what can be considered 
monomeric forms of the repetitive albumin-binding domains in protein G and DG12. 
Fig. 14 - Schematic presentation of protein MAG. The different functional domains are indicated by 
boxes (adapted from Jonsson et al., 1994) 
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Alignment of the albumin-binding domain of ZAG with the corresponding domains of other 
streptococcal proteins also reveals a close evolutionary relationship. In the N-terminus, ZAG 
protein presents a 52 amino acid sequence ABD with binding to human, rat, mouse, horse and 
dog serum albumin. Downstream from this region there are two 70-amino-acid repeats 
homologous to the IgG-binding domains of type III Fc receptors (Fig. 15) (Jonsson et al., 
1995). 
 
 
 
These proteins also found to interact with the plasma proteinase inhibitor α2M through a 
unique amino acid sequence that competes for the same or nearby binding site(s), as do 
proteins MIG and MAG (Jonsson et al., 1995). Pairwise amino acid sequence alignment of 
various functional domains of proteins MIG, MAG, ZAG and protein G shows a high 
homology in the signal sequence, followed by a region of low homology, representing the 
α2M-binding domains in proteins MIG, MAG and ZAG and by the functionally undefined 
region E in protein G (Jonsson et al., 1995; Olsson et al., 1990). The importance of proteins 
MIG, MAG and ZAG in infection and host defense is not known, but Valentin-Weigand and 
colleagues (Valentin-Weigand et al., 1995) have published interesting data showing that the 
binding of the proteinase-complexed α2M to animal group C streptococci inhibits 
phagocytosis in vitro. This finding indicates that this type of proteins have functional 
similarities to the streptococcal M proteins (Jonsson et al., 1995). 
 
III.2.1.3.5 - Protein H 
Protein H, is a multidomain protein present on the cell surface of some strains of 
Streptococcus pyogenes (Frick et al., 1994). This protein is identified in clinical isolates of the 
M1 serotype (Podbielski et al., 1993) and has affinity for the constant (IgGFc) region of 
immunoglobulin (Ig) G and serum albumin (Åkesson et al., 1990; Frick et al., 1994).  The M 
protein family comprises a large group of surface proteins in S. pyogenes, which contribute to 
the potential pathogenicity of these clinically significant bacteria. This family includes the M 
proteins and proteins with affinity for IgG and/or IgA (Fischetti, 1989), and can be divided 
Fig. 15 - Schematic presentation of protein ZAG. The different functional domains are indicated by 
boxes (adapted from Jonsson et al., 1995) 
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into two major classes, A and C, according to the type of repeat found (O’Toole et al., 1992). 
M proteins are regarded as major virulence determinants due to their anti-phagocytic 
properties, whereas the role for IgG Fc-binding bacterial proteins in pathogenicity and 
virulence remains unclear (Frick et al., 1995).  The protein H, like protein G (Björck et al., 
1987) and other streptococcal surface proteins, presents different binding sites for albumin 
and immunoglobulin G (Fig. 16). Protein H albumin-binding domain (ProtH) is closer to the 
bacterial cell wall and IgG-binding further towards the N-terminal. No homology was 
detected when the IgGFc-binding repeats where compared with the same regions of protein G, 
but the albumin-binding regions of protein G and H were shown to have evolved 
convergently. The albumin-binding region was mapped to three repeats (C1-C3) in the C-
terminal half of protein H (Frick et al., 1994). The C repeats are quite similar in various M 
proteins, and the protein H albumin-binding repeats have a high homology with the C repeats 
of protein M1, and also present a similarity of 94-95% among the three repeats (Åkensson et 
al., 1994).  In the C-terminal of protein H was also identified a D domain which attaches 
protein H to the bacterial cell wall. The D domain has a hydrophobic transmembrane region 
and contributes to the three-dimensional structure of the albumin-binding C-repeats rather 
than being directly involved in the interaction with albumin (Frick et al., 1994). In protein G, 
albumin-binding is in the N-terminal half and IgGFc binding in the C-terminus of the 
molecule (Åkerström et al., 1987). Competitive binding experiments demonstrated that 
protein G and H bound to the same or closely located sites in albumin, which has previously 
been mapped for protein G to disulfide loops 6-8 (Falkenberg et al., 1992). 
 
 
 
 
S. pyogenes is an exclusive human pathogen that can cause a variety of complications 
ranging from mild and superficial infections, such as pharyngitis and impetigo, to invasive 
and life-threatening conditions, including necrotizing fasciitis and streptococcal toxic shock 
syndrome (Cunningham, 2000). Serious sequelae following S. pyogenes infections are 
rheumatic fever and glomerulonephritis. In order to survive in human blood, S. pyogenes has 
Fig. 16 - Schematic presentation of protein H. The different functional domains are indicated by boxes 
(adapted from Frick et al., 1994) 
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evolved a number of defense mechanisms, that including anti-phagocytic M and M-like 
proteins, and some serotypes secrete a protein (protein SIC) that binds to and inactivates many 
antibacterial peptides (Frick et al., 2003). For instance, protein H and M1 protein released 
from the bacterial cell wall by polymorphonuclear neutrophils-derived proteases, bind beta-2 
glycoprotein I (β2GPI), a human heparin binding plasma protein with antibacterial activities, 
and inhibit the activity of β2GPI-derived antibacterial-peptides, as an immune defense system 
mechanism (Nilsson et al., 2008). Therefore, Protein H was shown to inhibit complement 
activation at the bacterial surface, suggesting that Ig-binding could contribute to resistance to 
phagocytosis, and is possible that the release of complement-activating IgG-protein H 
complexes from the bacterial surface could be involve in the development of severe 
complications associated with S. pyogenes infections (Berge et al., 1997; Kihlberg et al., 
1999).  Frick and colleagues proposed a role for protein H in the dissemination of streptococci 
from their initial site of colonization, through the formation of virulent aggregates, suggesting 
that induction of expression may be important in establishing an invasive infection (Frick et 
al., 2000). Furthermore, another study suggests that the expression of surface virulence 
factors like protein H, M and M-related proteins may not be essential for the invasion but are 
important for the survival once the organism disseminate and colonize organs (Smith et al., 
2003). These findings may provide a partial explanation of the continued emergence of 
virulent S. pyogenes isolates, but the role of protein H as a virulence factor in response to 
biological pressures in an infected host still needs further investigation. 
 
III.2.1.4 - Fusion to albumin-binding peptides  
Albumin-binding peptides (ABP) represent an alternative to the use of bacterial ABDs, 
having the advantage of being smaller in size. Dennis and co-workers at Genentech, Inc. 
published pioneering work on the attachment of  albumin-binding single-chain antibodies in 
which they discovered a peptide comprising 18 amino acids (Ac-
RLIEDICLPRWGCLWEDD-NH2) with high binding affinity for human serum albumin (KD 
~0.5 µM). A related sequence (QRLMEDICLPRWGCLWEDDF) comprising 20 amino acids 
was then fused with a single-chain antibody D3H44 Fab directed against the tissue factor and 
showed a similar affinity for HSA, and when injected in mice or rabbits, extended the plasma 
half-life 26-fold to 10.4 h and 37-fold to 34.2 h in rabbits, which corresponds to 25-43% of 
the half-life in these animals (Dennis et al., 2002). As a consequence, the same authors 
performed a study comparing the tumour uptake, tumour penetration as well as biodistribution 
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of Herceptin® (trastuzumab), of a Fab4D5 directed against HER2 and of Ab.Fab4D5 that 
additionally had the ABP. Their results showed that unlike Fab4D5, AB.Fab4D5 did not 
accumulate in kidneys, suggesting that association with albumin leads to an altered route of 
clearance and metabolism, and both Fab and ABP fusion molecule showed deep tumor 
penetration, that was more pronounced for the albumin-binding conjugate, due to the much 
smaller size of these molecules (Dennis et al., 2007). 
 
III.2.1.5 - Fusion to albumin-binding antibody fragments and other strategies  
Complexation with albumin can also be achieved through the use of bispecific antibody 
molecules binding with one arm to the target antigen and with the other arm to albumin. For 
example, the pharmacokinetics of nanobodies, which are derived from variable domains 
(VHH) of camelid heavy chain antibodies, were improved by fusion with an anti-albumin 
nanobody. VHH-based Ablynx technology for treatment of rheumatoid arthritis and cancer is 
described in Section V.   
A similar strategy was applied to dAbs, which are derived from human VH and VL domains 
with a size of only 11–13 kDa (Holt et al., 2003). Domantis Ltd (acquired in 2007 by 
GlaxoSmithKline) has developed a further strategy of binding biological molecules such as 
peptides, cytokines or receptors to albumin, using albumin fragments high affinity for 
albumin. Albumin-binding dAbs were selected using phage display from large synthetic dAb 
libraries. One of these molecules (dAbm16), which binds to mouse serum albumin (MSA), 
showed a 51-fold increase in the terminal half-life (from 42 minutes for a control dAb to 24 
hours) in mice. Similar improvements were observed for dAbs binding to rat serum albumin 
(RSA): a high-affinity binding dAb (13 nM) had the same half-life in rats as RSA (53 hours), 
while a low-affinity binder (1 mM) exhibited a reduced half-life of 43 hours, demonstrating a 
correlation between the strength of albumin binding and the half-life. The anti-MSA dAbm16 
was further used as a fusion partner for the human form of IL-1 receptor antagonist (IL-1ra), a 
potent inhibitor of Il-1 signalling approved for the treatment of rheumatoid arthritis. The half-
life of the fusion protein was 4.3 hours, compared with 2 minutes for IL-1ra. The fact that the 
fusion protein is much more rapidly cleared than dAbm16 alone indicates that additional 
mechanisms contribute to clearance of the fusion protein. In a collagen-induced arthritis 
model, improved efficacy was observed for the dAbm16-IL-1ra fusion protein compared with 
IL-1ra, demonstrating that improved pharmacokinetics translates into improved 
pharmacodynamics (Holt et al., 2008). In a more recent application, Walker and co-workers 
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fused an albumin-binding dAb (DOM7 h-14) to Interferon-α2b (IFN-α2b) and compared its 
pharmacokinetics and efficacy to IFN-α2b alone and Albinterferon-α2b (HSA-IFN-α2b). This 
comparison is of special interest because Novartis have discontinued the regulatory approval 
of Albinterferon-α2b. IFN-α2b-DOM7 h-14 showed a longer half-life than HSA-IFN-α2b in 
rats (22.6 h vs. 14.2h). More importantly, the antiviral activity of the albumin-binding IFN-
α2b-DOM7 h-14 was approximately 6-fold greater than HSA-IFN-α2b in a molar comparison 
and the superiority of IFN-α2b-DOM7 h-14 over HSA-IFN-α2b was confirmed in vivo in a 
human melanoma xenograft model (Walker et al., 2010). 
Recently, a novel class of albumin-binding derivatives were isolated using DNA-encoded 
chemical libraries, capable of forming kinetically stable complexes with both HSA and MSA, 
with promising results for half-life extension of small molecules. Dumelin and co-workers 
used 428-d-Lys as a portable albumin binder that shown to improve the in vivo circulatory 
time of agents of pharmaceutical interest by more than 100-fold. 428-d Lys derivatives of 
fluorescein and of metal ion–DTPA (diethylene triamine pentaacetic acid) complexes 
exhibited promising in vivo properties and are likely to represent superior blood-pool contrast 
agents for clinical applications by increasing the measurement time, reducing the 
extravasation, and thereby increasing the contrast (Dumelin et al., 2008). 
The AlbumodTM technology is an example of Affibody® technology that makes use of the 
high affinity of ABDs for HSA and extends the half-life of conjugated biopharmaceuticals. As 
a consequence, the resulting albumin drug complex essentially acquires pharmacokinetic 
properties similar to endogenous albumin and bound cytokines, single-chain antibodies or 
drugs containing the ABD have a significant increased plasma half-life. As an example, 
Affibody bound the granulocyte colony-stimulating factor (G-CSF), a peptide growth factor 
that stimulates the bone marrow to produce granulocytes and stem cells, to their ABD. The 
conjugate of G-CSF and ABD forms a stable complex with albumin and increased the plasma 
half-life by a factor of 10, compared to G-CSF alone, in rats. Recently, the company Algeta 
exclusively licensed two AlbumodTM antibodies labelled with the alpha particle emitter 
thorium-227 for therapeutic targeting HER2 or PDGFRβ expressing tumors (Elsadek and 
Kratz, 2012). 
  A recent interesting development of ABD is to add a new binding specificity to the ABD-
molecules while retaining the native albumin binding capacity. Based on their previous 
mutational analysis of the albumin binding epitope of ABD (Linhult et al., 2002), Hober and 
colleagues randomized 11 amino acid residues that should not interfere with albumin binding 
(Alm et al., 2010). AS scaffold, an in house ABD* that was stabilized to withstand alkaline 
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conditions by replacement of four asparagines in the structure (Gülich et al., 2000) was 
chosen. The library was displayed on bacteriophage and subjected to selections. The initial 
aim was to isolate a dual affinity purification handle for fusion proteins, and the protein A 
derivate, domain Z was chosen as target. Initial binders were characterized and a lead binder 
could be successfully affinity-purified both on HSA sepharose and from crude lysate on the 
commercially available MabSelect Sure matrix containing a modified domain Z and used for 
purification of monoclonal antibodies (Alm et al., 2010). Next, the group investigated the 
approach for creating dual ABD binders intended for therapeutic applications. Using the same 
library, binders were selected against human TNFα (Nilvebrant et al., 2011). First generation 
binders were identified, but although several were bispecific, a relatively high affinity for 
TNFα seemed to limit the affinity for albumin and vice-versa. Thus, a new affinity maturation 
library was designed and a bacterial-based cell display system was used for isolation of 
improved binders. As cell display enables the use of fluorescence-activated cell sorting 
(FACS), selections could be performed against both targets simultaneously by labelling TNFα 
and HSA with different fluorophores and indeed, bispecific binders with high affinity against 
both target could now be isolated. Therefore, ABD can be used not only as a fusion domain 
for extending the plasma half-life of proteins, but can also be used as a target-binding domain 
itself, with intrinsic long half-life. 
 
III.2.2 – Fusion to Ig-binding domains  
Besides the several IgBDs mentioned before in streptococcal cell surface proteins with 
albumin-binding domains (see section III.2.1.3), the most well-studied IgBD from 
Staphylococcus aureus protein A (SpA), was applied as a scaffold to create the Affibody® 
molecules (see section II.2) (Tolmachev et al., 2007).  
Non-covalent interaction with serum IgG might represents a feasible alternative to binding 
serum albumin, as a strategy to extend half-life of therapeutic proteins. IgBDs have a length 
of 50-60 amino-acid residues and form either a three-α-helix bundle or a compact structure 
composed of a four-stranded β-sheet and one-α-helix (Tashiro and Montelione, 1995). The 
primary binding site on IgG is located at the CH2-CH3 interface of the heavy chain 
(Deisenhofer, 1981). Though, most of the bacterial IgDBs from proteins A, G and L are also 
capable of binding to different regions of the Fab fragment (Tashiro and Montelione, 1995).  
In a recent study, the domain B of SpA was fused with the C-terminus of a single-chain 
diabody (scDbCEACD3) to extend the circulation time of the recombinant antibody. The 
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fusion protein retained full antigen-binding activity and was capable to simultaneously bind to 
IgG. The result was a prolonged half-life (11.8 h) compared with the unmodified scDb (1.3 h), 
although it did not reach the half-life seen for IgG, which might be due to competition for 
binding to FcRn (Unverdorben et al., 2012). Recently, an extended serum half-life was also 
shown for a fusion protein (ZZ-PE38) comprising two Z domains and a Pseudomonas 
exotoxin A (ETA) fragment (Mazor et al., 2007). This fusion protein was used to produce a 
large IgG-toxin immunoconjugate by complexation with a chimeric anti-HER2 monoclonal 
antibody in vitro. After i.v. injection into mice, the half-life was extended to 4 h for the 
antibody-ZZ-PE38 complex, compared with 18 min for an scFv-ETA molecule. Another 
study from Kontermann and colleagues compare the half-lives the same antibody fragment 
(scDBCEACD3) and a scFv, both fused with various IgBDs from SpA, SpG and Finelgoldia 
(formely Peptostreptococcus) protein L (PpL). Thus, binding to VH domains belonging to the 
VH3 family was shown for the domain D of SpA, and this site is structurally distinguished 
from its Fc binding site (Graille et al., 2000). Domain C4 from PpL is capable of binding to 
certain subgroups of Vƙ light chain domains (Graille et al., 2002; Åkerström and Björck, 
1989) and domain C3 of SpG has been shown to bind also to the CH1 domain of IgG 
molecules (Derrick and Wigley, 1994). Their results demonstrate that the half-lives in mice 
are prolonged to various extents depending on the applied IgDBs. The longest terminal half-
lives were seen for the fusion proteins containing the C3 of SpG (scDB-SpGC3 t1/2 = 23.3 h 
and scFv-C3 t1/2 = 20.8 h) and domains B (scDB-SpAB t1/2 = 11.8 h and scFv-SpAB = 4.4 h) 
and D (scDB-SpAD t1/2 = 9.0 h and scFv-SpAD = 4.9 h) of SpA (Hutt et al., 2011). These 
findings make these domains, especially the SpGC3, promising modules for half-life extension 
of small-sized therapeutics. 
 
IV - Anti-TNFα VHH as study model 
The application of albumin-binding antibodies has already reached clinical phase II studies 
for the treatment of rheumatoid arthritis (Elsadek and Kratz, 2012). The company Ablynx has 
developed a unique technique in which so-called camelid antibodies, targeting important 
acute and chronic diseases across a broad range of therapeutic areas including haematology, 
neurology, inflammation, pulmonary diseases and oncology.  
In this project we used a single-domain antibody (VHH) against rheumatoid arthritis from 
Ablynx (Silence et al. Patent US2007/0077249 A1), as a proof of concept, to validate the 
efficacy of two albumin-binding domains from cell surface proteins ZAG (Zag ABD) and 
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protein H (ProtH ABD) in the improvement of the pharmacokinetic properties of small 
therapeutic proteins.  
 
IV.1 - Rheumatoid arthritis 
Rheumatoid arthritis (RA) name was introduced in the 1850s, but classification criteria 
were only developed in 1956 (Ropes et al., 1959; Storey et al., 1994; Arnett et al., 1988). RA 
is one of the most frequent chronic inflammatory joint diseases as it affects about 0.5-1% of 
the world’s population. It is characterized by joint pain, swelling and stiffness due to joint 
inflammation and damage, causes disability and lost working capacity, and may cause 
premature death (Caporali et al., 2009). Before the advent of biological drugs, RA was treated 
with non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and disease-modifying 
anti-rheumatic drugs (DMARDs), which methotrexate (MTX) is currently the most widely 
used, alone or in combination with other DMARDs. Other frequently used DMARDs include 
sulphasalazine, hydroxychloroquine and leflunomide (O’Dell, 2004; Atzeni et al., 2013).  
RA has emerged as a prototypic immune-mediated inflammatory disease and is common 
focus of clinical studies of tumour necrosis factor antagonists. This is a chronic disease in 
which inflammation of the synovial tissue results in articular cartilage and bone destruction. 
Parallel advances in research on the pathogenesis of RA and cytokine biology converged on 
TNFα and interleukin-1 as key factors in inflammation and matrix destruction (Arend and 
Dayer, 1990; Saxne et al., 1988). The concept arose that elevated concentrations of TNFα at 
the sites of inflammation were driving disease pathology, and the removal of excess TNFα 
from sites of inflammation became a therapeutic goal (Knight et al., 1993; Brennan et al., 
1989). TNFα plays a role in lymphoid tissue development and have a homeostatic role in host 
defense against some bacterial infections and initiates the defense response to local injury. At 
low concentrations in tissues, is thought that TNFα has beneficial effects, such as the 
augmentation of host defense mechanisms against infections. At high concentrations, TNFα 
can lead to excess inflammation and organ injury (Tracey et al., 2008).  
TNFα biology presents a network of ligands, receptors and signaling pathways with several 
layers of complexity. Many immune and non-immune cells types can produce TNFα 
including macrophages, T cells, mast cells, granulocytes, natural killer (NK) cells, fibroblasts, 
neurons, keratinocytes and smooth muscle cells. First, TNFα is released from cells as a 
soluble cytokine (sTNF, a homotrimer of 17 kDa monomers) after being enzymatically 
cleaved from its cell-surface-bound precursor (tmTNF, a homotrimer of 26 kDa monomers) 
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by TNFα-converting enzyme (TACE). TNFα acts via two distinct receptors – TNF receptor 1 
(TNFR1) (p55, CD120a) and TNFR2 (p75, CD120b) – on a wide variety of cell types to 
mediate their biologic functions. Although, its affinity for TNFR2 is five times higher than its 
affinity for TNFR1. Both TNFR1 and TNFR2 are membrane glycoproteins that specifically 
bind TNFα and lymphotoxin α3 (LTα3), but they differ in their cellular expression profiles, 
affinities for ligands, cytoplasmic tail structures and signaling mechanisms. TNFR1 is 
constitutively expressed on virtually all cell types except erythrocytes, whereas TNFR2 is 
generally inducible and is preferentially expressed on endothelial and hematopoietic cells 
(Atzeni et al., 2013; Tracey et al., 2008).  
The biology of TNFα has been extensively studied, particularly with regard to its many 
activities when expressed at high concentrations in the context of inflammation and disease. 
TNFα is a pleiotropic cytokine, in that it mediates a wide variety of biologic activities. Some 
activities of TNFα are common to several diseases, such as those that modulate cell 
recruitment, cell proliferation, cell death and immune regulation (Schottelius et al., 2004; 
Feldmann, 2002). Other biologic activities of TNFα may be restricted to certain diseases, such 
as matrix degradation and osteoclastogenesis in RA or granuloma formation in Crohn’s 
disease. TNFα also plays an important role in the regulation of a cascade of pathogenic events 
in psoriasis and other diseases, exemplified by the rapid induction of cytokines, such as IL-1 
and IL-6, and the induction of acute-phase proteins, such as C-reactive protein (CRP) 
(Feldmann, 2002).   
In patients with RA, the synovial membrane lining the joint space becomes inflamed as a 
consequence of increased vascularity and influx of inflammatory cells. Similar histopathology 
is seen in murine collagen-induced arthritis, for which TNFα was observed within the intimal 
lining layer and synovial sublining at all stages of disease (Mussener et al., 1997). The 
staining of TNFα was particularly intense at the invasive front, the cartilage-pannus junction 
(Choy and Panayi, 2001). The hypothesis that TNFα drives much of the pathophysiology in a 
rheumatoid joint is supported by studies of TNFα overexpression or TNFα neutralization in 
animal models of RA (Klareskog and McDevitt, 1999; Butler et al., 1997). Many of the TNFα 
neutralization studies in mouse models of RA demonstrated amelioration of clinical disease 
similar to that seen in studies of TNFα antagonists in patients with RA, showing apparent 
differences in the impact on bone erosion. For instance, TNFα blockade in human TNFα-
transgenic mice suppressed joint destruction more than synovial inflammation (Zwerina et al., 
2004). Other studies of TNFα blockade in rat models of arthritis have also demonstrated 
significant suppression of cartilage and bone erosion (Bendele et al., 2000).   
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Understanding the role of TNFα in the pathogenesis of RA has been important to the 
development of drugs capable of 
controlling its clinical signs and 
symptoms, and halting its 
radiographic progression. Today, 
there are 5 registered TNF blockers in 
the United States and the European 
Union: Enebrel® (etanercept), 
Remicade® (infliximab), Humira® 
(adalimumab), Simponi® (golimumab) 
and Cimzia® (certolizumab) 
(www.fda.gov; www.ema.europa.eu). 
Pathophysiological role of cytokines 
and other mediators, and their 
inhibitors are illustrated in Fig. 17, 
that also describe the mechanism of 
TNF inhibition of etanercept, 
infliximab and adalimumab. All 
agents except etanercept are anti-TNF 
mAbs or fragments thereof.  
Infliximab, adalimumab and 
golimumab are full-length bivalent 
IgG mAbs, whereas certolizumab is a 
monovalent Fab antibody fragment 
covalently linked to polyethylene 
glycol. Infliximab is a chimeric 
protein containing ~25% mouse-
derived amino acids comprising the 
VH and VL domains and ~75% 
human-derived amino acids 
comprising the CH1 and Fc constant 
regions. Certolizumab is a humanized 
protein containing amino acid 
sequences in the CDR regions derived from a mouse anti-TNF mAb and inserted into human 
Fig. 17 - Pathophysiological role of cytokines, other 
mediators and their inhibitors in RA. In the current model 
of the pathogenesis of RA, an infective agent or other 
stimulus binds to receptors on dendritic cells, activating the 
innate immune system. Dendritic cells migrate into lymph 
nodes, presenting antigen to T cells, which are activated by 
the dual signal of antigen presentation and costimulation 
through CD28. Activated T cells proliferate and migrate into 
the joint. In the synovial tissue, T cells produce interferon-γ 
and other proinflammatory cytokines that stimulate 
macrophages and fibroblasts as well as chondrocytes, 
osteoclasts, and B cells. Activated macrophages and 
fibroblasts release a variety of cytokines, including TNFα. 
TNFα is a central component in the cascade of cytokines, 
stimulating the production of additional inflammatory 
mediators and the further recruitment of immune and 
inflammatory cells into the joint. Infliximab and adalimumab 
are monoclonal anti-TNFα antibodies that bind to TNFα with 
high affinity and prevent it from binding to its receptors. 
Etanercept is a fusion protein consisting of two p75 TNF 
receptors that are linked to the Fc portion of human IgG1. It 
also binds to TNF-α and prevents it from interacting with its 
receptors on cell surfaces (Scott et al., 2006). 
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VH and VL domains frameworks. Adalimumab and golimumab are fully human mAbs. The 
TNFα-antagonist mAbs also differ in their IgG isotypes, the Fc regions of which govern 
effector functions, like complement fixation and Fc receptor-mediated biologic activities. 
Infliximab, adalimumab and golimumab are IgG1 antibodies, which are capable of 
complement fixation and Fc-receptor binding. Certolizumab is a Fab fragment of an IgG1 
mAb and lacks effector functions because it has no Fc region. The hinge of certolizumab is 
modified and covalently linked to two crosslinked chains of a 20 kDa PEG to enhance 
solubility and half-life in vivo (Tracey et al., 2008; Weir et al., 2006). 
Tumour necrosis factor inhibitors and other biological agents have heralded a so-called 
therapeutic revolution, transforming the outlook for patients with rheumatoid arthritis (Scott 
et al., 2010). 
 
IV.2 - Ablynx VHH technology for treating rheumatoid arthritis and cancer 
Ablynx camelid antibodies comprise heavy-chain antibody fragments containing a single 
variable domain (VHH) and two constant domains (CH2 and CH3). The VHH domains 
combine high target specificity and affinity for their antigen target with low viscosity as 
compared to single-chain antibodies and ease of manufacturing in humanized variants in 
camels and llamas or meanwhile in eukaryocytes such as bacteria or yeasts (Muyldermans, 
2013; Freken et al., 2000; Freken et al., 1998), forming the basis of a new generation of 
therapeutic antibodies which Ablynx has named nanobodies.  
Using such camelid antibodies, murine trivalent antibodies were constructed with one 
molecule that bind human serum albumin and the other, two molecules target murine or 
human TNFα (Coppieters et al., 2006). In a collagen-induced arthritis model, a trivalent 
bispecific antibody MT1-MT1-AR1 (MT1 = anti-mouse TNFα nanobody, AR1 = albumin-
binding nanobody) demonstrated a convincing proof of concept (Fig. 18), and its efficacy 
exceeded that of the clinically used anti-TNFα antibody Enebrel® (Coppieters et al., 2006). 
Additionally, the binding affinity of the MT1-MT1-AR1 for albumin significantly prolonged 
its serum half-life and promoted its targeting to inflamed joints, as evaluated by 99mTc 
labeling and camera imaging, in comparison to the bivalent anti-TNFα nanobody MT1-MT1 
(Fig. 18b). Since albumin is known to accumulate in the inflamed joints in the collagen-
induced arthritis (Wunder et al., 2003) as well as the clinically used Nanocoll®, an albumin 
99mTc-labeled microparticle, this very likely explains the excellent therapeutic efficacy 
observed in vivo (Elsadek and Kratz, 2012). In parallel development, Ablynx had developed 
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an analogous trivalent antibody TR2-TR2-AR1 (MW ~45 kDa) that was directed against 
human TNFα. This trivalent molecule, named ATN-103, was developed for clinical 
evaluation, and in phase I studies showed good tolerability. Subsequently, AT-103 (now 
named Ozoralizumab) was licensed to Pfizer who have completed the recruitment of two 
phase II studies in 48 patients in Japan and the USA, with subcutaneous administration of 
Ozoralizumab every 4 weeks for 16 weeks in patients with rheumatoid arthritis, and have an 
open label extension of phase II study in 260 patients with rheumatoid arthritis ongoing to 
ensure long term safety of the novel albumin-binding nanobody (Kratz and Elsadek, 2012). 
Ozorolizumab addressed an extremely large market (US$ 16.9 billion for all TNFα 
inhibitors in 2008) and could have substantial advantages over three conventional and only 
partially humanized antibodies Remicade®, Enebrel® and Humira®, due to ease of 
manufacturing and reduced cost. This molecule also presents a better efficacy due to an 
albumin-mediated targeting to inflamed joints and a reduction of side effects compared to the 
currently approved 
antibodies.  That can 
include serious and 
sometimes fatal blood 
disorders, serious 
infections, lymphoma 
and solid tissue cancers, 
reports of serious liver 
injury, reactivation of 
hepatitis B, reactivation 
of tuberculosis, drug-
induced lupus, and 
demyelinating central 
nervous system 
disorders (Elsadek and 
Kratz, 2012). 
The advent of Ablynx 
nanobody technology using albumin-binding nanobodies has also been successfully explored 
for tumour targeting (Cortez-Retamozo et al., 2002: Cortez-Retamozo et al., 2004; Tijink et 
al., 2008). For example, to improve the pharmacokinetic properties of an anti-EGFR 
nanobody, a trivalent, bispecific nanobody construct was developed, which binds with two 
Fig. 18 - Therapeutic effects of Enebrel® (100 μg), the anti-TNF-α 
bivalent antibody MT1-MT1 (100 μg) and the anti-TNF-α trivalent 
antibody MT1-MT1-AR1 (100 μg) containing the albumin-binding domain 
AR1 in the collagen-induced arthritis model (9 mice per group). 
BOTTOM: Scintigraphic images comparing 99mTc-labeled MT1-MT1 and 
MT1-MT1-AR1 after 4 h and 24 h (left) and accumulation of MT1-MT1-
AR1 in the inflamed paws after 4 h and 24 h (right) (Elsadek and Kratz, 
2012). 
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arms to EGFR and with one arm to mouse serum albumin (Roovers et al., 2007). These 
nanobodies, due to its small size of only 15 kDa, are rapidly cleared from the circulation 
through the kidney, with a half-life of approximately 1.5 hours in mice. The trivalent fusion 
protein (molecular mass 50 kDa) exhibited an increased half-life of 44 hours in mice and 
improved tumour uptake (Tijink et al., 2008). Interestingly, faster and deeper tumour 
penetration was described for this bi-functional nanobody molecule compared with the anti-
EGFR antibody cetuximab. 
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OBJECTIVES 
 
 
Recombinant antibody fragments and single-domain antibodies are a promising class of 
biopharmaceuticals with very high potential in future therapeutic applications. However, 
owing to their low molecular weight (< 60kDa) they usually have short half-life’s ranging 
from a few minutes to a few hours. Consequently, high doses and repeated administration are 
necessary to maintain their therapeutic activity. As a result, there is a pressing need to identify 
and develop new strategies to enhance the in vivo circulating half-life of these molecules. 
Over the recent years, plasma protein binding has been shown as an effective approach to 
improve pharmacokinetic properties. Within this context, the aim of this research project is to 
explore the albumin binding approach to enhance the circulating half-life of small protein-
based fusion biodrugs.  
To achieve this goal, we will develop and compare two strategies based on protein fusions 
with albumin-binding domains (ABDs) from streptococcal cell surface proteins. These two 
new ABDs will be the Zag and protein H (ProtH) derived from Streptococcus zooepidemicus 
and Streptococcus pyogenes, respectively. To validate our ABDs half-life strategy and as a 
proof-of-concept, the Zag and ProtH domains will be fused with an anti-TNFα VHH single-
domain antibody. This anti-TNFα VHH is a well-studied molecule with promising results for 
treatment of rheumatoid arthritis that is being developed by the Belgium Company Ablynx 
(Silence et al. Patent US2007/0077249 A1). 
Therefore, the goals defined to be achieved are the following: 
1) Construction and engineering of Zag and ProtH ABDs fusions with the anti-TNFα 
VHH; 
2) Optimize the expression and purification conditions of Zag, ProtH, VHH and the 
fusion recombinant proteins, VHH-Zag and VHH-ProtH;  
3) Characterization of the fusion proteins properties: albumin and human TNFα bindings, 
thermal stability and human and mouse serum stability; 
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4) Evaluate the efficacy of the fusion proteins; 
5) Determine and compare the pharmacokinetics and biodistribution of both strategies;  
6) Study and characterization of the ProtH and Zag ABDs three-dimensional structure. 
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ALBUMIN-BINDING	DOMAIN	(ZAG)	FROM	
STREPTOCOCCUS	ZOOEPIDEMICUS	AS	A	
STRATEGY	TO	IMPROVE	HALF-LIFE	OF	
THERAPEUTIC	PROTEINS 
 
 
 
 
Brief Introduction 
Streptococcal albumin-binding domains have been successfully explored as fusion proteins 
to improve the pharmacokinetic properties of therapeutic proteins (Kontermann, 2012). 
ZAG is a protein G-related cell-surface protein from S. zooepidemicus, with an Ig-binding 
region located in the C-terminus and an ABD composed by 52 amino acids (Jonsson et al., 
1994).  
In this study we fused protein ZAG ABD (Zag) with a nanobody against TNFα from 
Ablynx, used as a proof of concept to validate our strategy to increase half-life of therapeutic 
proteins. Firstly, we intend to optimize the production of the recombinant proteins (VHH and 
VHH-ProtH) in E.coli, an easy way to obtain high amounts of protein with lower costs. Then 
we characterize the antigen and albumin binding of the Zag fusion protein and compare the 
therapeutic efficacy of the VHH-Zag with the unmodified antibody. We also evaluate the 
thermal stability and in vitro and in vivo serum stabilities of the both proteins. Finally, we 
determine the initial and terminal half-lives of VHH and VHH-Zag and the organ 
biodistribution profiles of both proteins, using 99mTc radiolabelling. 
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Background: Half-life extension is a key feature to improve pharmacokinetics of therapeutic low 
molecular weight proteins and peptides.  
Results: Fusion of streptococcal Zag albumin-binding domain (ABD) to a single-domain antibody 
(nanobody) resulted in an improvement in pharmacokinetic properties leading to a significant increase 
in circulation time in vivo.  
Conclusions: The Zag ABD fusion can be successfully applied to improve the pharmacokinetics of 
short half-life therapeutic molecules. 
Significance: This work demonstrates the potential of a new approach to increase the half-life 
of therapeutic proteins by using the ZAG albumin-binding domain from Streptococcus 
zooepidemicus. 
 
ABSTRACT 
Recombinant antibody fragments and single-domain antibodies are a promising class of 
biopharmaceuticals with very high potential in future therapeutic applications. However, due 
to their small size are rapidly cleared from circulation. Plasma protein binding can be an 
effective approach to improve pharmacokinetic properties of short half-life molecules. Aimed 
at improving the pharmacokinetic properties of therapeutic proteins, we propose herein a 
bacterial albumin-binding domain (Zag) derived from Streptococcus zooepidemicus. To 
validate our approach and as a proof of concept, the Zag ABD was fused with an anti-TNFα 
VHH single-domain antibody. Our results shown that the VHH-Zag fusion recombinant 
protein could be stably expressed in the soluble format in Escherichia coli and, specifically 
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recognize TNFα and serum albumins (human, rat and mouse). Moreover, data also 
demonstrated that VHH activity against the therapeutic target was not affected when fused 
with Zag ABD. Importantly, Zag ABD strongly increased the half-life of the VHH in 39-fold 
(47 min for VHH versus 31 hours for VHH-Zag) and the residence in mouse serum (2 hours 
for VHH versus 72 hours for VHH-Zag). The prolonged circulation time also lead to a 
reduction of the VHH-Zag in kidneys and an increase of the presence of the fusion VHH in 
blood and other organs, e.g. liver, intestine, muscle and lungs. These findings demonstrate that 
the Zag ABD fusion strategy is a promising approach to increase the half-life of therapeutic 
proteins, without affecting their therapeutic efficacy.  
  
INTRODUCTION 
Recombinant antibody fragments and single-domain antibodies have been under 
investigation and development with promising results for clinical applications. However, 
owing to their low molecular weight (< 60kDa) they usually have short half-life’s ranging 
from a few minutes to a few hours. Consequently, high doses and repeated administration are 
necessary to maintain their therapeutic activity1. Within this context, in the past decade 
several efforts have been undertaken towards the development and implementation of half-life 
extension strategies to prolong the circulation time of these molecules and consequently 
improve their pharmacokinetic properties and therapeutic potential2. Some of these strategies 
have focused on increasing hydrodynamic volume, e.g. PEGylation and glycosylation1,2. For 
instance, PEGylation has been successfully applied to prolong the half-life of several 
recombinant antibodies and antibody fragments for clinical use3. Although this approach is an 
industry-established method, several studies also indicate that PEGylation can lead to reduce 
antigen binding and bioactivity2,4. As an alternative, other half-life extension approaches are 
based on implementing FcRn-mediated recycling, responsible for the long half-life of the 
human plasma proteins albumin (~19 days) and immunoglobulin G (~21 days)1,2. These new 
strategies to improve pharmacokinetic disposition of small therapeutic proteins are focused on 
fusion to the Fc region, on binding to or fusion with long-circulating serum plasma proteins 
such as albumin, or on fusion with albumin-binding domains and peptides, or 
immunoglobulin-binding domains1,2,5. Dennis and colleagues developed a strategy based on 
the fusion of an albumin-binding peptide, using peptide phage display to develop peptides 
with high affinity to albumin. One of the selected albumin-binding peptides was added to a 
Fab antibody fragment, by recombinant fusion, with an increase in half-life of 26-fold to   
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10.4 h in mice6. Moreover, fusion to the albumin-binding domain 3 (ABD3) from protein G of 
Streptococcus strain G148 has been extensively studied and several in vivo studies have 
demonstrated significant improvement of the plasma half-life and pharmacokinetic properties 
of therapeutic proteins1,5-8. Jonsson and co-workers have described a plasma protein receptor, 
a protein-G related cell surface protein from Streptococcus zooepidemicus, termed protein 
ZAG, a 45 kDa protein that binds α2-macroglobulin, serum albumin and immunoglobulin G 
(IgG). The IgG-binding domains from ZAG are homologous to the IgG-binding domains in 
protein G and to the corresponding domains in proteins MIG and MAG from Streptococcus 
dysgalactiae9. Protein ZAG shows an albumin-binding profile similar to those of protein G10 
and the albumin-binding DG12 protein from a bovine group G streptococcus11. In the N-
terminus, ZAG protein presents a 52 amino acid sequence (Zag ABD) with binding to human, 
rat, mouse, horse and dog serum albumin. Downstream from this region there are two 70-
amino-acid repeats homologous to the IgG-binding domains of type III Fc receptors9. 
In the present study, we used the Zag ABD as a new approach for extension of the 
circulation time of therapeutic proteins. To validate our strategy and as a proof-of-concept, the 
Zag ABD was fused with an anti-TNFα VHH single-domain antibody. The fusion protein 
showed specific binding to serum albumin and compared with the parental VHH nanobody, 
exhibited a strong increase of serum half-life in mice to approximately 39-fold. These results 
demonstrate, for the first time, the ability of this new streptococcal ABD to improve 
pharmacokinetic disposition of therapeutic proteins.  
 
EXPERIMENTAL PROCEDURES 
Materials – Human serum albumin (HSA) (catalog no. A3782), rat serum albumin (RSA) 
(catalog no. A6272), mouse serum albumin (MSA) (catalog no. A3139), human (catalog no. 
H4522) and mouse serum (catalog no. H5905), and pT7-FLAG2 expression vector were 
purchased from Sigma-Aldrich (USA). HRP-conjugated anti-His-tag, HRP-conjugated anti-
HA-tag, anti-HA affinity matrix, 2,2'-Azino-di-[3-ethylbenzthiazoline sulfonate (6)] 
diammonium salt (ABTS), tetrazolium salt WST-1 and cOmplete EDTA-free protease 
inhibitors cocktail were acquired from Roche (Germany). Recombinant human TNFα and 
Amicon centrifugal filter units were purchase from Millipore (USA). PD-10 columns and G25 
Sephadex were purchase from GE Healthcare (UK) and Sigma-Aldrich, respectively. 
Radioactivity measurements were done on a dose calibrator (Aloka Curiemeter, IGC-3, Japan) 
or on a gamma-counter (Berthold LB 2111, Germany). 
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Cloning of recombinant proteins – DNA encoding anti-TNFα VHH#3E clone (Silence et al. 
Patent US2007/0077249 A1)12 was synthesized by Nzytech adding a SfiI restriction site at 5’ 
and 3’ ends, respectively, for cloning into the pComb3x plasmid13. pComb3X contains a 
leader peptide sequence ompA (LP) and sequences encoding peptide tags for purification 
(His7) and detection (HA). A fragment encoding the LP-VHH-His-HA was amplified by PCR 
with primers HindIII-LP-SfiI-F (5’-CCC AAG CTT ATG AAA AAG ACA GCT ATC GCG 
ATT GCA GTG GCA CTG GCT GGT TTC GCT ACC GTG GCC CAG GCG GCC-3’)  and 
His-HA-KpnI-R (5’-CGG GGT ACC CCG CTA AGA AGC GTA GTC CGG AAC GTC 
GTA CGG GTA TGC GCC ATG GTG ATG GTG ATG GTG ATG GTG GCT GCC TCC-
3’) and subcloned into the expression vector pT7-FLAG2 (Sigma) into the HindIII and KpnI 
restriction sites. To construct the VHH-Zag fusion protein, a DNA fragment comprising the 
entire Zag albumin-binding domain of S. zooepidemicus9 was generated by PCR with primers 
Zag-1 (5’-GAC ATT ACA GGA GCA GCC TTG TTG GAG GCT AAA GAA GCT GCT 
ATC AAT GAA CTA AAG CAG TAT GGC ATT AGT GAT TAC TAT GTG ACC TTA 
ATC-3’) and Zag-2 (5’-GTA TGG CAT TAG TGA TTA CTA TGT GAC CTT AAT CAA 
CAA AGC CAA AAC TGT TGA AGG TGT CAA TGC GCT TAA GGC AGA GAT TTT 
ATC AGC TCT ACC G-3’), adding SpeI and NcoI restriction sites at the fragment 5’ and 3’ 
ends, respectively. The resulting PCR fragments were gel-purified, digested with the SpeI and 
NcoI restriction enzymes and cloned into the appropriately cut pT7-VHH vector. A short GS 
linker (SGGGGS) was used to link the VHH and Zag ABD. VHH and VHH-Zag constructs 
were verified by sequencing. 
Expression and purification of proteins – VHH and VHH-Zag were expressed in E. coli strain 
BL21(DE3). One liter of LB, containing 100 µg/ml ampicillin was  inoculated with 10 ml of 
overnight culture of bacterial cells transformed with the plasmids pT7-VHH and pT7-VHH-
Zag and grown to exponential phase (A600 = 0.6-0.9) at 37 ºC. Expression was induced by the 
addition of 1 mM isopropyl β-ᴅ-1-thiogalactopyranoside (IPTG) and growth during 16 h at 18 
ºC. Cells were harvested by centrifugation (4000  g for 15 min at 4 ºC) and resuspended in 
50 ml equilibration buffer (50 mM HEPES, 1 M NaCl, 5 mM CaCl2, 30 mM imidazole, pH 
7.5) supplemented with protease inhibitors. Cells were lysed by sonication. Centrifugation 
(14000  g for 30 min at 4 ºC) was used to remove cell debris, and the supernatant was 
filtered through a 0.2 µm syringe filter. The VHH and VHH-Zag were purified using AKTA 
FPLC System (GE Healthcare) by nickel chelate affinity chromatography with HisTrap HP 
columns. After a washing step (50 mM HEPES, 1 M NaCl, 5 mM CaCl2, 60 mM imidazole, 
53 
 
pH 7.5) the recombinant antibody fragments were eluted with a linear imidazole gradient 
from 60 to 300 mM in 50 mM HEPES, 1 M NaCl, 5 mM CaCl2, pH 7.5. Protein fractions 
were pooled, then desalted and concentrated in 50 mM HEPES, 100 mM NaCl, 5 mM CaCl2, 
pH 7.5 using Amicon 10K (Millipore). The samples were loaded onto a HiPrep 16/60 
Sephacryl S-100 HR gel filtration column (GE Healthcare), fractions were pooled and protein 
purity was analyzed by SDS-PAGE. Protein concentration was determined 
spectrophotometrically in Nanodrop ND-1000 at 280 nm and calculated using the calculated ε 
value of each protein (εVHH = 34380 L mol−1 cm−1; εVHH-Zag = 38850 L mol−1 cm−1). 
Size Exclusion Chromatography – Apparent molecular weight of recombinant antibody and 
formation of antibody/albumin complexes was determined by FPLC-SEC on a HiLoad 
Superdex 200 HR column (GE Healthcare) with a flow rate of 0.7 ml/min and PBS1x as 
running buffer at 4 ºC. The following standard proteins were used: apoferritin (443 kDa, RS 
6.1 nm), β-amylase (200 kDa, RS 5.4 nm), alcohol dehydrogenase (150 kDa, RS 4.55 nm), 
bovine serum albumin (67 kDa, RS 3.55 nm), ovalbumin (45 kDa, RS 3.05), myoglobin (17.6 
kDa, RS 1.91 nm), ribonuclease A (13.7 kDa, RS 1.64 nm) and cytochrome c (12.4 kDa, RS 
1.77 nm). Blue dextran and L-tyrosine were used to determine the void and total column 
volume, respectively. Elution volume of the protein standard was used to create a standard 
curve of Stokes’ radius (RS) versus (-log Kav)1/2 that was used to calculate the Stokes radius of 
recombinant antibody and antibody/albumin complexes. Complex formation of VHH-Zag 
with HSA and MSA was analyzed by incubating equimolar amounts of VHH-Zag and 
albumin (10 M) in PBS1x at room temperature and subsequent analysis by SEC. SDS-PAGE 
analysis of collected samples was performed to evaluate albumin binding. 
ELISA – Binding properties of VHH and VHH-Zag fusion proteins were determine in 96-well 
coated with HSA, RSA, MSA (10 µg/well) and human TNFα (200 ng/well) overnight at 4 ºC. 
After 1 h blocking with 5% soya milk, purified recombinant antibodies and serum samples 
were titrated in triplicate and incubated for 1 h at room temperature. Human TNFα binding 
was evaluated in the presence and absence of HSA (1 mg/ml). Detection was performed with 
HRP-conjugated anti-HA-tag antibody using ABTS substrate. Absorbance was measured at 
405 nm in an ELISA reader. GraphPad Prism Software version 5 was used for data analysis. 
Affinity measurements – The binding affinities between VHH-Zag and HSA, RSA and MSA 
were obtained using surface plasmon resonance (SPR) (BIAcore 2000, BIAcore Inc.) Human, 
rat and mouse albumins were captured on a CM5 chip using amine coupling at ~1000 
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resonance units. VHH-Zag fusion protein at 0, 10, 50, 100, 200, 300, 400 and 500 nM were 
injected for 4 min. The bound protein was allowed to dissociate for 10 min before matrix 
regeneration using 10 mM glycine, pH 1.5. The signal from an injection passing over an 
uncoupled cell was subtracted from that of an immobilized cell to generate sensograms of the 
amount of protein bound as function of time. The running buffer, HBS was used for all 
sample dilutions. BIAcore kinetic evaluation software (version 3.1) was used to determinate 
KD from association and dissociation rates using a one-to-one binding model. VHH was used 
as a control. 
Neutralization of TNF-dependent cytolytic activity – In order to measure the anti-TNFα VHH 
and VHH-Zag blocking effect on TNFα/TNFR (TNF receptor) interaction, a murine 
aneuploidy fibrosarcoma cell line (L929) was used as a cytotoxic-mediated assay. Briefly, 
L929 cells were grow to 90% confluence in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal bovine serum, penicillin (100 units/ml), streptomycin sulfate 
(10 μg/ml), and L-glutamine (2 mM). Cells were plated in 96-well plates at density of 25,000 
cell/well and then incubated overnight. Serial dilutions of anti-TNFα antibody fragments were 
mixed with a cytotoxic concentration of TNFα (final assay concentration 1 ng/ml) or in 
absence of this cytokine in order to measure the cell viability. Actinomycin D was added to a 
final concentration of 1 μg/ml to increase the cell sensitivity. After at least 2 h of incubation at 
37 ºC with shaking, the mixture was added to the plated cells. Cells were incubated for 24 h at 
37 ºC in an atmosphere of 5% CO2. Cell viability was determined using the tetrazolium salt 
WST-1 (10 μg/well) from Roche, after at least 30 min of incubation by measuring the 
absorbance at 450 nm. GraphPad Prism Software version 5 was used for data analysis. 
Protein thermal stability and in vitro serum stability – Melting temperatures of the studied 
proteins were determined using the Protein Thermal Shift Kit and 7500 Fast Real-Time PCR 
System (Applied Biosystems) according manufacturer’s instructions. Protein samples (5 
µg/well) were tested in MicroAmpTM Fast Optical 96-well Reaction Plates and analyzed in 
quadruplicate using and diluted in 50 mM HEPES, 100 mM NaCl, 5 mM CaCl2, pH 7.5,  and 
Protein Thermal ShiftTM Dye 1x. Collected data were analyzed with Protein Thermal Shift 
Software version 1.1. 
 To evaluate mouse and human serum stability of recombinant antibodies, VHH and 
VHH-Zag were incubated at a concentration of 10 µg/ml for up to 4 days and 24 days, 
respectively, at 37 ºC. The in vitro stability of VHH and VHH-Zag in the human and mouse 
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serum was evaluated by ELISA and Western Blot using HRP-conjugated anti-His-tag 
antibody as described above. 
Pharmacokinetics – Animal care and all pharmacokinetic (PK) studies were conducted 
according to guidelines for animal care and ethics for animal experiments outlined in the 
National and European Law. CD-1 mice (Charles River, female, 6-8 weeks, 25-30g weight 
(n=2) were administered with intravenous injections in the tail vein with 25 µg of VHH and 
VHH-Zag. Plasma samples were obtained from injected animals at regular intervals of 5, 30, 
60, 120, and 360 min, 24, 48 and 72 hours, and fused or unfused recombinant antibody were 
quantified by ELISA. Briefly, human TNFα was immobilized in 384 well-plates (100 ng/well) 
overnight at 4 ºC. After 1 h blocking with PIERCE blocking, mouse serum samples were 
titrated in duplicates and incubated for 1 h at RT. Detection was performed with HRP-
conjugated anti-HA antibody using ABTS substrate. Absorbance was measured at 405 nm in 
an ELISA reader. As described by Stork and co-workers, determined serum concentrations of 
TNFα-binding proteins were interpolated to the corresponding calibration curves. For 
comparison, the first time point (5 min) was set to 100%. Pharmacokinetic parameters area 
under the curve (AUC), t1/2α and t1/2β were calculated with Excel, using the first three time 
points to calculate t1/2α and the last three time points to calculate t1/2β.   
Radiolabelling of 99mTc(CO)3-VHH and 99mTc(CO)3-VHH-Zag proteins – Na[99mTcO4] was 
eluted from a 99Mo/99mTc generator. The radioactive precursor fac-[99mTc(CO)3(H2O)3]+ was 
prepared using a IsoLink® kit (Covidien) and its radiochemical purity checked by RP-HPLC 
and ITLC-SG. The radiolabeled proteins fac-[99mTc(CO)3]-VHH and fac-[99mTc(CO)3]-VHH-
Zag were obtained by reacting the recombinant antibodies with fac-[99mTc(CO)3(H2O)3]+. 
Briefly, a specific volume of the  fac-[99mTc(CO)3(H2O)3]+ solution was added to a  nitrogen-
purged closed glass vial containing a solution of  the His-tag containing proteins VHH or 
VHH-Zag in order to get a final concentration of 1 mg/ml. The mixture reacted for 3 hours at 
37 ºC and the radiochemical purity of fac-[99mTc(CO)3]-VHH and fac-[99mTc(CO)3]-VHH-
Zag was checked by ITLC-SG (Varian) analysis every hour using a 5% HCl (6 M) solution in 
MeOH as eluent. [99mTc(CO)3(H2O)3]+ and [TcO4]- migrate in the front of the solvent (Rf = 
1), whereas  the radioactive antibodies remain at the origin (Rf = 0).  Radioactivity 
distribution on the ITLC-SG strips was detected by a radioactive scanner (Berthold LB 2723, 
Germany) equipped with 20 mm diameter NaI(Tl) scintillation crystal. Radioactivity 
measurements were done on a dose calibrator (Aloka Curiemeter, IGC-3, Japan) or on a 
gamma-counter (Berthold LB 2111, Germany). Purification of the 99mTc-radiolabeled 
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antibodies was performed by gel filtration through Shepadex G-25 or PD-10 column, using 20 
nM sodium chloride solution as eluent. After radioactive decay (10 half-lifes), the VHH and 
VHH-Zag proteins were tested by ELISA to ensure that their binding capacities were 
unaffected (data not shown).  
Partition coefficient – Partition coefficient was evaluated by the “shake-flask” method. The 
radioactive antibodies were added to a mixture of octanol (1 ml) and 0.1 M PBS1x pH 7.4 (1 
m), which has been previously saturated with each other by stirring. This mixture was 
vortexed and centrifuged (3000 rpm, 10 min) to allow phase separation. Aliquots of both 
octanol and PBS1x were counted in a γ-counter. The partition coefficient (Po/w) was 
calculated by dividing the counts in the octanol phase by those in the buffer, and the results 
were expressed as log Po/w±SD. 
Biodistribution studies of 99mTc(CO)3-VHH and 99mTc(CO)3-VHH-Zag – In vivo evaluation 
studies of radiolabelled VHH and VHH-Zag were performed in healthy female CD-1 Charles 
River, 6-8 weeks, 25-30g weight (n=3)  mice at 5 min, 30 min, 1 h, 4 h and 24 h. All animal 
experiments were performed in accordance with the guidelines for animal care and ethics for 
animal experiments outlined in the National and European Law. Animals were intravenously 
injected into the tail vein with 100 μl of the radiolabeled compounds (2.6–3.7 GBq). Mice 
were sacrificed by cervical dislocation at 5 min, 30 min, 1 h, 4 h and 24 h after injection. The 
dose administered and the radioactivity in the sacrificed animals was measured using a dose 
calibrator. The difference between the radioactivity in the injected and that in the killed 
animals was assumed to be due to excretion. Tissues of interest were dissected, rinsed to 
remove excess blood, weighed, and their radioactivity was measured. The total activity uptake 
for blood, bone, muscle, was estimated assuming that these organs constitute 6, 10, and 40% 
of the total body weight, respectively. Blood and urine was also collected at the sacrifice time 
and analyzed by ITLC.    
 
RESULTS 
Expression and purification of VHH and VHH-Zag  
The VHH-Zag construct was generated by fusing the Zag ABD from ZAG streptococcal 
surface protein to the anti-TNFα VHH#3E (Silence et al. Patent US2007/0077249 A1)12  
clone, including histidine (His6) and HA tags in C-terminal (Fig. 1A and 1B).  The fusion 
protein obtained presents 235 amino acid residues with a calculated molecular weight of 
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~25.2 kDa. The VHH was also constructed as described in the material and methods section 
and used as control. VHH and VHH-Zag were expressed in E. coli BL21 (DE3) and purified 
by IMAC and gel filtration. SDS-PAGE and Western Blot results showed a single protein 
band with the expected molecular weights for VHH and VHH-Zag under reducing and non-
reducing conditions (Fig. 1C and 1D). After expression and purification of one liter of culture 
we obtain 20-25 mg of VHH-Zag comparing with 15-20 mg for the VHH. 
Binding activity of VHH-Zag against TNFα 
After purification, the VHH-Zag binding activity to human TNFα was tested in an ELISA 
assay as described in the material and methods section. The VHH was used as control and as 
shown in figures 2A and 2B, both proteins specifically bound to TNFα.  Importantly, binding 
of VHH-Zag to TNFα was not affected by the presence of HSA (without HSA EC50 = 0.130 
nM; with HSA EC50 = 0.118 nM) and was similar with the binding of the parental VHH 
nanobody (without HSA EC50 = 0.100 nM; with HSA EC50 = 0.132 nM). Thus, the antigen-
binding sites in VHH-Zag are accessible for TNFα binding and the presence of albumin does 
not interfere with antigen targeting.  
Binding activity of VHH-Zag to albumins 
In order to determine the in vitro relative binding activities of the VHH-Zag fusion protein 
to human, rat and mouse albumins, an ELISA was performed at neutral (pH 7.0) and acidic 
environment (pH 6.0) (Material and Methods section). As shown in figures 3A and 3B, the 
Zag fusion recombinant protein specifically bound to human, rat and mouse albumins. 
Moreover, binding of VHH-Zag to albumins at pH 6.0 (Table 1) was slightly increased (EC50 
(HSA) = 0.324 nM; EC50 (RSA) = 0.377 nM; EC50 (MSA) = 0.175 nM) compared with binding at 
pH 7.4 (EC50 (HSA) = 1.074 nM; EC50 (RSA) = 1.698 nM; EC50 (MSA) = 4.354 nM) (Fig. 3). After 
albumin binding confirmation, Biacore analysis was performed to evaluate affinities behavior 
and parameters of the Zag fusion protein. Affinities of VHH-Zag for human, rat and mouse 
albumin were in the lower nanomolar range (Fig. 4), showing a higher affinity for HSA and 
RSA at neutral pH, with KD of 4.57 nM and KD of 0.42 nM, respectively, then for MSA, with 
a KD of 40.6 nM (Table 2). Affinities were also measured at acid pH and similar results were 
obtained (data not shown).    
Size exclusion chromatography (SEC) analysis was also performed to analyze the 
interaction between VHH-Zag and human and mouse serum albumin in solution (Fig. 5 and 
Table 3). VHH-Zag eluted with a predominant peak (65%) corresponding to an apparent 
molecular mass of 26.4 kDa (RS 2.59 nm) (Fig. 5A and Table 3). HSA revealed a major peak 
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(93%) corresponding to the monomeric form with an apparent molecular mass of 68.1 kDa 
(RS 3.67 nm) and minor peak (7%) of 163 kDa (Fig. 5B). Incubation of equimolar 
concentrations of VHH-Zag and HSA shifted the HSA peaks to higher apparent molecular 
masses, 230.5 kDa (28%) and 101.2 kDa (50%), the later corresponding to a stoichiometry of 
1:1 of the complex VHH−Zag/monomeric HSA (RS 4.16 nm). The unbound VHH-Zag 
corresponded to ~17%. Similar results were obtained for the MSA. However, MSA showed 
higher molecular mass forms than the human counterpart (Fig. 5D) and a major peak (40%; 
monomeric form) with an apparent molecular mass of 64.3 kDa (RS 3.60 nm). Incubation of 
MSA with VHH-Zag resulted in the shift of the monomeric MSA to 98.6 kDa (RS 4.01 nm; 26 
%). Unbound VHH-Zag was slighter higher when compared with human albumin (36%).  
Thermal stability and in vitro serum stability 
The thermal stability of VHH and VHH-Zag was calculated using the Protein Thermal 
Shift Kit and Protein Thermal Shift Software. The results obtained showed melting 
temperatures (Tm) of 71.53 to 72.34 ºC for VHH and 69.77 to 70.24 ºC for VHH-Zag (Table 
4). These results demonstrate that both proteins have similar Tm and are highly stable. 
Moreover, these data showed that the fusion of the ZagABD to the anti-TNFα nanobody did 
not affect its stability. In vitro serum stability was analyzed by incubation VHH and VHH-
Zag proteins with human and mouse serum at 37 ºC. Samples were incubated during 4 and 24 
days in mouse and human serum, respectively. The detection of VHH and VHH-Zag in the 
collected samples was examined by Western Blot. As shown in figures 7A and 7B, both 
proteins were detected with the expected molecular weights and no degradation was observed. 
Moreover, the binding activities were confirmed by ELISA in all the samples and were 
similar to samples before incubation (Day 0) (data not shown). 
Neutralization of TNFα-dependent cytolytic activity by VHH and VHH-Zag 
 With the aim of measuring the VHH and VHH-Zag blocking effect on TNF-α/TNFR 
interaction, we have selected a murine aneuploid fibrosarcoma cell line (L929) as a cytotoxic 
TNFα-mediated assay (material and methods section). As shown in figure 6, both VHH and 
VHH-Zag inhibited the TNFα-induced cell death of L929 in a dose-dependent manner. 
Importantly, the inhibitory profiles of VHH and VHH-Zag were almost identical, thus 
indicating that the fusion with the Zag ABD does not interfere with the activity of the anti-
TNFα VHH. 
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Pharmacokinetic and organ biodistribuition of VHH and VHH-Zag  
The pharmacokinetic properties of VHH and VHH-Zag were evaluated in CD-1 mice, after 
a single i.v. injection (25 µg) into the tail vein. This dose injection was selected according to 
doses applied in other studies with recombinant antibodies in mice7,8. Serum concentrations of 
VHH and VHH-Zag were determined by ELISA at different time points as described in the 
material and methods section. Compared with VHH, VHH-Zag showed a highly prolonged 
residence time in blood and remaining organism (Fig. 8 and Table 5), with the terminal half-
life (t1/2β) increasing from 0.79 h (VHH) to 30.55 h (VHH-Zag), corresponding to a 39-fold 
increase. Moreover, distribution phase half-life (t1/2α) showed a 7-fold increase, from 0.52 h 
(VHH) to 3.71 h (VHH-Zag). The improvement of pharmacokinetic properties was also 
demonstrated by comparison of the AUC. For VHH-Zag the AUC(0-24) was increased by a 
factor of  20 comparing with VHH. To confirm the presence and identity of VHH and VHH-
ZAG at each time point, a Western Blot was performed. As illustrated in figure 9, comparing 
with the unmodified VHH nanobody (residence in serum during 2 h), VHH-Zag can be 
detected by immunoblot in mouse serum until 72 h after injection. 
In order the analyze the biodistribution profile of each molecule, VHH and VHH-Zag were 
radiolabeled with the “99mTc(CO)3” core and injected in CD-1 mice. Tissue distribution and in 
vivo stability were monitored over a period of 48 h (Fig. 10 and Tables 6 and 7). For all time 
points, a total of 84 to 99% of injected activity was recovered. Organ to blood ratio at 24 h 
(Table 8) showed a very high radioactivity accumulation within the kidney for VHH, with 
390 times more concentrated than in the blood. Moreover biodistribution assay also showed a 
trend for 99mTc(CO)3-VHH accumulation within the highly perfused organs intestine, muscle 
and liver, respectively with 3 times, 5 times and 11 times more concentrated in these organs 
than in the blood. For the lung and bone 99mTc(CO)3-VHH  also showed a 2-fold increase in 
concentration when compared to blood. For other organs (spleen, heart, stomach and 
pancreas), VHH showed a lower concentration when compared to blood. On the contrary, 
99mTc(CO)3-VHH-Zag showed only a slight accumulation within the liver and kidney, with 
approximately 1.5 times more concentrated in these two organs when compared to blood. For 
the rest of collected organs, no accumulation was observed. When biodistribution results are 
normalized to organ weight (Fig. 10, Tables 6 and 7), it is evident the higher radioactivity 
retention of 99mTc(CO)3-VHH in the kidney when compared to 99mTc(CO)3-VHH-Zag. This 
finding is in agreement with the predominant urinary excretory route of VHH. 
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DISCUSSION 
Herein we have evaluated the ability of the Zag albumin-binding domain (ABD) of 
streptococcal protein ZAG, a protein-G related surface protein, to extend the circulation half-
life of therapeutic proteins.  For this purpose and to validate our strategy, the Zag ABD was 
fused with an anti-TNFα VHH nanobody. Our results, demonstrated that both VHH and 
VHH-Zag constructs were stably produced in E. coli, with high yields of protein of several 
milligrams per liter of culture. The binding of VHH-Zag fusion protein to human TNFα and 
human, rat and mouse serum albumin was confirmed by ELISA. Importantly, we demonstrate 
that the presence of HSA (1 mg/ml) did not affect the binding of VHH-Zag to human TNFα, 
showing similar values to the unmodified nanobody. These results demonstrate that VHH-Zag 
is active when exposed to the therapeutic target in the presence of albumin. Moreover, 
binding of VHH-Zag to human, rat and mouse albumin was not reduced at pH 6.0, showing 
that VHH-Zag binding to albumin is stable at low pH e.g., found in endosomes. Accordingly, 
the measured affinities of VHH-Zag for human, rat and mouse albumins at neutral pH, were 
in the range of nanomolar affinity, with values of 4.57, 0.42 and 40.6 nM, respectively. These 
affinities values, were similar to those obtained in previous studies, for the streptococcal 
protein G ABD7,15,16. The SEC results, indicate the formation of VHH-Zag/albumin 
complexes in vitro with an increased hydrodynamic radius (4.01 nm versus 1.84 nm for the 
VHH), confirming the albumin binding of VHH-Zag. These findings support the proposal that 
VHH-Zag uses the albumin binding to achieve extension of the circulation time, probably 
triggered by the reduced renal clearance and FcRn-mediated recycling mechanism. 
Accordingly, a previous study using the ABD from protein G in fusion with a single-chain 
diabody for circulation time extension, confirmed that the long half-life of this therapeutic 
protein is achieved through the recycling of albumin mediated by the FcRn17. Besides the 
VHH-Zag maintain the albumin binding capacities of the original ABD9, the TNFα-
neutralization assays showed that the Zag fusion did not affect the efficacy of the anti-TNFα 
VHH. Our results indicate that the TNFα- and albumin-binding abilities of the parental anti-
TNFα nanobody were retained in the recombinant molecule VHH-Zag. Furthermore, fusion 
of Zag with the unmodified VHH did not disturb the high thermal stability of the nanobody 
(VHH Tm = ~70 ºC versus VHH-Zag Tm = ~72 ºC). Serum stability studies also demonstrate 
the high stability in human and mouse serum of VHH and VHH-Zag proteins (Fig. 7). 
Regarding the pharmokinetic, when compared to VHH, VHH-Zag showed an extraordinary 
39-fold increase of the terminal elimination half-life (47 min versus 31 h for the Zag fusion 
61 
 
nanobody). Although VHH-Zag presents a plasma half-life of 31 h, the fusion protein can be 
detected in mouse serum until 72 h after injection, comparing the short presence of 2 h for 
VHH (Fig. 9). The half-life of VHH-Zag is slightly higher than the circulation times 
determined for scDbCEACD3-ABD (27.6 h)9 and for scDbCEACD3-HSA fusion proteins 
(25.0 h)8. This improvement of half-life probably can be compared with the half-lives of 
serum albumin, which are 1.07-1.6 days for mouse serum albumin and ~19 days for human 
serum albumin18-20. The organ distribution of 99mTc(CO)3-VHH  and 99mTc(CO)3-VHH-Zag 
(Fig. 10) exhibited a different biodistribution profile in radiolabeled both proteins. 
99mTc(CO)3-VHH, was rapidly cleared from the blood and showed high kidney accumulation 
after 5 min (Fig. 10A and Table 6). 99mTc(CO)3-VHH-Zag had a strongly increased residence 
in the blood, which led also to increased values in all the other organs (Fig. 10B and Table 7).  
A comparable biodistribution profile was recently reported by us using 67Ga as 
radionuclide21. In this study we showed that the Zag domain affected the pharmacokinetic 
properties of VHH, with impressive differences in blood clearance and total excretion. The 
biodistribution profile of 67Ga-NOTA-VHH exhibited a rapid clearance from blood and most 
tissues. On the other hand, 67Ga-NOTA-VHH-Zag presented a slow washout from blood, 
muscle and bone, and an accumulation in highly irrigated organs such as liver, spleen and 
lung21. Similar results were also described in other study performed by Stork and 
colleagues17.  
A previous study from Coppieters and co-workers presented similarities results with ours 
in the TNFα-neutralizating capacities and half-life extension, with bivalent molecules in 
fusion with AR1, an anti-TNFα VHH targeting murine and human albumin. The trivalent 
molecules intend to increase the accumulation of the anti-TNFα VHH in the target tissue 
(inflamed joints) and to prolong its serum half-life (54 min for the unmodified nanobody 
versus 2.2 days for the AR1 fusion protein). Their biodistribution studies demonstrated 
significantly higher amounts of the bispecific anti-TNFα VHH in fusion with AR1 
accumulated in inflamed joints and that this uptake was correlated with the higher clinical 
scores for the corresponding limbs22. Several findings show that large amounts of albumin 
accumulate and are metabolized in the inflamed joints of rheumatoid arthritis patients23-26. 
Preclinical mouse studies also demonstrated the possibility of albumin behaves as a carrier of 
therapeutics in rheumatoid arthritis27-29. These findings indicate that albumin might be a 
useful drug-carrier, allowing specific targeting of protein therapeutics to sites of 
inflammation.  
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Although Zag ABD has shown considerable improvements in pharmacokinetic properties 
of the single-domain antibody, concerns with the immunogenicity of these molecules for 
therapeutic applications may occur. For instance, immunogenicity of the albumin-binding 
domain of protein G, in the amino acid sequence 254-299, was detected in mice strains30. For 
therapeutic purposes, particularly in small proteins that require administration by repeated 
injections, it will be necessary reduce or ideally eliminate the immunogenicity. There are 
several de-immunization strategies that can be applied to reduce the immunogenicity of these 
ABDs31-33. Indeed, we have de-immunization ongoing studies being performed into the Zag 
ABD. The data already obtained reveals that although there is a slight decrease in Zag 
affinity, the albumin binding specificity is not affected neither the half-life extension 
properties.  
In conclusion, the present study demonstrates that Zag ABD fusion is a promising strategy 
for half-life extension of therapeutic proteins. Within this context, we envision that this 
strategy can be an efficient approach used to improve the pharmacokinetic and 
pharmacodynamic properties protein or peptides without affecting the efficacy of these 
molecules. Moreover, due to the accumulation of albumin in inflamed joints, the anti-TNF 
VHH-Zag fusion approach also has a particular interest for the treatment of rheumatoid 
arthritis.   
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ABBREVIATIONS 
ABD, albumin-binding domain; AUC, area under the curve; FcRn, neonatal Fc receptor; 
HSA, human serum albumin; IgG, immunoglobulin G; PEG, polyethylene glycol; MSA, 
mouse serum albumin; RSA, rat serum albumin; TNFα, tumour necrosis factor, VHH, 
camelid single-domain antibody or nanobody; Zag, ABD from streptococcal cell surface ZAG 
protein. 
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FIGURE LEGENDS 
Fig. 1: Construction and expression of VHH and VHH-Zag. (A) Schematic representation 
of the VHH and VHH-Zag constructs including the N-terminal leader peptide (LP), the C-
terminal histidine (His7) and HA tags. (B) Sequence of the wild-type ZAG ABD9. (C) SDS-
PAGE and (D) Western Blot analysis of the VHH and VHH-Zag purified proteins (3 µg/lane) 
under reducing (lanes 1 and 2) and non-reducing conditions (lanes 3 and 4). Gels were stained 
with Coomassie brilliant blue (C) or immunoblotted with an anti-HA-tag antibody (D). 
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Fig. 2: Binding of VHH and VHH-Zag to human TNFα. ELISA plates were coated with 
human TNFα (200 ng/well) and binding of VHH and VHH-Zag fusion protein was measured 
in the presence (A) and absence (B) of HSA (1 mg/ml). Detection was achieved using an 
HRP-conjugated anti-HA-tag antibody. 
Fig. 3: Binding of VHH-Zag to human, rat and mouse albumin. Binding of VHH-Zag 
fusion protein was evaluated in ELISA at neutral pH - pH 7.4 (A); and acidic pH - pH 6.0 (B). 
Bound proteins were detected using an HRP-conjugated anti-HA-tag antibody. 
Fig. 4: Binding affinity measurements. Representative sensorgrams from Biacore SPR-
analysis of VHH-Zag against immobilized HSA, RSA and MSA. Binding curves were fitted 
in triplicates. VHH was used as control.  
Fig. 5: Formation of VHH-Zag/albumin complexes. Size exclusion chromatography 
analysis of VHH-Zag (A), HSA (B), VHH-Zag/HSA complex (C), MSA (D) and VHH-
Zag/MSA complex (E). VHH-Zag was incubated at equimolar concentrations with albumin in 
PBS1x at room temperature. Peak positions of marker proteins are indicated. 
Fig. 6: TNFα-neutralization of VHH and VHH-Zag. Dose-response curves of VHH and 
VHH-Zag proteins to examine the TNFα-mediated cytoxicity in the presence of 0.5 ng/ml 
human TNFα, on the TNF-sensitive mouse fibroblast cell line L929.   
Fig. 7: In vitro stability in human and mouse serum of VHH and VHH-Zag. In vitro 
stability of the recombinant proteins was determined in human serum (A) and mouse serum 
(B) at 37 ºC, during 24 days and 4 days, respectively. Proteins were detected by Western Blot, 
using an anti-His-tag antibody. 
Fig. 8: Pharmacokinetic properties. Both VHH and VHH-Zag fusion protein were i.v. 
injected into CD-1 mice (25 µg/animal) and absorbance pharmacokinetic profiles of these 
proteins were calculated by ELISA. Data were normalized considering maximal concentration 
at the first time point (5 min).  
Fig. 9: In vivo stability in mouse serum of VHH and VHH-Zag. In vivo stability of VHH-
Zag (A) and VHH (B) was evaluated by Western Blot with anti-HA-tag antibody, in the mice 
serum samples collected during the pharmacokinetic assay. 
Fig. 10: Biodistribution 99mTc(CO)3-VHH  and 99mTc(CO)3-VHH-Zag. Organ distribution 
of  99mTc-VHH (A) and 99mTc-VHH-Zag (B) proteins in CD-1 mice. 
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TABLES 
Table 1: Binding of VHH-Zag to HSA, RSA and MSA. 
Protein EC50 for HSA 
(nM) 
EC50 for RSA 
(nM) 
EC50 for MSA 
(nM) 
VHH-Zag pH 6.0 0.324 ± 0.06 0.377 ± 0.07 0.175 ± 0.07 
VHH-Zag  pH 7.4 1.074 ± 0.03 1.698 ± 0.06 4.354 ± 0.08 
 
 
Table 2: Affinities of VHH-Zag for HSA, RSA and MSA by SPR measurements. 
Protein Kon (M-1s-1) Koff (s-1) Koff/Kon KD 
HSA 8.68x104± 0.42 3.96x10-4± 0.07 4.57x10-9± 0.22 4.57 ± 0.42 nM 
RSA 1.06x105± 0.02 4.41x10-5± 0.08 4.15x10-10± 0.01 0.42 ± 0.01 nM 
MSA 9.88x104± 0.18 4.26x10-3± 0.14 4.06x10-8± 0.12 40.6 ± 2.1 nM 
 
Table 3: Molecular mass and hydrodynamic radius. 
Protein or 
complex 
Length Calculated Mra SEC apparent Mr Stokes’ 
radius (RS) 
 aa kDa kDa nm 
VHH 180 19.4 14.9 1.84 
VHH-Zag 235 25.2 26.4 2.59 
HSA 585 66.5 68.1 3.67 
MSA 584 65.9 64.3 3.60 
VHH-Zag/HSA − 91.7 101.2 4.16 
VHH-Zag/MSA − 91.1 98.6 4.01 
aCalculated based on the amino acid sequence. 
 
 
Table 4: Thermal stability of VHH and VHH-Zag. 
Protein 
Tm B - Mean 
(°C) 
Tm B – Median 
(°C) 
Tm D - Mean 
(°C) 
Tm D - Median 
(°C) 
VHH 71.53 ± 0.14 71.56 ± 0.14 72.34 ± 0.25 72.43 ± 0.25 
VHH-Zag 69.77 ± 0.14 69.87 ± 0.14 70.24 ± 0.23 70.24 ± 0.23 
Tm B - Calculated Boltzamnn melting temperature; Tm D - Calculated Derivated melting temperature.  
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Table 5: Pharmacokinetic parameters of VHH and VHH-Zag. 
Protein t1/2α (h) t1/2β (h) AUC(0-24 h) (%*h) 
VHH 0.52 ± 0.25  0.79  ± 0.12 72.75 ± 7.35 
VHH-Zag 3.21 ± 0.30 30.55 ± 0.14 1461.15 ± 152,98 
 
 
Table 6: Biodistribution of 99mTc VHH (values presented as mean±SD % injected 
activity/organ weight (g); CV%a). 
Organ 0.08 h 0.50 1.0 4.0 24 48 
Blood 6.02 ± 1.06 ;  
18% 
1.22 ± 0.47; 
39% 
0.98 ± 0.30; 
30% 
0.30 ± 0.02; 
8% 
0.07 ± 0.05; 
67% 
0.04 ± 0.01; 
14% 
Liver 1.94 ± 0.34; 
18% 
2.22 ± 0.24; 
11% 
0.58 ± 0.19; 
33% 
0.51 ± 0.21; 
41% 
0.35 ± 0.15; 
44% 
0.45 ± 0.05; 
11% 
Intestine 1.51 ± 0.15; 
10% 
0.13 ± 0.01; 
10% 
0.24 ± 0.06; 
24% 
0.32 ± 0.10; 
30% 
0.09 ± 0.05; 
55% 
0.06 ± 0.02; 
31% 
Spleen 1.22 ± 0.14; 
11% 
1.41 ± 0.84; 
60% 
0.31 ± 0.12; 
39% 
0.34 ± 0.07; 
21% 
0.21 ± 0.16; 
73% 
 
Heart 2.24 ± 0.26; 
12% 
0.46 ± 0.06; 
12% 
0.36 ± 0.16; 
44% 
0.19 ± 0.03; 
16% 
0.06 ± 0.01; 
11% 
 
Lung 6.31 ± 1.81; 
29% 
4.78 ± 0.98; 
20% 
0.98 ± 0.12; 
12% 
0.51 ± 0.04; 
9% 
0.34 ± 0.26; 
77% 
 
Kidney 107.67 ± 
15.39; 14% 
116.97 ± 
15.27 ; 13% 
134.74 ± 
12.39; 9% 
178.43 ± 
34.81; 20% 
57.37 ± 5.52; 
10% 
38.08 ± 15.08; 
40% 
Muscle 1.55 ± 0.26; 
17% 
0.42 ± 0.05; 
12% 
0.32 ± 0.09; 
28% 
0.08 ± 0.03; 
36% 
0.03 ± 0.00; 
16% 
 
Bone 1.64 ± 0.23; 
14% 
0.43 ± 0.04; 
10% 
0.29 ± 0.05; 
18% 
0.08 ± 0.02; 
20% 
0.05 ± 0.00; 
8% 
 
Stomach 0.62 ± 0.24; 
38% 
0.12 ± 0.03; 
28% 
0.34 ± 0.17; 
50% 
0.30 ± 0.15; 
51% 
0.06 ± 0.03 ; 
52% 
 
Pancreas 1.20 ± 0.13; 
11% 
0.31 ± 0.09; 
28% 
0.22 ± 0.07; 
32% 
0.13 ± 0.04; 
27% 
0.05 ± 0.00; 
6% 
 
a% CV: coefficient of variation %. 
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Table 7: Biodistribution of 99mTc VHH-Zag (values presented as mean±SD % injected 
activity/organ weight (g); CV%a). 
Organ 0.08 h 0.50 h 1.0 h 4.0 h 24 h 48 h 
Blood 33.70; 12% 5.83; 24% 10.17; 28% 6.95; 22% 1.73; 34% 2.07; 33% 
Liver 8.56; 17% 7.39; 8% 11.96; 20% 9.44; 69% 2.73; 40% 1.74; 25% 
Intestine 0.42; 20% 0.33; 54% 0.77; 12% 2.64; 64% 0.26; 38% 0.32; 59% 
Spleen 4.12; 27% 5.49; 19% 12.54; 36% 2.70; 58% 1.82; 61%  
Heart 6.00; 39% 1.82; 23% 1.76; 7% 1.68;27% 0.64; 83%  
Lung 10.64;45% 3.13; 15% 2.43; 52% 1.73; 21% 0.60; 52%  
Kidney 13.50; 13% 28.52; 11% 29.08; 22% 25.17; 27% 8.18; 4% 3.82; 30% 
Muscle 1.16; 11% 0.63; 18% 0.68; 14% 0.31; 75% 0.27; 4%  
Bone 2.44; 25% 0.86; 10% 1.17; 12% 0.47; 14% 0.42; 12%  
Stomach 0.28; 41% 0.26; 30% 0.87; 29% 2.10; 81% 0.10 12%  
Pancreas 1.40; 22% 0.61; 13% 0.74; 8% 0.40; 78% 0.24; 45%  
a% CV: coefficient of variation %. 
 
Table 8: Organ to blood ratio of 99mTc-VHH and 99mTc-VHH-Zag at 24 h time point. 
Organ VHH VHH-Zag 
Liver 11.3 1.82 
Intestine 3.42 0.365 
Spleen 0.413 0.129 
Heart 0.122 0.0342 
Lung 1.80 0.0505 
Kidney 390 1.37 
Muscle 4.77 1.14 
Bone 2.09 0.442 
Stomach 0.600 0.0514 
Pancreas 0.140 0.0189 
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Figure 10 
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BIODISTRIBUTION	OF	A	67GA-LABELED	
ANTI-TNF	VHH	SINGLE-DOMAIN	ANTIBODY	
CONTAINING	A	BACTERIAL	ALBUMIN-
BINDING	DOMAIN	(ZAG) 
 
 
 
 
Brief Introduction 
Bacterial albumin-binding domains have been extensively studied and used as fusion 
proteins to improve the half-life of recombinant antibodies formats or therapeutic proteins 
(Kontermann, 2011). 
ZAG is a cell-surface protein G-related from S. zooepidemicus, with an Ig-binding region 
located in the C-terminus, and an ABD composed by 52 amino acids (Jonsson et al., 1994).  
In this research work we used 67Ga-radiolabelling to investigate the organ biodistribution 
of protein ZAG ABD (Zag) fusion with an anti-TNFα VHH from Ablynx, used as a study 
model to validate our strategy to increase circulation time of therapeutic proteins.  
Firstly, we intend to optimize the production of the recombinant proteins (VHH and VHH-
Zag) in E.coli, an easy way to obtain high amounts of protein with lower costs. Furthermore, 
we analyze the human serum albumin and TNFα binding of VHH and VHH-Zag proteins, 
after the conjugation with NOTA and 67GA-NOTA radiolabelling, in order to see if the 
chemical process could affect the binding properties of the recombinant antibodies. Finally, 
we evaluate the organ biodistribution profiles of both proteins. 
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ALBUMIN-BINDING	DOMAIN	(PROTH)	FROM	
STREPTOCOCCUS	PYOGENES,	A	NEW	
APPROACH	TO	INCREASE	HALF-LIFE	OF	
THERAPEUTIC	PROTEINS	 
 
 
 
 
Brief Introduction 
Streptococcal albumin-binding domains have been successfully investigated as fusion 
proteins to improve the pharmacokinetics of recombinant antibodies or therapeutic proteins 
(Kontermann, 2012). 
Protein H is a cell surface protein from S. pyogenes, with an Ig-binding region located in 
the N-terminus and an ABD in the C-terminus, composed by three C repeats with a high 
amino acid sequence homology between them (Frick et al., 1995)  
In this study we fused protein H ABD (ProtH) with a nanobody against TNFα from 
Ablynx, used as a study model to validate our strategy to increase half-life. Firstly, we intend 
to optimize the production of the recombinant proteins (VHH and VHH-ProtH) in E.coli, an 
easy way to obtain high amounts of protein with lower costs. Then we characterize the 
antigen and albumin binding of the ProtH fusion protein and compare the therapeutic efficacy 
of the VHH-ProtH with the unmodified antibody. We also evaluate the thermal stability and 
in vitro and in vivo serum stabilities of the both proteins. Finally, we determine the initial and 
terminal half-lives of VHH and VHH-ProtH and the organ biodistribution profiles of both 
proteins, using 99mTc radiolabelling. 
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Background: Half-life extension is a key feature to improve pharmacokinetics of therapeutic low 
molecular weight proteins and peptides.  
Results: Fusion of streptococcal protein H albumin-binding domain (ABD) – ProtH – to a single-
domain antibody (nanobody) resulted in a significant increase in circulation time in vivo, improving 
the pharmacokinetics of the therapeutic molecule.  
Conclusions: This strategy can be successfully applied to improve the pharmacokinetics of short half-
life therapeutic molecules. 
Significance: This work demonstrates the potential of a new approach to increase the half-life of 
therapeutic proteins by using the ProtH albumin-binding domain from Streptococcus pyogenes  
 
ABSTRACT 
Recombinant antibody fragments and single-domain antibodies present a great potential as 
new biodrugs in the treatment of several relevant diseases. However, due to their relatively 
low-molecular weight (< 60 kDa) they are rapidly cleared from circulation. To solve this 
problem, plasma protein binding can be an effective approach to improve pharmacokinetic 
properties of short half-life molecules. Aimed at improving the pharmacokinetic properties of 
therapeutic proteins, we propose herein a bacterial albumin-binding domain (ProtH) derived 
from Streptococcus pyogenes protein H. To validate our approach and as a proof of concept, 
the ProtH ABD was fused with an anti-TNFα VHH nanobody. The results obtained show that 
the ProtH ABD fused to a small therapeutic protein (anti-TNFα VHH) presents a strong 
binding to mouse, rat and human albumins. Furthermore, the results obtained reveal that the 
VHH-ProtH antigen-binding sites were still accessible for TNFα binding and the presence of 
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albumin does not interfere with antigen targeting. Importantly, the VHH fusion with ProtH 
resulted in a half-life increase of 26-fold in mice (VHH = 47 min versus VHH-ProtH = 20.54 
h) and a residence until 48 h (versus 2 h for the VHH). The biodistribution studies of the 
radiolabelled 99mTc-recombinant proteins (VHH and VHH-ProtH) in healthy mice indicated a 
similar distribution and elimination profile for both proteins, showing high radioactivity 
accumulation within the highly perfused organs, especially in the kidney. This study 
demonstrates the great potential of ProtH ABD as a strategy to increase the half-life of 
therapeutic proteins. Due to the accumulation of albumin in arthritic joints, our results also 
reveal the special interest of this ABD for the pharmacokinetic improvement of proteins for 
the treatment of rheumatoid arthritis. 
 
INTRODUCTION 
Recombinant antibody fragments and single-domain antibodies represent the fastest 
growing class of pharmaceutical biotechnology1. To date, more than 20 monoclonal 
antibodies (mAbs) are available for a variety of therapeutic applications2 and more than 600 
are currently in clinical development3,4. With the exception of whole antibodies and Fc-fusion 
proteins, many of these biodrugs present molecular weights below 60 kDa3. For instance, anti-
TNFα camelid nanobodies (VHH) from Ablynx and domain antibodies (Dab) from 
Domantis/GSK are in clinical development, showing promising results for the treatment of 
rheumatoid arthritis5. However, due to their small size they have short half-life’s and present a 
rapid clearance from circulation. The limitations of small size protein drugs have led to the 
development and implementation of several half-life extension strategies to prolong 
circulation of these molecules and thus improve their administration, pharmacokinetic and 
pharmacodynamics properties3,4,6. Several approaches have been proposed to improve the 
pharmacokinetics of small proteins based on implementing neonatal Fc receptor (FcRn)-
mediated recycling. The long half-lives of albumin (~19 days) and IgG (~21 days) are caused 
by a recycling process mediated by FcRn, expressed, for example, by endothelial cells3,4. The 
FcRn is capable of binding albumin and IgGs in a pH-dependent manner. Therefore, after 
cellular uptake of plasma proteins through macropinocytosis, albumin and IgG will bind to 
FcRn in the acidic environment of the endosomes. This binding diverges albumin and IgG 
from degradation in the lysosomal compartment and redirects them to the plasma membrane, 
where they are released back into the blood plasma because of the neutral pH7-9. This 
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mechanism offers other opportunities to extend or modulate the half-life of proteins, for 
example, through fusion to albumin or albumin fusion moieties, or to Fc region of IgG3,4.  
The streptococcal protein G ABD fusion has been extensively studied, being able to extend 
the circulation time of recombinant antibodies. Stork and co-workers investigated a 
recombinant antibody fusion to the protein ABD3 as strategy to prolong circulation time 
using a bispecific single-chain diabody (scDb) developed for the retargeting of cytotoxic T 
cells to CEA-expressing tumor cells with successful improvements in half-life extension10.  
Protein H, a molecule expressed at the surface of some strains of Streptococcus pyogenes, 
is found in clinical isolates of the M1 serotype11 and has affinity for the constant (IgGFc) 
region of IgG and serum albumin12.  The role for protein H and other IgG-binding proteins in 
S. pyogenes pathogenicity and virulence is unclear. The protein H, like protein G13, has 
separate binding sites for albumin and IgG. The ABD from protein H is located in the N-
terminus closer to the bacterial cell wall and IgG-binding region. No homology was detected 
when the IgGFc-binding repeats were compared with the same regions of protein G, but the 
albumin-binding regions of protein G and H were shown to have evolved convergently12. 
Competitive binding experiments demonstrated that protein G and H bound to the same or 
closely located sites in albumin, which has previously been mapped for protein G to disulfide 
loops 6-814. 
In the present study, we used the ProtH ABD as a new approach for extension of the 
circulation time of therapeutic proteins. To validate our strategy and as a proof-of-concept, the 
ProtH ABD was fused with an anti-TNFα VHH single-domain antibody. The fusion protein 
showed specific binding to serum albumin and compared with the parental VHH nanobody, 
exhibited a strong increase of serum half-life in mice to approximately 26-fold. In summary, 
our results demonstrate for the first time, the ability of this new streptococcal ABD to 
improve pharmacokinetic disposition of therapeutic proteins.  
 
EXPERIMENTAL PROCEDURES 
Materials – Human serum albumin (HSA) (catalog no. A3782), rat serum albumin (RSA) 
(catalog no. A6272), mouse serum albumin (MSA) (catalog no. A3139), human (catalog no. 
H4522) and mouse serum (catalog no. H5905), and pT7-FLAG2 expression vector were 
purchased from Sigma-Aldrich (USA). HRP-conjugated anti-His-tag,  HRP-conjugated anti-
HA-tag, anti-HA affinity matrix, 2,2'-Azino-di-[3-ethylbenzthiazoline sulfonate (6)] 
diammonium salt (ABTS), tetrazolium salt WST-1 and cOmplete EDTA-free protease 
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inhibitors cocktail were acquired from Roche (Germany). Recombinant human TNFα and 
Amicon centrifugal filter units were purchase from Millipore (USA). PD-10 columns and G25 
Sephadex were purchase from GE Healthcare (UK) and Sigma-Aldrich, respectively. 
Radioactivity measurements were done on a dose calibrator (Aloka Curiemeter, IGC-3, Japan) 
or on a gamma-counter (Berthold LB 2111, Germany). 
Cloning of recombinant proteins – DNA encoding anti-TNF VHH#3E clone (Silence et al. 
Patent US2007/0077249 A1)15 was synthesized by Nzytech adding a SfiI restriction site at 5’ 
and 3’ ends. All the constructs were cloned in pT7-FLAG2 with the leader peptide sequence 
ompA (LP) from pComb3x plasmid in N-terminal and in histidine and human influenza 
hemagglutinin (HA) tags in C-terminal16. A fragment encoding the LP-VHH-His-HA was 
generated by PCR with primers HindIII-LP-SfiI-F (5’-CCC AAG CTT ATG AAA AAG 
ACA GCT ATC GCG ATT GCA GTG GCA CTG GCT GGT TTC GCT ACC GTG GCC 
CAG GCG GCC-3’)  and His-HA-KpnI-R (5’-CGG GGT ACC CCG CTA AGA AGC GTA 
GTC CGG AAC GTC GTA CGG GTA TGC GCC ATG GTG ATG GTG ATG GTG ATG 
GTG GCT GCC TCC-3’) and subcloned into the expression vector pT7-FLAG2 (Sigma) into 
the HindIII and KpnI restriction sites. To construct the VHH-ProtH fusion protein, a DNA 
comprising the ProtH albumin-binding domain was amplified by PCR with primers ProtH-F 
(5’- CCC ACT AGT AAG CAA ATC TCG GAA GCA AGC CG-3’) and ProtH-R (5’- CAT 
GCC ATG CTT CTT TCA GAG CCT TGG CCT CC-3’), adding SpeI and NcoI restriction 
sites at the fragment 5’ and 3’ ends, respectively. The resulting PCR fragments were gel-
purified, digested with the SpeI and NcoI restriction enzymes and cloned into the 
appropriately cut pT7-VHH vector. A short GS linker (SGGGGS) was used to link the VHH 
and VHH-ProtH. The VHH and VHH-ProtH constructs were verified by sequencing. 
Expression and purification of proteins – VHH and VHH-ProtH were expressed in 
Escherichia coli strain BL21(DE3). One liter of LB, containing 100 µg/ml ampicillin was 
inoculated with 10 ml of overnight culture of transformed BL21(DE3) and grown to 
exponential phase (A600 = 0.6-0.9) at 37 ºC. Expression was induced by the addition of 1 mM 
isopropyl β-ᴅ-1-thiogalactopyranoside (IPTG) and growth continued overnight at 18 ºC. Cells 
were harvested by centrifugation and resuspended in equilibration buffer (50 mM HEPES, 1 
M NaCl, 5 mM CaCl2, 30 mM imidazole, pH 7.5) supplemented with protease inhibitors. 
Cells were lysed by sonication. Centrifugation (14000  g for 1h at 4 ºC) was used to remove 
cell debris, and the supernatant was filtered through a 0.2 µm syringe filter. The VHH and 
VHH-ProtH were purified using AKTA FPLC System (GE Healthcare) by nickel chelate 
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affinity chromatography with HisTrap HP columns. After a washing step (50 mM HEPES, 1 
M NaCl, 5 mM CaCl2, 60 mM imidazole, pH 7.5) the recombinant antibody fragments were 
eluted with a linear imidazole gradient from 60 to 300 mM in 50 mM HEPES, 1 M NaCl, 5 
mM CaCl2, pH 7.5. Protein fractions were pooled, then desalted and concentrated in 50 mM 
HEPES, 100 mM NaCl, 5 mM CaCl2, pH 7.5 using Amicon 10K (Millipore). The samples 
were loaded onto a HiPrep 16/60 Sephacryl S-100 HR gel filtration column (GE Healthcare), 
fractions were pooled and concentrated with Amicon 10K. The protein purity was analyzed 
by reducing and non-reducing SDS-PAGE. Protein concentration was determined 
spectrophotometrically in Nanodrop ND-1000 at 280 nm and calculated using the calculated ε 
value of each protein (εVHH = 34380 L mol−1 cm−1; εVHH-ProtH = 34380 L mol−1 cm−1). 
ELISA – TNFα (200 ng/well), HSA, RSA and MSA (10 µg/well) were coated in 96-well 
plates overnight at 4 ºC and the remaining binding sites were blocked with 5% (w/v) soya 
milk/PBS1x. To evaluate the binding of VHH and VHH-ProtH fusion proteins to TNFα and 
serum albumin, several dilutions of the purified samples were incubated in triplicates 
incubated for 1 h at room temperature. To validate the binding of the recombinant proteins to 
TNFα in presence and absence of albumin, the purified protein samples were incubated with 1 
mg/ml of HSA. Detection was performed with HRP-conjugated anti-HA-tag antibody using 
ABTS substrate. Absorbance was measured at 405 nm in an ELISA reader. GraphPad Prism 
Software version 5 was used for data analysis. 
Size Exclusion Chromatography – Apparent molecular weight of recombinant antibody and 
formation of antibody/albumin complexes was determined by FPLCSEC on a HiLoad 
Superdex 200 HR column (GE Healthcare) with a flow rate of 0.7 ml/min and PBS as running 
buffer at 4 ºC. The following standard proteins were used: apoferritin (443 kDa, RS 6.1 nm), 
β-amylase (200 kDa, RS 5.4 nm), alcohol dehydrogenase (150 kDa, RS 4.55 nm), bovine 
serum albumin (67 kDa, RS 3.55 nm), ovalbumin (45 kDa, RS 3.05), myoglobin (17.6 kDa, RS 
1.91 nm), ribonuclease A (13.7 kDa, RS 1.64 nm) and cytochrome c (12.4 kDa, RS 1.77 nm). 
Blue dextran and L-tyrosine were used to determine the void and total column volume, 
respectively. Elution volume of the protein standard was used to create a standard curve of 
Stokes’ radius (RS) versus (-log Kav)1/2 that was used to calculate the Stokes’ radii of 
recombinant antibody and antibody/albumin complexes. Complex formation of VHH-ProtH 
with HSA and MSA was analyzed by incubating equimolar amounts of VHH-ProtH and 
albumin (10 µM), unless otherwise specified, in PBS1x at room temperature and subsequent 
analysis by SEC. The relative amounts of the oligomeirc forms were calculated by 
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deconvolution of the obtained chromatograms using the PeakFit software (Systat Software 
Inc). SDS-PAGE analysis of collected samples was performed to evaluate albumin binding. 
Protein thermal stability and in vitro serum stability – Melting temperatures of the studied 
proteins were determined using the Protein Thermal Shift Kit and 7500 Fast Real-Time PCR 
System (Applied Biosystems) according manufacturer’s instructions. Protein samples (5 
µg/well) were tested in MicroAmpTM Fast Optical 96-well Reaction Plates and analyzed in 
quadruplicate using and diluted in 50mM HEPES, 100 mM NaCl, 5 mM CaCl2, pH 7.5,  and 
Protein Thermal ShiftTM Dye 1x. Collected data were analyzed with Protein Thermal Shift 
Software version 1.1. 
 To evaluate human and mouse serum stability of recombinant antibodies, VHH and VHH-
ProtH were incubated at a concentration of 10 µg/ml for up to 24 days and 4 days, 
respectively, at 37 ºC. The in vitro stability of VHH and VHH-ProtH in the human and mouse 
serum was evaluated by ELISA and Western Blot using HRP-conjugated anti-His-tag 
antibody.   
Neutralization of TNF-dependent cytolytic activity – In order to measure the anti-TNFα VHH 
and VHH-ProtH blocking effect on TNF-α/TNFR (TNF receptor) interaction, a murine 
aneuploidy fibrosarcoma cell line (L929) was used as a cytotoxic-mediated assay17. Briefly, 
L929 cells were grow to 90% confluence in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal bovine serum, penicillin (100 U/ml), streptomycin sulfate (10 
μg/ml), and L-glutamine (2 mg/ml). Cells were plated in 96-well plates at density of 25,000 
cell/well and then incubated overnight. Serial dilutions of VHH and VHH-ProtH antibody 
fragments were mixed with a cytotoxic concentration of TNFα (final assay concentration 1 
ng/ml) or in absence of this cytokine in order to measure the cell viability. Actinomycin D 
was added to a final concentration of 1 μg/ml to increase the cell sensitivity. After at least 2 h 
of incubation at 37 ºC with shaking, the mixture was added to the plated cells. Cells were 
incubated for 24 h at 37 ºC in an atmosphere of 5% CO2. Cell viability was determined using 
the tetrazolium salt WST-1 (10 μg/well), after at least 30 min of incubation by measuring the 
absorbance at 450 nm.  
Pharmacokinetics – Animal care and all pharmacokinetic (PK) studies were conducted 
according to guidelines for animal care and ethics for animal experiments outlined in the 
National and European Law. CD-1 mice (Charles River, female, 6-8 weeks, weight 25-30g) 
(n=2) were administered with 25 µg of VHH and VHH-ProtH intravenous injections. Plasma 
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samples were collected from mice at regular intervals of 5, 30, 60, 120, and 360 min, 24, 48 
and 72 hours, and fused or unfused antibody were quantified by ELISA. TNFα was 
immobilized in 384 well-plates (100 ng/well) overnight at 4ºC. After 1 h blocking with 5% 
soja milk, recombinant antibody fragments were titrated in duplicates and incubated for 1 h at 
RT. Detection was performed with HRP-conjugated anti-HA antibody using ABTS substrate. 
Absorbance was measured at 405 nm in an ELISA-reader. As described by Stork and co-
workers10, determined serum concentrations of TNFα-binding proteins were interpolated to 
the corresponding calibration curves. For comparison, the first time point (5 min) was set to 
100%. Pharmacokinetic parameters area under the curve (AUC), t1/2α and t1/2β were 
calculated with Excel, using the first three time points to calculate t1/2α and the last three time 
points to calculate t1/2β. To evaluate the residence time of VHH and VHH-ProtH in mouse 
serum in vivo, the serum samples collected during the pharmacokinetic assays were incubated 
with an anti-HA affinity matrix overnight at 4 ºC. Afterwards, the VHH and VHH-ProtH 
proteins were detected by Western Blot with an anti-HA-tag antibody.  
Radiolabelling of 99mTc-VHH and 99mTc-VHH-ProtH proteins – The precursor fac-
[99mTc(CO)3(H2O)3]+ was prepared using the Isolink kit (Covidien) and its radiochemical 
purity checked by RP-HPLC and ITLC. Compounds fac-[99mTc(CO)3]- VHH and fac-
[99mTc(CO)3]-VHH-ProtH were obtained by reacting the antibodies with fac-
[99mTc(CO)3(H2O)3]+. Briefly, a solution of fac-[99mTc(CO)3(H2O)3]+ was added to an 
microtube vial containing VHH or VHH-ProtH to get a final concentration of 1 mg/ml. The 
mixture reacted for 3 hours at 37 ºC and the radiochemical purity of fac-[99mTc(CO)3]-VHH 
and fac-[99mTc(CO)3]-VHH-ProtH was checked by ITLC analysis every hour. The 
[99mTc(CO)3(H2O)3]+ and [TcO4]- migrate in the front of the solvent (Rf = 1), while the 
radioactive small domain antibodies remain at the origin (Rf = 0).  Purification of 99mTc-
radiolabeled antibodies was performed by gel filtration through Shepadex G-25 or PD-10 
column, using 20 nM sodium chloride solution as eluent. After labeling, VHH and VHH-
ProtH proteins were tested in ELISA to ensure that their binding capacities were unaffected 
(data not shown). 
Partition coefficient – Partition coefficient was evaluated by the “shake-flask” method. The 
radioactive antibodies were added to a mixture of octanol (1 ml) and 0.1 M PBS1x pH 7.4 (1 
m), which has been previously saturated with each other by stirring. This mixture was 
vortexed and centrifuged (3000 rpm, 10 min) to allow phase separation. Aliquots of both 
octanol and PBS1x were counted in a γ-counter. The partition coefficient (Po/w) was 
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calculated by dividing the counts in the octanol phase by those in the buffer, and the results 
were expressed as log Po/w±SD. 
Biodistribution studies of 99mTc-VHH and 99mTc-VHH-ProtH proteins – In vivo evaluation 
studies of the radiolabelled recombinant proteins were performed in healthy female CD-1 
mice (Charles River, female, 6-8 weeks, weight 25-30g) (n=3) at 5 min, 30 min, 1, 4 and 24 h 
and 48 h. All animal experiments were performed in accordance with the guidelines for 
animal care and ethics for animal experiments outlined in the National and European Law. 
Animals were intravenously injected into the tail vein with 100 μl of the radiolabeled 
compounds (2.6–3.7 GBq). Mice were sacrificed by cervical dislocation at different time 
points after injection (p.i.). The radioactive dose administered (A.I.) and the radioactivity in 
the sacrificed animals were measured using a dose calibrator. The difference between the 
radioactivity in the injected and that in the sacrificed animals was assumed to be due to 
excretion. Tissues of interest were dissected, rinsed to remove excess blood, weighed, and 
their radioactivity was measured in a gamma counter. The total activity uptake for blood, 
bone, muscle, was estimated assuming that these organs constitute 6, 10, and 40% of the total 
body weight, respectively. Blood and urine was also collected at the sacrifice time and 
analyzed by ITLC. 
 
RESULTS 
Expression and purification of VHH and VHH-ProtH  
The VHH-ProtH construct was generated by fusing the ProtH ABD from streptococcal 
surface protein H to the anti-TNFα VHH#3E clone (Silence et al. Patent US2007/0077249 
A1)15 , including histidine (His7) and HA tags in C-terminal (Fig. 1A and B). The VHH-ProtH 
fusion protein obtained presents 321 amino acid residues with a calculated molecular weight 
of ~34.7 kDa. The VHH was also constructed as described in the material and methods 
section and used as control. VHH and VHH-ProtH proteins were expressed in E. coli 
BL21(DE3) and purified by IMAC. SDS-PAGE and Western Blot results showed a protein 
band for VHH and VHH-ProtH with the expected molecular weights under reducing and non-
reducing conditions (Fig. 1C and D). After expression and purification of one liter of culture 
we could obtain 25-30 mg of VHH-ProtH and 15-20 mg of VHH. 
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Antigen binding of VHH and VHH-ProtH proteins  
After purification, the VHH-ProtH binding activity to human TNFα was tested in an 
ELISA assay as described in the material and methods section. The VHH was used as control 
and as shown in figure 2 (A and B), both proteins specifically bound to TNFα. Importantly, 
binding of VHH-ProtH to TNFα was not affected by the presence of HSA (with HSA EC50 = 
0.106 nM; without HSA EC50 = 0.180 nM;) and was slightly higher than the VHH binding 
(with HSA EC50 = 1.030 nM; without HSA EC50 = 1.385 nM). These results reveal that VHH-
ProtH antigen binding sites are accessible for TNFα binding and the presence of albumin does 
not interfere with antigen targeting.  
Binding of VHH-ProtH to serum albumins 
In order to determine the in vitro relative binding activities of the VHH-ProtH fusion 
protein against human, rat and mouse albumins, an ELISA was performed at neutral (pH 7.4) 
and acidic environment (pH 6.0). As shown in figures 3A and B, ProtH domain specifically 
bounds to all albumins. Moreover, binding of the VHH-ProtH fusion protein to albumins at 
pH 6.0 (EC50 (HSA) = 53.03 nM; EC50 (RSA) = 40.76 nM; EC50 (MSA) = 36.74 nM) was similar 
with binding at pH 7.4 (EC50 (HSA) = 39.70 nM; EC50 (RSA) = 42.88 nM; EC50 (MSA) = 16.50 
nM) (Table 1).  
Size exclusion chromatography (SEC) was also used to evaluate interaction between VHH-
ProtH and human and mouse serum albumin (Fig. 4 and Table 2). The VHH-ProtH 
recombinant protein eluted predominantly as a peak that was deconvoluted as a mixture of 
trimers (97.2 kDa, RS 4.11, 42%) and dimers (75.6 kDa, RS 3.79; 37%) (Fig. 4A). 
Interestingly, neither VHH nor ProtH form oligomers when expressed alone (data not shown). 
HSA revealed a major peak (93%) corresponding to the monomeric form with an apparent 
molecular mass of 68.1 kDa (RS 3.67 nm) and minor peak (7%) of 163 kDa (Fig. 4B). Since 
unbound VHH-ProtH and human albumin eluted in the same molecular mass range, we 
incubated HSA with VHH-ProtH in a 1.1 (w/w) ratio. A new peak around 200 kDa appeared 
and it could be deconvoluted in two peaks corresponding to complexes of HSA and VHH-
ProtH: complex I (218 kDa, RS 5.30 nm; 31%) and complex II (147 kDa, RS 4.67 nm; 17%). 
A peak around 76 kDa (32%) corresponded mainly to unbound VHH-ProtH (Fig. 4C, inset). 
The stoichiometry of the complexes is not clear, but at least complex I appear to contain more 
than one monomer of HSA. Mouse serum albumin demonstrated higher molecular mass 
forms when compared with the human counterpart (Fig. 4D) and a major peak (40%; 
monomeric form) with an apparent molecular mass of 64.3 kDa (RS 3.60 nm). Incubation of 
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MSA with VHH-ProtH resulted in the shift of the monomeric MSA to a large peak that could 
be deconvoluted into two peaks (Fig. 4E). The main component was centered at 98.9 kDa (RS 
4.01 nm) and corresponded to ~88% of the total protein. SDS-PAGE analysis (Fig. 4E, inset, 
lane b) reveals that the peak is a complex of MSA and VHH-ProtH. Contrary to the observed 
with the human albumin, the mouse albumin seems to form a complex with a stoichiometry 
1:1 with VHH-ProtH. 
Thermal stability and in vitro stability 
The thermal stability of VHH and VHH-ProtH was calculated using the Protein Thermal 
Shift Kit and Protein Thermal Shift Software.  Similar melting temperatures (Tm) were 
obtained for both proteins (VHH: 71.53 to 72.34 ºC; VHH-ProtH: 71.73 to 73.58 ºC) (Table 
3). These results demonstrated that both recombinant proteins are highly stable and the ProtH 
fusion did not affect the stability of the anti-TNFα nanobody.  In vitro serum stability was 
analyzed by incubation of VHH and VHH-ProtH proteins with human and mouse serum at 37 
ºC. Samples were incubated during 4 and 24 days in mouse and human serum, respectively. 
The presence of VHH and VHH-ProtH in the collected samples was examined by Western 
Blot. As shown in figures 6A and 6B, both proteins were detected with the expected 
molecular weights and no degradation was observed. The binding activities were confirmed 
by ELISA in all the samples and were similar to samples before incubation (Day 0) (data not 
shown). 
Neutralization of TNFα-dependent cytolytic activity by VHH and VHH-ProtH 
In order to measure the VHH and VHH-ProtH blocking effect on TNF-α/TNFR 
interaction, a murine aneuploid fibrosarcoma cell line (L929) was used as a cytotoxic TNFα-
mediated assay (material and methods section). As shown in Fig. 5, both VHH (EC50 = 68.29 
nM) and VHH-ProtH (EC50 = 19.02 nM) inhibited TNFα-induced cell death of L929 in a 
dose-dependent manner. The data shown that the inhibitory profiles of both recombinant 
proteins were similar, thus indicating that the fusion with the ProtH ABD does not interfere 
with the efficacy of the anti-TNFα VHH nanobody.  
Pharmacokinetic properties of VHH-ProtH 
The pharmacokinetic properties of VHH and VHH-ProtH were evaluated into CD-1 mice, 
after a single i.v. injection (25 µg) into the tail vein. This dose injection was selected 
according to doses applied in other studies with recombinant antibodies in mice10,18. Serum 
concentrations of VHH and VHH-ProtH were determined by ELISA at different time points 
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as described in the material and methods section. When compared with VHH, VHH-ProtH 
exhibited a highly prolonged residence time in blood and mice (Fig. 7 and Table 4), with the 
terminal half-life (t1/2β) increasing from 0.79 h (VHH) to 20.54 h (VHH-ProtH), 
corresponding to a 26-fold increase. Moreover, distribution phase half-life (t1/2α) showed a 7-
fold increase, from 0.52 h (VHH) to 3.59 h (VHH-ProtH). The improvement of 
pharmacokinetic properties was also demonstrated by comparison of the AUC. For VHH-
ProtH the AUC(0-24) was increased by a factor of  21 comparing with VHH. To confirm the 
presence and identity of VHH and VHH-ProtH at each time point, a Western Blot was 
performed. As illustrated in figure 8, comparing with the unmodified VHH nanobody 
(residence in serum during 2 h), VHH-ProtH can be detected in mouse serum until 48 h after 
injection. 
Biodistribution of 99mTc(CO)3-VHH  and 99mTc(CO)3-VHH-ProtH  
In order the analyze the biodistribution profile of each molecule, VHH and VHH-ProtH 
were radiolabeled with the “99mTc(CO)3” core and injected in CD-1 mice. Tissue distributions 
as well as in vivo stability were monitored over a period of 48 h. The biodistribution data of 
both 99mTc-recombinant proteins were expressed as percentage of injected activity per gram of 
organ (% I.A./g ± S.D.) (Fig. 9). For all time points, a total of 85% to 99% of injected activity 
was recovered.  These results clearly indicate similar uptake and elimination rates from major 
organs for both radiolabeled antibody fragments, 99mTc(CO)3-VHH and 99mTc(CO)3-VHH-
ProtH, as well as the same excretory pathway. Most of the activity is rapidly taken by the 
kidney and excreted through the urinary tract.  
Organ to blood ratio (Table 5) showed for both radiolabelled VHH and VHH-ProtH, a 
similar steady state biodistribution behavior, with a high radioactivity accumulation and 
retention within the kidney (390 times and 205 times more concentrated than in the blood, 
respectively, at 24 h p.i.). This high retention is common biological feature of radiolabelled 
proteins and peptides which is assigned to tubular reabsorption. Consequently, the total 
radioactivity excretion is not too rapid (70.2 ± 4.3 % I.A. and 62.6 ± 1.1% I.A. at 24 h p.i. for 
99mTc-VHH and 99mTc-VHH-ProtH, respectively). Moreover biodistribution profile also 
showed a trend for both antibodies to accumulate within highly perfused organs like liver (11 
times and 18 times more concentrated than in the blood, at 24 h p.i. for 99mTc-VHH and 
99mTc-VHH-ProtH, respectively) and intestine (3 times more concentrated). No important 
radioactivity accumulation was found for any other organ with a lower concentration when 
compared to blood, except in the muscle and bone. 
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Chromatographic analysis of blood samples collected at sacrifice time demonstrated that 
both radiolabelled proteins are stable in blood serum, as no metabolite was detected. Most of 
the radioactivity (> 95%) is excreted in the urine as unidentified metabolites that were 
detected by ITLC after 1 h p.i. 
 
DISCUSSION 
Herein, we have evaluated the ability of the ProtH ABD of S. pyogenes to extend the 
circulation half-life of therapeutic proteins.  For this purpose and to validate our strategy, the 
ProtH ABD was fused with an anti-TNFα VHH nanobody. 
We have selected this single-domain antibody because VHH proteins are well-studied and 
natural monomeric antigen binders. Moreover, they can be easily produced and purified, and 
have high solubility and stability properties19-22.  
Our results, demonstrated that both VHH and VHH-ProtH proteins were stably produced 
in E. coli, with high yields of protein of several milligrams per liter of culture (25-30 mg for 
the VHH-ProtH and 15-20 mg for the unmodified nanobody). 
The binding results obtained demonstrate that the presence of HSA (1 mg/ml) did not 
affect the binding of VHH-ProtH to human TNFα, showing similar values to the unmodified 
nanobody.  
 Moreover and importantly, the ProtH domain was shown to specifically bind to human, 
mouse and rat albumins. VHH-ProtH presented similar EC50 values in the nanomolar range at 
acidic and neutral pH. These results are according with a previous study that determined a 
high affinity of the ABD from streptococcal protein H to albumin (Ka = 7.8 nM) by surface 
plasmon resonanace (SPR)12. Other studies also reported albumin binding of the ABD from 
streptococcal protein G, alone and in fusion with recombinant antibodies, with affinities in the 
nanomolar range 10,18,23.  We also observed the formation of VHH-ProtH complexes with 
HSA and MSA in vitro, when incubated at different mass ratios. Interestingly, VHH-ProtH 
forms preferably dimers and trimers in solution with 2-fold increase of radius when 
comparing with the VHH (4.11/3.79 nm versus 1.84 nm). These findings are supported by the 
observation that protein H forms temperature-dependent dimers and high molecular mass 
forms (at temperatures lower than 30 ºC)12,24-27, probably through the D region and/or the C 
repeats. The protein H dimers had showed a higher affinity for albumin12,24. In this study the 
binding of VHH-ProtH to HSA or MSA seems to produce complexes in different mass 
ranges. Binding of VHH-ProtH to HSA produces complexes with high molecular mass, as it 
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has been seen for protein H binding to IgG26, whereas binding of VHH-ProtH H to MSA 
produces complexes that contain fewer subunits of VHH-ProtH. 
Furthermore, fusion of ProtH with the nanobody did not affect the high thermal stability of 
the nanobody (VHH Tm = ~70 ºC versus VHH-ProtH Tm = ~72 ºC). Serum stability studies 
also demonstrate the high stability in human and mouse serum of VHH and VHH-ProtH 
proteins (Fig. 6). Additionally, the TNF-neutralization assay results indicated a higher 
inhibition of TNFα activity of VHH-ProtH (EC50 = 19.02 nM versus EC50 = 68.29 nM), which  
is in accordance with the TNFα binding, showing that at nanomolar level the ProtH ABD 
fusion improved the efficacy of the anti-TNFα VHH.  
Regarding the pharmokinetics, when compared to VHH, VHH-ProtH showed an 
extraordinary 26-fold increase of the terminal elimination half-life (47 min versus 20.5 h for 
the ProtH fusion nanobody). Moreover, the VHH-ProtH AUC was increased by a factor of 21 
and the VHH-ProtH could be detected in the mouse serum until 48 h after injection (Fig. 
8).The organ distribution of 99mTc(CO)3-VHH  and 99mTc(CO)3-VHH-ProtH (Fig. 9) exhibited 
similar biodistribution profiles, presenting a kidney retention in both proteins (Fig. 9), 
common in radiolabelled proteins and peptides which is assigned to tubular reabsorption. 
Moreover biodistribution profile also showed a trend for both recombinant antibodies to 
accumulate within highly perfused organs, like the intestine. 
Previous studies presented a similar strategy to extend half-life, using the ABD3 from 
streptococcal protein G in fusion with a bispecific single-chain diabody (scDb) developed for 
retargeting cytotoxic T cells to CEA-expressing tumor cells10,18,28. The terminal half-life of 
VHH-ProtH is similar of the circulation times determined for scDbCEACD3-ABD (27.6 h)10 
and for the same scDbCEACD3 in fusion with human serum albumin (25,0 h)29. This 
improvement of half-life probably can be compared with the half-lives of serum albumin, 
which are 1.07-1.6 days for mouse serum albumin and ~19 days for human serum albumin30-
32. These findings indicate that VHH-ProtH utilizes binding to mouse albumin to achieve an 
extension in circulation time, most likely caused by reduced renal clearance and FcRn-
mediated recycling effects of VHH-ProtH albumin complexes formed in vivo. Stork and co-
workers, compared the half-life of the scDbCEACD3-ABD in the wild-type and neonatal Fc 
receptor (FcRn) heavy chain knockout mice and confirmed that the half-life extension of this 
fusion bispecific single-chain diabody is mediated through recycling by the FcRn28.  
A previous study developed bivalent nanobodies in fusion with AR1, an anti-TNFα VHH 
targeting murine and human albumin, to increase the accumulation of the single-domain 
antibody in the target tissue (inflamed joints) and to prolong its serum half-life. Their 
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biodistribution results demonstrated a significant increase of the bispecific anti-TNFα VHH in 
fusion with AR1 accumulated in inflamed joints and that this uptake was correlated with the 
higher clinical scores for the corresponding limbs. The bispecific anti-TNFα VHH in fusion 
with AR1, also revealed promising results in circulation time extension improvement. 
Consequently, the fusion with an anti-albumin anti-TNFα VHH substantially increased the 
half-life of the bivalent molecules targeting human (54 min and 35 min for monovalent VHH 
versus 2.2 days for the AR1 fusion) and mouse TNFα (47 min versus 1.9 days for the 
albumin-binding molecule fusion)33. 
Other studies indicated that high quantities of albumin accumulate and are metabolized in 
the inflamed joints of patients with active rheumatoid arthritis, which frequently develop 
hypoalbuminemia34-37. Preclinical models have demonstrated the possibility of albumin works 
as a biocarrier of therapeutic drugs in rheumatoid arthritis38-40. This information shows that 
albumin might be an attractive drug carrier to target biodrugs to inflammed joints of patients 
with rheumatoid arthritis.  
Even though ProtH ABD has shown substantial progresses in pharmacokinetic properties 
of the nanobody, concerns with the immunogenicity of bacterial molecules for therapeutic 
applications may occur. For therapeutic use, particularly in small proteins that require 
administration by repeated injections, it will be necessary reduce or ideally eliminate the 
immunogenicity, and several de-immunization strategies can be applied to solve the 
immunogenicity of the ABD41,42. 
In summary, these experiments show that the fusion with ProtH ABD increase the half-life 
of a nanobody against human TNFα, improving the pharmacokinetic disposition of the 
parental VHH without affecting its therapeutic efficacy. VHH-ProtH is a promising example 
of the importance of drug carriers in developing a new generation of targeted therapeutic 
drugs. Targeting inflamed joints by fusion to ProtH ABD might be an attractive strategy in the 
treatment of rheumatoid arthritis. Using the properties of albumin as a drug carrier, this 
strategy to improve pharmacokinetic behavior of therapeutic proteins, can be a promising 
approach to use as a fusion partner with other molecules for the treatment of several diseases. 
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ABBREVIATIONS  
ABD, albumin-binding domain; AUC, area under the curve; FcRn, neonatal Fc receptor; 
HSA, human serum albumin; IgG, immunoglobulin G; MSA, mouse serum albumin; PEG, 
polyethylene glycol; ProtH, ABD from streptococcal cell surface protein H; RSA, rat serum 
albumin; TNFα, tumour necrosis factor, VHH, camelid single-domain antibody or nanobody.  
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FIGURE LEGENDS 
Fig. 1: Construction and production of VHH and VHH-ProtH. (A) Domain structure of 
VHH and VHH-ProtH including the N-terminal leader peptide (LP) and the C-terminal 
histidine (His7) and HA tags. (B) Sequence of the wild-type ABD. (C) SDS-PAGE and (D) 
Western Blot analysis of the VHH and VHH-ProtH purified proteins (3 µg/lane) under 
reducing (lanes 1 and 2) and non-reducing conditions (lanes 3 and 4). Gels were stained with 
Coomassie brilliant blue (C) or immunoblotted with an anti-HA-tag antibody (D). 
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Fig. 2: Binding of VHH and VHH-ProtH to human TNFα. ELISA plates were coated with 
human TNFα (200 ng/well) and binding of VHH and VHH-ProtH fusion protein was 
measured in the presence (A) and absence (B) of HSA (1 mg/ml). Detection was achieved 
using an HRP-conjugated anti-HA-tag antibody. 
Fig. 3: Binding of VHH-ProtH to human, rat and mouse albumin. Binding of VHH and 
VHH-ProtH fusion protein was evaluated in ELISA at neutral pH - pH 7.4 (A); and acidic pH 
- pH 6.0 (B). Bound proteins were detected using an HRP-conjugated anti-HA-tag antibody. 
Fig. 4: Formation of VHH-ProtH/albumin complexes. Size exclusion chromatography 
analysis of VHH-ProtH (A), HSA (B), VHH-ProtH/HSA complex (C), MSA (D) and VHH-
ProtH/MSA complex (E). VHH-ProtH was incubated at 1:1 (w/w) with albumins in PBS1x at 
room temperature. Peak positions of marker proteins are indicated. Chromatograms in C and 
E were resolved into individual Gaussian peaks by using linear least-squares fit (PeakFit, 
Systat Software Inc). Insets in C and E represent SDS-PAGE analysis of selected fractions. 
M, molecular weight marker.   
Fig. 5: TNFα-neutralization capacities of VHH and VHH-ProtH. Dose-response curves of 
VHH and VHH-ProtH proteins to examine the TNFα-mediated cytoxicity were calculated in 
the presence of 0,5 ng/ml human TNFα, on the TNF-sensitive mouse fibroblast cell line 
L929s.   
Fig. 6: In vitro stability in human and mouse serum of VHH and VHH-ProtH. In vitro 
stability of the recombinant proteins was determined in human serum (A) and mouse serum 
(B) at 37 ºC, during 24 days and 4 days, respectively. Proteins were detected by Western Blot, 
using an anti-His-tag antibody. 
Fig. 7: Pharmacokinetic properties. Both VHH and VHH-ProtH fusion protein were i.v. 
injected into CD-1 mice (25 µg/animal) and absorbance pharmacokinetic profiles of these 
proteins were calculated by ELISA, at different time points. Data were normalized 
considering maximal concentration of protein at the first time point (5 min). 
Fig. 8: In vivo stability in mouse serum of VHH and VHH-ProtH. In vivo stability of 
VHH-ProtH (A) and VHH (B) was evaluated by western blot with an anti-HA-tag antibody, 
in the mice serum samples collected during the pharmacokinetic assay. 
Fig. 9: Biodistribution of 99mTc(CO)3-VHH  and 99mTc(CO)3-VHH-ProtH. Organ 
distribution of  99mTc-VHH (A) and 99mTc-VHH-ProtH (B) proteins in CD-1 mice. 
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TABLES 
Table 1: Binding of VHH-ProtH to HSA, RSA and MSA. 
Protein EC50 for HSA 
(nM) 
EC50 for RSA 
(nM) 
EC50 for MSA 
(nM) 
VHH-ProtH pH 6.0 53.03 ± 0.02 40.76 ± 0.04 36.74 ± 0.08 
VHH-ProtH pH 7.4 39.70 ± 0.03 42.88 ±0.05 16.50 ± 0.07 
 
Table 2: Molecular mass and hydrodynamic radius. 
Protein or complex Lengt
h 
Calculated 
Mra 
SEC apparent Mr Stokes’ radius 
(RS) 
 aa kDa kDa nm 
VHH 180 19.4 14.9 1.84 
VHH-ProtH 321 34.7 97.2/75.6 4.11/3.79 
HSA 585 66.5 68.1 3.67 
MSA 584 65.9 64.3 3.60 
VHH-ProtH /HSA − 101.2 218/147 5.30/4.67 
VHH-ProtH /MSA − 100.6 98.9 4.01 
cCalculated based on the amino acid sequence. 
 
Table 3: Thermal stability of VHH and VHH-ProtH. 
Protein Tm B - Mean 
(°C) 
Tm B – Median 
(°C) 
Tm D - Mean 
(°C) 
Tm D - Median 
(°C) 
VHH 71.53 ± 0.14 71.56 ± 0.14 72.34 ± 0.25 72.43 ± 0.25 
VHH-ProtH 71.73 ± 0.08 71.57± 0.08  73.58 ± 0.10 73.70 ± 0.10 
Tm B - Calculated Boltzamnn melting temperature; Tm D - Calculated Derivated melting temperature. 
 
Table 4: Pharmacokinetic parameters of VHH and VHH-ProtH. 
Protein t1/2α (h) t1/2β (h) AUC(0-24 h) (%*h) 
VHH 0.52 ± 0.25  0.79  ± 0.12 72.75 ± 7.35 
VHH-ProtH 3.59 ± 0.24 20.54 ± 0.12 1539.17 ± 92.39 
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Table 5: Organ to blood ratio of 99mTc-VHH and 99mTc VHH-ProtH at 24 h time point  
Organ VHH VHH-ProtH 
Liver 11.3 18.6 
Intestine 3.42 3.45 
Spleen 0.413 0.456 
Heart 0.122 0.121 
Lung 1.80 0.375 
Kidney 390 205 
Muscle 4.77 5.87 
Bone 2.09 2.03 
Stomach 0.600 0.500 
Pancreas 0.140 0.167 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 5  
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Figure 9 
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ALBUMIN-BINDING	CHARACTERIZATION	
AND	THREE-DIMENSIONAL	STRUCTURE	OF	
ZAG	ABD	FROM	STREPTOCOCCUS	
ZOOEPIDEMICUS 
 
 
 
Brief Introduction 
Streptococcal albumin-binding domains have been extensively studied as fusion proteins to 
improve the pharmacokinetic properties of therapeutic proteins and as protein scaffolds for 
therapeutic applications (Kontermann, 2012). 
ZAG is a cell-surface protein G-related from S. zooepidemicus, with an Ig-binding region 
located in the C-terminus and an ABD composed by 52 amino acids, showing an albumin-
binding profile similar to the protein G (Jonsson et al., 1994). Protein G albumin-binding 
domain (SpG) presents a three-α-helix three-dimensional structure (Kraulis et al, 1996), and 
has been successfully explored as a protein scaffold (Fredj, 2012). 
In this research work we characterize the protein ZAG ABD (Zag) ability to bind albumin 
and stability. We also report the circular dichroism (CD) measurements of Zag ABD and 
Zag/albumin complex conformations, and the assignment of the NMR 15N and 13C backbones 
resonances of Zag ABD to determine its three-dimensional structure. Firstly, we optimize the 
production of the Zag ABD in E.coli, an easy way to obtain high amounts of protein with 
lower costs. Then we characterize the albumin binding and stability of the Zag motif. Finally, 
we investigated the conformation of Zag ABD in the presence and absence of human serum 
albumin and determined the three-dimensional structure of Zag motif by NMR. 
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Background: Albumin-binding domains (ABD) have been extensively studied and engineered to 
improve half-life of therapeutic proteins and as protein scaffolds for therapeutic applications. 
Results: Streptococcal Zag ABD could be stably produced in bacteria, presenting high binding to 
human, rat and mouse serum albumins. By NMR spectroscopy we could determine the solution 
structure of the Zag protein and show that it has a three-alpha helix conformation.  
Conclusions: The Zag ABD albumin-binding moiety exhibit albumin-binding properties and a three-
dimensional structure similar with other protein G-related proteins.  
Significance: This study further establishes Zag albumin-binding domain as a possible scaffold   that 
can be further engineered as a therapeutic protein and as a strategy to improve pharmacokinetics of 
small therapeutic proteins or peptides. 
 
ABSTRACT 
Zag, a protein G-related cell surface protein from Streptococcus zooepidemicus, presents a 
multiple domain structure comprising an albumin-binding domain (ABD), immunoglobulin G 
(IgG)-binding domains and a α2-macroglobulin binding site. Streptococcal albumin-binding 
domains structure and function have been extensively studied in the last years, with promising 
results for therapeutic applications as scaffolds or used as albumin-binding moieties to 
improve the pharmacokinetics of small therapeutic proteins. In the present study, we 
characterize and solved the structure of the Zag ABD from S. zooepidemicus. Our results 
shown that the Zag protein could be stably expressed in the soluble format in Escherichia 
coli, presented high thermal stability properties and specifically recognize mouse, rat and 
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human albumins. Furthermore, Far-UV circular dichroism analysis of the Zag secondary 
structure in buffer reveals a high helical content also shows that when the protein is bound to 
human serum albumin (HSA), the formed complex is also α-helical structured. Importantly, 
by NMR spectroscopy we could determine the solution structure of the Zag protein and show 
that it has a three-alpha helix conformation. 
Our findings show the great potential of Zag albumin-binding domain as a possible 
scaffold that can be further engineered as a therapeutic protein and as a strategy to improve 
pharmacokinetics of small therapeutic proteins. 
 
INTRODUCTION 
Since the early 90’s, a broad class of three-helix albumin-binding domains have been 
investigated and described. The protein G albumin-binding domains structure and properties 
have been extensively studied, and their applications for improving pharmacokinetics of 
therapeutic antibodies has been well documented1-4. Previous work from de Château and 
Björck with PAB cell surface protein from Peptosteptococcus magnus, a mosaic albumin-
binding bacterial protein, representing for the first time an example of a shuffled bacterial 
module5. The protein G albumin-binding domain, or other protein G-related albumin-binding 
modules, as the GA module from PAB protein, showed three-helix bundle architectures6,7. 
Recent studies used molecule based-structure methods to develop new scaffolds for 
therapeutic applications in several diseases, e.g. cancer and inflammatory diseases8-10. 
Affibody molecules are small (6-7 kDa) high affinity and robust 3-helix proteins, based on a 
modified immunoglobulin-binding B domain of staphylococcal protein A. Affibody scaffolds 
are a successful example of the therapeutic potential of these kind of molecules11-14. 
 Depending on the bacterial strain, albumin-binding domains (ABDs) and Ig-binding 
domains (IgBDs) can contain one, two or three repeats of approximate 50-60 amino acid 
residues4,5,15,16. Interestingly, like streptococcal ABDs, IgBDs can also present a three-α-helix 
bundle and additionally, there were described compact structures composed of a four-stranded 
β-sheet and one-α-helix17,18. At least 16 repeated albumin-binding domains, also known as 
GA modules, with relatively high sequence identity have been identified in several bacterial 
species19. The interactions between these GA modules with albumin may play an important 
role in the pathogenesis of these microorganisms. Therefore, pathogenic bacteria may have 
surface proteins with these domains to allow coating their surfaces with host proteins in 
mammalian plasma during the infectious process20. 
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Jonsson and co-workers described a plasma protein receptor, a protein-G related cell 
surface protein from Streptococcus zooepidemicus, termed protein ZAG, a 45 kDa protein 
with distinct bind sites for α2-macroglobulin, serum albumin and immunoglobulin G (IgG). 
The IgG-binding domains from ZAG are homologous to the IgG-binding domains in protein 
G and to the corresponding domains in proteins MIG and MAG from S. dysgalactiae4. Protein 
ZAG shows an albumin-binding profile similar to those of protein G21 and the albumin-
binding DG12 protein from a bovine group G streptococcus20. In the N-terminus, ZAG 
protein presents a 52 amino acid sequence ABD with binding to human, rat, mouse, horse and 
dog serum albumin. Downstream from this region there are two amino acid repeats 
homologous to the IgG-binding domains of type III Fc receptors4. 
In the present study, we characterize and solved the structure of the Zag ABD from S. 
zooepidemicus. For this propose, the Zag/albumin binding activity was characterized by 
ELISA, SEC and circular dichroism (CD) assays. To solve the Zag ABD structure nuclear 
magnetic resonance (NMR) 15N and 13C backbone resonances technique was applied. 
 
EXPERIMENTAL PROCEDURES 
Materials – Human serum albumin (HSA) (catalog no. A3782), rat serum albumin (RSA) 
(catalog no. A6272), mouse serum albumin (MSA) (catalog no. A3139) and pT7-FLAG2 
expression vector were purchased from Sigma-Aldrich (USA). Antibody HRP-conjugated 
anti-His-tag, 2,2'-Azino-di-[3-ethylbenzthiazoline sulfonate (6)] diammonium salt (ABTS), 
and cOmplete EDTA-free protease inhibitors cocktail were acquired from Roche (Germany). 
HisTrap HP columns and Amicon were purchased from GE Healthcare (UK) and Millipore, 
respectively.  
Construction of pT7-Zag – DNA encoding the Zag albumin-binding domain of Streptococcus 
zooepidemicus4 was generated by PCR with primers HindIII-Zag-F (5’ -CCC AAG CTT ATG 
GAC ATT ACA GGA GCA GCC TTG- 3’) and Zag-BglII-R: (5’ -GGA AGA TCT CTA 
GTG ATG GTG ATG GTG ATG GCT GCC TCC GCC AGA CGG TAG AGC TGA TAA-
3’), using the pT7-VHH-Zag vector previously constructed22, adding HindIII and BglII 
restriction sites at the fragment 5’ and 3’ ends, respectively and the sequences encoding 
peptide tag (His6) for purification and detection. The resulting PCR fragments were gel-
purified, digested with the restriction enzymes and cloned into the appropriately cut pT7-
FLAG2 vector.  A short GS linker (SGGGGS) was used to link the Zag ABD to the His6-tag. 
The pT7-Zag construct was verified by sequencing. 
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Expression and purification of Zag – Zag ABD was expressed in Escherichia coli strain 
BL21(DE3). One liter of LB, containing 100µg/ml ampicillin were inoculated with 10 ml of 
overnight culture of bacterial cells transformed with the plasmid pT7-Zag and grown to 
exponential phase (A600 = 0.6-0.9) at 37 ºC. Expression was induced by the addition of 1 mM 
isopropyl β-ᴅ-1-thiogalactopyranoside (IPTG) and growth during 16 h at 18 ºC. Cells were 
harvested by centrifugation (4000  g for 15 min at 4 ºC) and resuspended in 50 ml 
equilibration buffer (50 mM HEPES, 1 M NaCl, 5 mM CaCl2, 30 mM imidazole, pH 7.5) 
supplemented with protease inhibitors. Cells were lysed by sonication. Centrifugation (9000 
rpm for 30 min at 4 ºC) was used to remove cell debris, and the supernatant was filtered 
through a 0.2 µm syringe filter. The Zag protein was purified using AKTA FPLC System (GE 
Healthcare) by nickel chelate affinity chromatography with HisTrap HP columns. After a 
washing step (50 mM HEPES, 1 M NaCl, 5 mM CaCl2, 60 mM imidazole, pH 7.5) the 
recombinant antibody fragments were eluted with a linear imidazole gradient from 60 to 300 
mM in 50 mM HEPES, 1 M NaCl, 5 mM CaCl2, pH 7.5. Protein fractions were pooled, then 
desalted and concentrated in 50 mM HEPES, 100 mM NaCl, 5 mM CaCl2, pH 7.5 using 
Amicon 3K (Millipore). The purity of samples was analyzed by SDS-PAGE. Protein 
concentration was determined spectrophotometrically at 280 nm. 
Protein thermal stability – Melting temperature of the Zag was determined using the Protein 
Thermal Shift Kit and 7500 Fast Real-Time PCR System (Applied Biosystems, USA) 
according manufacturer’s instructions. Protein samples (5 µg/well) were tested in 
MicroAmpTM Fast Optical 96-well Reaction Plates and analyzed in quadruplicate using and 
diluted in 50mM HEPES, 100 mM NaCl, 5 mM CaCl2, pH 7.5,  and Protein Thermal ShiftTM 
Dye 1x. Collected data were analyzed with Protein Thermal Shift Software version 1.1. 
ELISA – Binding properties of Zag ABD was determine in 96-well coated with HSA, RSA, 
MSA (10 µg/well) overnight at 4 ºC. After 1 h blocking with 5% soya milk, purified protein 
samples were titrated in triplicate and incubated for 1 h at room temperature. Detection was 
performed with HRP-conjugated anti-His-tag antibody using ABTS substrate. Absorbance 
was measured at 405 nm in an ELISA reader. GraphPad Prism version 5 was used for data 
analysis. 
Size Exclusion Chromatography – Apparent molecular weight of Zag ABD and formation of 
Zag/albumin complexes was determined by FPLC-SEC on a HiLoad Superdex 200 HR 
column (GE Healthcare) with a flow rate of 0.7 ml/min and PBS1x as running buffer. The 
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following standard proteins were used: apoferritin (443 kDa, RS 6.1 nm), β-amylase (200 kDa, 
RS 5.4 nm), alcohol dehydrogenase (150 kDa, RS 4.55 nm), bovine serum albumin (67 kDa, 
RS 3.55 nm), ovalbumin (45 kDa, RS 3.05), myoglobin (17.6 kDa, RS 1.91 nm), ribonuclease 
A (13.7 kDa, RS 1.64 nm) and cytochrome c (12.4 kDa, RS 1.77 nm). Blue dextran and L-
tyrosine were used to determine the void and total column volume, respectively. Elution 
volume of the protein standard was used to create a standard curve of Stokes’ radius (RS) 
versus (-log Kav)1/2 that was used to calculate the Stokes’ radii of recombinant antibody and 
antibody/albumin complexes. Complex formation of Zag with HSA and MSA was analysed 
by incubating equimolar amounts of Zag and albumin (10 M) in PBS1x at room temperature 
and subsequent analysis by size exclusion chromatography (SEC). SDS-PAGE analysis of 
collected samples was performed to evaluate albumin binding. 
Circular dichroism measurements – CD spectra were obtained on a Jasco J-815 instrument 
(Jasco Co, Tokyo, Japan) using a 1 mm path length cuvette. Spectra were collected from 190 
to 260 nm at 37ºC , with a scan speed of 50 nm/min. Samples were prepared in 50 mM Tris 
buffer with 100 mM NaCl, 5 mM CaCl2, pH 7.5. HSA and Zag ABD spectra were measured 
at 4 µM and 20 µM respectively. The CD signal of Zag ABD protein was also recorded in the 
presence of albumin. Zag ABD protein was added to a HSA 4 µM solution at ratios from 
1:0.25 to 1:1. All spectra were further corrected by subtracting the contribution of the 
appropriate blank.   
Expression and purification of 13C 15N-labelled Zag ABD – The Zag expression protocol was 
performed has previously described by Marley and co-workers23. 13C-glucose and 
(15NH4)2SO4, purchased from Cambridge Isotopes Laboratory (Cambridge, MA) were the 
only carbon and nitrogen sources, respectively, and the other reagents were purchased from 
Sigma-Aldrich (USA). The culture medium was supplemented with: 1g/L (15NH4)2SO4, 4 g/L 
13C-glucose, 100mg/L thiamine, 1 ml 0,01 M FeCl3 and MEM Vitamins 1x. Expression was 
induced by the addition of 1 mM isopropyl β-ᴅ-1-thiogalactopyranoside (IPTG) and growth 
during 16 h at 20 ºC. Cells were harvested by centrifugation (7000 rpm, 15 min at 4 ºC) and 
washed in M9 Salts medium 1x without any source of carbon and nitrogen. After another 
centrifugation step (10000 rpm, 10 min at 4 ºC) the cells were frozen at -20 ºC at least during 
30 min. For protein purification, cells were re-suspended in 50 ml equilibration buffer (50 
mM HEPES, 1 M NaCl, 5 mM CaCl2, 30 mM imidazole, pH 7.5) supplemented with protease 
inhibitors (Roche, Germany). Cells were lysed by sonication. Centrifugation (9500 rpm for 30 
128 
 
min at 4 ºC) was used to remove cell debris, and the supernatant was filtered through a 0.2 µm 
syringe filter. The Zag protein was purified using AKTA FPLC System by nickel chelate 
affinity chromatography with HisTrap HP columns. After a washing step (50 mM HEPES, 1 
M NaCl, 5 mM CaCl2, 60 mM imidazole, pH 7.5) the Zag protein was eluted with a linear 
imidazole gradient from 60 to 300 mM in 50 mM HEPES, 1 M NaCl, 5 mM CaCl2, pH 7.5. 
Protein fractions were pooled, then desalted and concentrated in 50 mM HEPES, 100 mM 
NaCl, 5 mM CaCl2, pH 7.5 using Amicon 3K (Millipore, USA). Protein concentration was 
determined spectrophotometrically at 280 nm. 
NMR spectroscopy – A 1 mM sample of 15N and 15N/13C purified Zag protein in 10 mM Tris-
HCl, 100 mM NaCl, 10% D2O, pH 7.5 was used for structural characterization of backbone 
and side-chain assignments. NMR spectra were collected at 25 C on a Bruker Avance II+ 
400 MHz and 600 MHz both with a 5 mm x,y,z-shielded pulse field gradient triple-resonance 
probe (the 600 MHz is equipped with a cryoprobe) all supported by the National NMR 
Network (PTNMR) at the Chemistry Department, Faculdade de Ciências e Tecnologia, 
Universidade Nova de Lisboa. A series of three-dimensional spectra [CBCA(CO)NH, 
HNCACB, HNCO, CC(CO)NH, 15N-TOCSY-HSQC, HCCH-COSY, 1H-1H-15N-NOESY-
HSQC, 1H-1H-13C-NOESY-HSQC] and two-dimensional [1H-15N HSQC] were collected for 
complete assignment and NOE measurement (mixing time of 120 ms). The number of 
complex points and spectral width are summarised in Table 1. For Fourier transformation all 
dimensions were zero-filled twice and linear prediction and zero filling were equally 
employed. All NMR data were processed using NMRPipe24 and analyzed using CCPN25. 
Structure calculations were performed with the programs ATNOS/CANDID26,27 implemented 
in UNIO in combination with CYANA28, using as input the amino sequence, the chemical 
shift lists, and the three 1H, 1H, NOE experiments: three-dimensional 13C- and 15N-resolved 
NOESY recorded at 600 MHz with a mixing time of 120 ms. The standard protocol with 
seven cycles of peak picking using ATNOS, NOE assignment with CANDID, and structure 
calculation with CYANA-2.128 was applied.  and  dihedral angle constraints were derived 
from the chemical shift index29 and TALOS analysis30. In each UNIO cycle, the angle 
constraints were combined with the updated NOE upper distance constraints in the input for 
the subsequent CYANA-2.1 structure calculation cycle. The 20 conformers with the lowest 
residual target function values and without violations of dihedral angle restraints or distance 
were subjected to restrained energy minimization in explicit water with Xplor-NIH31,32. The 
quality of the structures was evaluated using the programs PROCHECK-NMR33 and 
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WHATIF34. The root mean square deviation to the mean structure for the structured region of 
the protein (residues 3–60) is 2.24  0.55 Å for the backbone and 2.86  0.50 Å for all heavy 
atoms. The Ramachandran plot for the ensemble of 20 structures determined with 
PROCHECK-NMR33 had 90.2% of residues in core regions, 9.6% of residues in allowed 
regions and 0.2% of residues in disallowed regions. Summary WHAT IF statistics34 are 
shown below. These statistics provide an overall summary of the quality of the structure as 
compared with current reliable structures. Structure Z-scores show a number of constraint-
independent quality indicators. RMS Z-scores mostly give an impression of how well the 
model conforms to common refinement constraint values. The standard deviation shows 
variation over models in the ensemble, where appropriate. 
Structure Z-scores: first-generation packing quality, -0.77±0.36; second-generation packing 
quality, -2.77 ± 0.48; Ramachandran plot appearance, -2.49 ± 0.46; 1/2 rotamer normality, -
2.46 ± 0.46; backbone conformation, 5.63 ± 0.66. RMS Z-scores: bond lengths, 0.68 ± 0.03; 
bond angles, 0.66 ± 0.04;  angle restraints, 0.80 ± 0.08; side-chain planarity, 0.77 ± 0.20; 
improper dihedral distribution, 0.85 ± 0.07; inside/outside distribution, 1,17 ± 0.03. 
 
RESULTS 
Expression and purification of Zag  
Zag ABD is composed by 52 aa and the DNA sequence published by Jonsson and co-
workers (1995)4 . In order to characterize the Zag ABD, the Zag gene was cloned into the  
pT7 vector with an hexahistidyl (His6) in C-terminus (Fig. 1A). The ABD was expressed in E. 
coli BL21(DE3) and purified by IMAC. The observed expression yield per liter of shake-flask 
culture without optimization was relatively high for the Zag protein (8-10 mg/L) (Fig. 1B). 
SDS-PAGE and Western Blot results of the final purified samples of protein showed a single 
protein band for Zag under reducing (Fig. 1C and D).  
Zag ABD thermal stability 
The thermal stability of Zag ABD was calculated using the Protein Thermal Shift Kit and 
Protein Thermal Shift Software (Table 2). The results indicate a high thermal stability of the 
albumin-binding domain in a range of temperature of 67 to 75ºC.  
Binding of Zag ABD to albumins 
In order to evaluate the albumin-binding capacity of Zag ABD, ELISA assays were 
performed at neutral pH 7.4 and at pH 6.0, to simulate the acidic environment, existing in 
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endosomes, where neonatal Fc receptor (FcRn) mediates the recycling of albumin in order to 
maintain the long life of this plasma protein35. The human, rat and mouse serum albumin 
binding of Zag was similar in both pH conditions (Fig. 2A and 2B, Table 3). Binding of Zag 
to albumin at pH 6.0 was slightly increased (EC50 (HSA) = 0.12 nM; EC50 (RSA) = 0.11 nM) 
when compared with binding at pH 7.4 (EC50 (HSA) = 0.36 nM; EC50 (RSA) = 3.26 nM), except 
for MSA (EC50 = 0.21 nM at pH 6.0 versus EC50 = 0.13 nM at pH 7.4) that presented similar 
values. 
Moreover, SEC analysis also shows the interaction between Zag and human and mouse 
serum albumin in solution (Fig. 3 and Table 3). Zag and albumins were incubated at 1:1, 
molar (corresponding to ~1:4, (w/w) Zag:HSA) in PBS1x at room temperature. Peak positions 
of marker proteins are indicated. Zag eluted as a monomer with an apparent molecular mass 
of 10.3 kDa (RS 1.62 nm). HSA major peak (monomer) with an apparent molecular mass of 
68.1 kDa (RS 3.67 nm) and MSA monomer with an apparent mass of 64.3 kDa (RS 3.60 nm) 
were shifted after incubation with Zag to 82.4 kDa (RS 3.78 nm) and 89 kDa (RS 3.87 nm), 
respectively. 
Circular dichroism  
CD spectroscopy allowed the study of Zag structure and possible conformational changes 
after HSA binding. HSA spectrum in buffer solution shows two negative bands near 208 and 
222 nm and a positive band near 195 nm, typical of α-helical conformation (Fig. 4A)36. Zag 
protein spectrum presents also the negative bands typical of the helical conformation with the 
positive band less pronounced (Fig. 4B). The addition of Zag protein to a HSA solution 
revealed that the formed complex maintains a helical structure and also that adding increasing 
concentrations of Zag to HSA solution results in an increase in the helical content (Fig. 4C). 
Zag NMR  
A 2D 1H-15N HSQC spectrum is a reliable method to judge the suitability of a particular 
protein for structural determination by NMR spectroscopy. A well-folded protein would 
display a wide dispersion of amide proton chemical shifts in 2D 1H-15N HSQC spectrum, as 
seen on Fig. 5 for Zag protein. Such good dispersion of the cross-peaks in the spectrum is 
undoubtedly a sign of a correct folding. Towards the complete structure determination of 
Im7H3M3 by NMR spectroscopy, backbone and side-chain assignments are essential. 
Complete backbone resonance assignment of Im7H3M3 was achieved, excluding the His-tag 
tail in the N-terminus of the protein. 
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The chemical shift index (CSI) analysis on Zag has shown the presence of helix 
conformations between residues A9 to Q24 (helix 1), D29 to K37 (helix 2) and V41 to S53 
(helix 3). The helical regions of the repeated protein G-related albumin-binding domains, 
known as GA modules, found in streptococci protein G (G148-GA3)7 and Peptostreptococcis 
magnus protein PAB (ALB8-GA)6 exhibit ~60% sequence identity and both fold to form 
three-helix bundle structures. In protein G ABD, helix I ranges from residues 7 or 8 to 20 or 
21, helix II ranges from residues 26 to 35 or 36, and helix III ranges from 38 to 517. Protein 
PAB ABD three-helix bundle starts in the first helix at Ala-17 or Asn-18 and ends with Lys-
33. The second helix begins with Asp-38 and ends with Asn-45. The third helix spans Val-50 
to Ala-626. A three-alpha-helix bundle similar to these ABDs is also present in the Ig-binding 
domain (IgBD) from staphylococcal protein A37,38. However, a comparison of the amino acid 
sequences of ABDs with IgBD from protein A revealed no detectable significant sequence 
homology. 
 
DISCUSSION 
In the present study, we characterize the Streptococcus zooepidemicus Zag ABD albumin-
binding properties and determine its three-dimensional structure. Our data shown that the Zag 
ABD was stably produced in E. coli, with high yields of protein of several milligrams per liter 
of culture (Fig. 1B). Our findings of Zag binding to serum albumin were in the range of 
nanomolar. For instance, at pH 6.0 Zag ABD binding to HSA, RSA and MSA was slightly 
increased with values of EC50 = 0.12 nM, 0.11 nM and 0.21 nM, respectively, compared with 
binding at pH 7.4 with EC50 values of 0.36 nM, 1.26 nM and 0.13 nM. Quite a few studies 
evaluated the binding capacities between different bacterial serum albumin-binding domains, 
showing different results usually with affinities in the range of nanomolar 4,16,21,39. Jonsson 
and co-workers investigated the binding properties of ZAG surface proteins and discovered 
that protein ZAG bind serum albumin of human, horse, rat, mouse, and dog origin, but not 
pig, rabbit, sheep, cow, hen or goat origin. The interaction of ZAG cell surface protein with 
different ligands was also calculated by surface plasmon resonance and the Koff values of the 
interaction with HSA and α2M were 8.3 x 107 and 1.4 x 108 M-1, respectively4.  
The SEC results of Zag binding to human and mouse albumin also support the efficient 
binding of this ABD to serum albumin, showing the formation of complexes of Zag/albumin 
with the increase of the Stokes radius. Stork and colleagues also verified that a recombinant 
diabody fusion with ABD3 from protein G presented a slightly increased binding at pH 6.0 
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then pH 7.4 with KD of 1.7 nM versus 0.9 nM, respectively40. Protein G optimal binding was 
confirmed at acidic pH and was lower at higher temperatures41. 
Moreover, our measured affinity of Zag in fusion with an anti-TNFα VHH23 for HSA, 
RSA and MSA, were in the range of nanomolar affinity, with values of KD = 4.57 nM, 0.42 
nM and 40.6 nM (data not shown), respectively, showing similar results to those obtained in 
previous studies, reporting affinities in the same range for the streptococcal protein G 
ABD16,39-41.  Furthermore, binding of VHH-Zag to human, rat and mouse albumin was not 
reduced at pH 6.0 (data not shown), demonstrating that VHH-Zag binding to albumin is stable 
at low pH e.g., found in endosomes. These findings and the formation of Zag/albumin 
complexes in vitro, support the fact that Zag ABD binds to albumin and can be triggered by 
FcRn-mediated recycling mechanism to achieve a long half-life, i.e. albumin has a half-life of 
~19 days in humans35.  
Zag ABD also exhibit high thermal stability, presenting melting temperatures in the range 
of 67 to 75 ºC (Table 2). These data are consistent with our previous work were we fused the 
Zas ABD with an anti-TNF VHH single domain antibody22.  
Our CD studies support also the efficient formation of the Zag and HSA complex. Spectra 
of isolated HSA and Zag in buffer solution are typical of α-helical proteins (Fig. 4). The 
addition of increasing concentrations of Zag protein to a 4 µM HSA solution show that the 
formed complex maintains the helical structure. Moreover, the increase of the negative bands 
signal while increasing Zag concentration indicates higher helical content in the complex 
structure (Fig. 4C). 
The NMR assignments are according with the CD measurements and revealed that Zag 
ABD exhibit a three-alpha-helix conformation (Fig. 6). These results are similar with the 
structure of the ABDs from proteins G and PAB, previously determined by NMR 
spectroscopy to be left-handed three-helix bundles6,7. The ABD from protein G human 
albumin binding site involves residues mainly in the second α-helix16. The crystal structure of 
HSA in complex with the GA module of protein PAB with a resolution 2.7 Å reveals a novel 
binding epitope located in domain II of the albumin molecule, in residues close to a cleft 
bounded by helices 2 and 3 in domain IIA, helices 7 and 8 in domain IIB, and the loop region 
before helix 7 in IB. In the GA module, residues from the second helix and the two loops 
surrounding it are involved in HSA binding42. Additionally, the presence of fatty acids 
bounded to HSA seems to influence HSA-GA complex formation, proposing that the PAB 
GA module is capable of binding to different conformations of HSA43,44. 
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However, it will be necessary more structural data, using NMR or X-ray crystallography to 
determine the binding sites of Zag ABD in human serum albumin and to analyze the 
interactions of Zag/albumin.  
The high degree of similarity between these ABDs with respect to sequence, structure and 
stability, and the observed differences in dynamics, binding affinity and binding specificity to 
different albumins suggest the emergence of an evolutionary pattern. Bacterial strains with 
GA modules and thereby HSA-binding activity are more virulent and protein PAB-expressing 
strains of P. magnus are resistant to the antibiotic tetracycline, suggesting that the transfer of 
these GA modules is probably the result of a selective pressure driven by broad spectrum 
antibiotics43. Previous studies also propose that plasma protein binding may contribute for the 
pathogenesis and virulence of these microorganisms, and the binding adds selective 
advantages to the bacteria by promoting their growth19. 
Our biodistribution results of an anti-TNFα VHH in fusion with Zag ABD to extend the 
circulation time and improve the pharmacokinetic properties of the single-domain antibody, 
show that the novel antibody molecule presents specific binding to serum albumin, compared 
with the parental antibody. Likewise, the fusion with this ABD can improve the in vivo 
performance of the nanobody, decreasing the blood clearance, renal retention and excretion. 
These findings demonstrate that the Zag fusion can be considered as a promising approach to 
improve the pharmacokinetics of therapeutic proteins. Characterization of binding properties 
and structural information of Zag ABD also reveal high similarities with other bacterial ABDs 
used as protein scaffolds in pharmaceutical industry currently, showing the potential of this 
domain to be further developed as a protein scaffold for therapeutic applications. 
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FIGURE LEGENDS 
Fig. 1: Construction and expression of Zag ABD. (A) Sequence of Zag albumin-binding 
domain (B) SDS-PAGE of the samples collected during IMAC purification, (C) SDS-PAGE 
and (D) Western Blot analysis of the Zag purified protein (3 µg/lane) under non-reducing 
conditions. Gel was stained with Coomassie brilliant blue (B and C) or immunobloted with an 
anti-His-tag antibody (D). 
Fig. 2: Binding of Zag to human, rat and mouse albumin at pH 6.0 and 7.4. Binding of 
Zag ABD to serum albumin was evaluated in ELISA at neutral pH -  pH 7.4 (A); and acidic 
pH - pH 6.0 (B). Bound proteins were detected using an HRP-conjugated anti-His-tag 
antibody. 
Fig. 3: Size exclusion chromatography for Zag/albumin complexes analysis. Zag (A), 
HSA (B), Zag + HSA (C), MSA (D) and Zag + MSA (E). Zag ABD was incubated at 
equimolar concentrations with albumin in PBS1x at room temperature. Peak positions of 
marker proteins are indicated. 
Fig. 4: CD studies of Zag and Zag/HSA binding. Far UV-CD spectra of HSA (A), Zag 
ABD in the absence (B) and presence of HSA (C). HSA was kept at 4 µM (A). Zag protein 
was measured at 20 µM (B) and added to a HSA solution at 1:0.25, 1:0.5, 1:0.75 and 1:1 
ratios (C, black arrow). 
Fig. 5: 1H-15N HSQC spectrum of Zag ABD. 1H-15N HSQC spectrum at 600 MHz of Zag in 
10 mM Tris-HCl, 100 mM NaCl, 10% D2O, pH 7.5 at 25 C. The spectrum showed a good 
chemical shift dispersion for both nuclei (1H and 15N) as occurs in a folded protein. 
Fig. 6: Three-dimensional structure of Zag ABD determined by NMR.  
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TABLES 
Table 1: NMR experiments for Zag assignment. 
 Complex points  Spectral width (Hz) Scans 
 1H 13C 15N  1H 13C 15N 
Backbone assignment         
CBCA(CO)NH 
HNCACB 
HNCO 
2048 
2048 
2048 
40 
40 
40 
128 
128 
128 
 7591 
7591 
7591 
1905 
1905 
1905 
11318 
11320 
3333 
16 
16 
16 
         
Side-chain assignment         
CC(CO)NH 
15N-TOCSY-HSQC 
HCCH-COSY 
2048 
2048 
2048 
40 
42 
64 
128 
296 a 
144 a 
 9615 
6356 
4242 
1905 
1905 
6667 
11318 
6403 a 
4269 a 
16 
8 
16 
         
NOE measurement         
1H-1H-15N-NOESY-HSQC 
1H-1H-13C-NOESY-HSQC 
2048 
2048 
40 
64 
256 a 
256 a 
 7591 
7813 
1905 
11318 
7591 a 
7802 a 
16 
8 
 
a The dimension should be read as 1H 
Table 2: Thermal stability of Zag ABD. 
Protein 
Tm B - Mean 
(°C) 
Tm B – Median 
(°C) 
Tm D - Mean 
(°C) 
Tm D - Median 
(°C) 
Zag 73.79 ± 3.15 75.39 ± 3.15 66.68 ± 6.64 68.97 ± 6.64 
Tm B - Calculated Boltzamnn melting temperature; Tm D - Calculated Derivated melting temperature. 
 
Table 3: Binding of Zag to HSA, RSA and MSA. 
Protein EC50 for HSA (nM) EC50 for RSA (nM) EC50 for MSA (nM) 
Zag pH 6.0 0.12 ± 0.11 0.11 ± 0.06 0.21 ± 0.09 
Zag pH 7.4 0.36 ± 0.11 1.26 ± 0.06 0.13 ± 0.06 
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Table 4: Zag ABD and Zag/albumin complexes molecular mass and hydrodynamic 
volume. 
Protein or 
complex Length 
Calculated 
Mra 
SEC apparent Mr 
Stokes’ 
radius (RS) 
 aa kDa kDa nm 
Zag 67 7.7 10.3 1.62 
HSA 585 66.5 68.1 3.67 
MSA 584 65.9 64.3 3.60 
Zag/HSA - 74.2 82.4 3.78 
Zag/MSA - 73.6 89.0 3.87 
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Figure 2 
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ALBUMIN-BINDING	CHARACTERIZATION	
AND	IN	SILICO	STRUCTURE	PREDICTION	OF	
PROTEIN	H	ABD	FROM	STREPTOCOCCUS	
PYOGENES 
 
 
 
Brief Introduction 
Streptococcal albumin-binding domains have been broadly investigated as fusion proteins 
to improve the pharmacokinetic properties of therapeutic proteins and as protein scaffolds for 
therapeutic applications (Kontermann, 2012). 
Protein H is a cell-surface protein from S. pyogenes, with an Ig-binding region located in 
the N-terminus and an ABD in the C-terminus, composed by three C repeats with a high 
amino acid sequence homology between them (Frick et al., 1995).  
In this research work we characterize the protein H ABD (ProtH) ability to bind albumin 
and predicted in silico the three-dimensional structure of this module. Firstly, we optimize the 
production of the ProtH ABD (C1C2C3) and C repeats (C1, C2, C3, C1C2 and C2C3) in 
E.coli, an easy way to obtain high amounts of protein with lower costs. Then we characterize 
the albumin binding and stability of the ProtH ABD and C repeats. Finally, we investigated 
the conformation of ProtH ABD (C1C2C3) in the presence and absence of human serum 
albumin and predicted in silico the three-dimensional structure of ProtH motif. 
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Background: Albumin-binding domains (ABD) have become extremely important as therapeutic 
scaffolds and as a promising strategy to extend the half-life of therapeutic proteins. Streptococcal 
ProtH albumin-binding domain (ABD) is a part of protein H cell surface protein. 
Results: Streptococcal protein H ABD was stably produced in bacteria, presenting high binding 
activity to serum albumin (mouse, rat and human) and shown to have a predicted alpha-helix three 
dimensional conformation. 
Conclusions: The protein H ABD domain has albumin-binding properties similar to other 
streptococcal ABDs, e.g. protein G ABD3 and can be useful as a therapeutic scaffold and as half-life 
extension approach. 
Significance: This study establishes the ProtH ABD as a possible scaffold that can be further 
engineered for several therapeutic applications, such as the improvement of the pharmacokinetics of 
therapeutic proteins. 
 
ABSTRACT 
Protein H, a cell surface protein from Streptococcus pyogenes, presents a multiple domain 
structure comprising an albumin-binding domain (ABD) composed by three C repeats 
(C1C2C3), an immunoglobulin G (IgG)-binding region and a α2-macroglobulin binding site. 
In this study, we characterize the albumin binding properties of ProtH ABD and their C 
repeats domains and also predict the three-dimensional conformation of this molecule by an in 
silico approach. Firstly, ProtH ABD (C1C2C3) and C repeats constructs were stably produced 
in bacteria and thermal stability was determined, showing a high thermal stability for ProtH 
ABD (58 to 63 ºC) and all constructs, specially observed for the C1 repeat (74 ºC). To 
characterize the albumin binding of ProtH ABD and C repeats, ELISA assays and size 
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exclusion chromatography (SEC) were performed. The ProtH ABD (C1C2C3) exhibit a high 
binding to human, rat and mouse serum albumin and, from all constructs, C1 repeat presented 
the highest binding to human albumin. Furthermore, ProtH/albumin complexes were isolated 
by SEC, confirming the albumin-binding of the ABD also seen by ELISA, and the presence of 
monomers of ProtH ABD alone and for the complexes ProtH/human serum albumin (HSA) 
and ProtH/mouse serum albumin (MSA). Furthermore, Far-UV circular dichroism analysis of 
the ProtH secondary structure indicates a high helical content and shows that when bound to 
HSA, the formed complex is also α-helical structured. Finally, structure prediction in silico 
also suggests that ProtH ABD has an α-helical three dimensional structure.  These findings 
demonstrate the great potential of ProtH ABD as an application for half-life improvement of 
therapeutic proteins and peptides, and as a protein scaffold for therapeutic uses.  
   
INTRODUCTION 
Protein H, is a multidomain protein present on the cell surface of some strains of 
Streptococcus pyogenes1. This protein is found in clinical isolates of the M1 serotype2 and has 
affinity for the constant (IgGFc) region of immunoglobulin (Ig) G and serum albumin1.  The 
role for protein H and other immunoglobulin-binding proteins in S. pyogenes pathogenicity 
and virulence is unclear. The protein H, like protein G3, presents different binding sites for 
albumin and immunoglobulin G (IgG). Protein H albumin-binding domain (ProtH ABD) is 
closer to the bacterial cell wall and was mapped to three repeats (C1-C3) in the C-terminal 
half of protein H1, whereas IgG-binding domain is located towards the N-terminal. No 
homology was detected when the IgGFc-binding repeats were compared with the same 
regions of protein G, but the albumin-binding regions of protein G and H were shown to have 
evolved convergently4. In protein G, albumin-binding is in the N-terminal half and IgGFc 
binding in the C-terminus of the molecule4. Competitive binding experiments demonstrated 
that protein G and H bound to the same or closely located sites in albumin, which has 
previously been mapped for protein G to disulfide loops 6-85. 
In the last 20 years, a broad class of bacterial albumin-binding domains have been 
investigated and described6,7. A previous study from de Château and Björck showed, for the 
first time, that peptostreptococcal protein PAB from Finegoldia magna, it is a mosaic 
albumin-binding bacterial protein, representing an example of a shuffled bacterial module8. 
Several structural studies with bacterial albumin-binding domains showed similar structural 
organization in these molecules, identifying a three-helix-bundle structure in protein G-related 
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albumin-binding (GA)9-11 modules and immunoglobulin-binding domains (IgBD)12,13. The 
structures of GA modules from proteins PAB7,8 and G9 show a three-alpha-helix architecture, 
and recent studies used these molecules based-structure to develop new scaffolds for 
therapeutic applications in several diseases, e.g. cancer and inflammatory diseases14-16. For 
instance, affibody molecules are robust 3-helix protein scaffolds based on a modified B-
domain of staphylococcal protein A, and represent a successful example of the therapeutic, 
diagnosis, and biotechnological applications of protein scaffolds derived from bacterial 
domains with affinity for plasma proteins17,18. Another successful application of these ABDs 
is the fusion with therapeutic proteins or peptides to improve the pharmacokinetic properties 
of these molecules. The bacterial ABDs properties have been extensively studied for this 
purpose, with promising results in the circulation time extension of short half-life molecules19-
23. Within this context, ABD scaffolds have demonstrated particular promise in the 
therapeutic and diagnostic area and have been the subject of considerable interest by 
Academia and Industry. Therefore, in the present study, we characterize the albumin-binding 
properties of the bacterial ProtH ABD derived from Streptococcus pyogenes cell surface 
protein H and investigate the secondary structure and the predicted three dimensional 
structure of this ABD. 
 
EXPERIMENTAL PROCEDURES 
Materials – Human serum Albumin (HSA) (catalog no. A3782), rat serum albumin (RSA) 
(catalog no. A6272) and mouse serum albumin (MSA) (catalog no. A3139). Antibody HRP-
conjugated anti-HA-tag, 2,2'-Azino-di-[3-ethylbenzthiazoline sulfonate (6)] diammonium salt 
(ABTS) and cOmplete EDTA-free protease inhibitors cocktail were acquired from Roche 
(Germany).  
Cloning of ProtH and ProtH domains –All constructs were cloned in pT7-PL-VHH-
HISHA, previous constructed by Morais and colleagues19. The DNA encoding the ProtH 
(C1C2C3) albumin-binding domain of Streptococcus pyogenes was generated by PCR. For 
amplification we used the primers H-SfiI-F (5’-GGG CCC AGG CGG CCA AGC AAA TCT 
CGG AAG CAA GCC G- 3’) and H-SfiI-R (5’-CCT GGC CGG CCT GGC CTT CTT TCA 
GCG CCT TGG CCT CC-3’), by means of a plasmid synthesized by DNA 2.0 (pJ201:27789 
– H peptide_opt) with the DNA sequence of the ProtH ABD as a template, adding SfiI 
restriction sites at the fragment 5’ and 3’ ends, respectively. The resulting PCR fragments 
were gel-purified, digested with the restriction enzymes and cloned into the appropriately cut 
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pT7-PL-VHH-HisHA vector. A short GS linker (SGGGGS) was used to link the ProtH ABD 
to the His and HA tags. For the construction of ProtH domains C1, C2, C3, C1C2 and C2C3, 
the procedure was repeated using the following primers for amplification: H-SfiI-F; H-SfiI-R 
5’-CCT GGC CGG CCT GGC CCT CTT TCA ACT TCT GGT GCT CGG-3’; HC2-SfiI-F 
5’-GGG CCC AGG CGG CCG ACA AGC AGA TTA GCG ACG CG-3’; HC2-SfiI-R 5’-
CCT GGC CGG CCT GGC CTT CTT TCA GCT TCT GAT GTT CCG C-3’; HC3-SfiI-F 5’-
GGG CCC AGG CGG CCG ATA AGC AAA TCT CCG ACG CCA-3’ and H-SfiI-R. All 
constructs were verified by sequencing. 
Expression and purification of ProtH – The ProtH ABD was expressed in Escherichia coli 
strain BL21(DE3). One liter of LB, containing 100 µg/ml ampicillin was inoculated with 10 
ml of overnight culture of bacterial cells transformed with all the constructs and grown to 
exponential phase (A600 = 0.6-0.9) at 37 ºC. Expression was induced by the addition of 1 mM 
isopropyl β-ᴅ-1-thiogalactopyranoside (IPTG) and growth during 16 h at 18 ºC. Cells were 
harvested by centrifugation (4000  g for 15 min at 4 ºC) and resuspended in 50 ml 
equilibration buffer (50 mM HEPES, 1 M NaCl, 5 mM CaCl2, 30 mM imidazole, pH 7.5) 
supplemented with protease inhibitors. Cells were lysed by sonication. Centrifugation (9000 
rpm for 30 min at 4 ºC) was used to remove cell debris, and the supernatant was filtered 
through a 0.2 µm syringe filter. Each protein was purified using AKTA FPLC System (GE 
Healthcare) by nickel chelate affinity chromatography with HisTrap HP columns (GE 
Healthcare). After a washing step (50 mM HEPES, 1 M NaCl, 5 mM CaCl2, 60 mM 
imidazole, pH 7.5), all the constructs were eluted with a linear imidazole gradient from 60 to 
300 mM in 50 mM HEPES, 1 M NaCl, 5 mM CaCl2, pH 7.5. Protein fractions were pooled, 
then desalted and concentrated in 50 mM HEPES, 100 mM NaCl, 5 mM CaCl2, pH 7.5 using 
Amicon 3K (Millipore). The samples fractions were pooled and protein purity was analyzed 
by SDS-PAGE. Protein concentration was determined spectrophotometrically at 280 nm at 
Nanodrop ND-1000. 
Protein thermal stability - Melting temperature of the ProtH and ProtH C-repeats were 
determined using the Protein Thermal Shift Kit and 7500 Fast Real-Time PCR System 
(Applied Biosystems, USA) according manufacturer’s instructions. Protein samples (5 
µg/well) were tested in MicroAmpTM Fast Optical 96-well Reaction Plates and analyzed in 
triplicate using and diluted in 50 mM HEPES, 100 mM NaCl, 5 mM CaCl2, pH 7.5, and 
Protein Thermal ShiftTM Dye 1x. Collected data were analyzed with Protein Thermal Shift 
Software version 1.1. 
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ELISA – Albumin-binding of ProtH ABD was evaluated in 96-well coated with HSA, 
RSA, MSA (10 µg/well) overnight at 4 ºC. After 1 h blocking with 5% soya milk in PBS1×, 
purified ProtH constructs and serum samples were titrated in triplicate and incubated in 
PBS1×-soya milk 1% for 1 h, at room temperature. Detection was performed with HRP-
conjugated anti-HA-tag antibody using ABTS substrate. Absorbance was measured at 405 nm 
in an ELISA reader. The blocker solution (PBS1×-soya milk 1%) was used as negative 
control. GraphPad Prism version 5 was utilized for data analysis. 
Size Exclusion Chromatography – Molecular weight of ProtH ABD and formation of 
ProtH/albumin complexes was determined by FPLCSEC on a HiLoad Superdex 200 HR 
column (GE Healthcare) with a flow rate of 0.7 ml/min and PBS as running buffer. The 
following standard proteins were used: apoferritin (443 kDa, RS 6.1 nm), β-amylase (200 kDa, 
RS 5.4 nm), alcohol dehydrogenase (150 kDa, RS 4.55 nm), bovine serum albumin (67 kDa, 
RS 3.55 nm), ovalbumin (45 kDa, RS 3.05), myoglobin (17.6 kDa, RS 1.91 nm), ribonuclease 
A (13.7 kDa, RS 1.64 nm) and cytochrome c (12.4 kDa, RS 1.77 nm). Blue dextran and L-
tyrosine were used to determine the void and total column volume, respectively. Elution 
volume of the protein standard was used to create a standard curve of Stokes’ radius (RS) 
versus (-log Kav)1/2 that was used to calculate the Stokes’ radii of  ProtH and ProtH/albumin 
complexes. Complex formation of ProtH ABD with HSA and MSA was analyzed by 
incubating equimolar amounts of the ABD and albumin (10 M) in PBS at room temperature 
and subsequent analysis by SEC. SDS-PAGE analysis of collected samples was performed to 
evaluate albumin binding. 
Circular dichroism measurements – CD spectra were obtained on a Jasco J-815 instrument 
(Jasco Co, Tokyo, Japan) using a 1 mm path length cuvette. Spectra were collected from 190 
to 260 nm at 37 ºC, with a scan speed of 50 nm/min. Samples were prepared in 50 mM Tris 
buffer with 100 mM NaCl, 5 mM CaCl2, pH 7.5. HSA, ProtH ABD C1 and ProtH ABD 
spectra were measured at 4 µM, 50 µM and 20 µM respectively. The CD signal of ProtH 
ABD protein was also recorded in the presence of albumin.  The protein was added to a HSA 
4 µM solution at the ratios 1:0.25 and 1:1. All spectra were further corrected by subtracting 
the contribution of the appropriate blank.    
Structure prediction of ProtH ABD – The three dimensional structure of ProtH ABD 
(UniProtKB/Swiss-Prot: P50470.1) was predicted in silico using the I-TASSER (as ”Zhang-
Server”) server from the University of Michigan (http://zhanglab.ccmb.med.umich.edu/I-
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TASSER/). I-TASSER server is an on-line platform for protein structure and function 
predictions. This server builds 3D models based on multiple-threading alignments by 
LOMETS (Local Meta-Threading-Server) and iterative template fragment assembly 
simulations. Function inslights are derived by matching the 3D models with BioLiP protein 
function database24. Protein Data Base format (pdb) files obtained with I-TASSER, were 
analyzed using USCF Chimera software version 1.9.  
 
RESULTS 
Expression and purification of ProtH ABD constructs  
ProtH ABD is composed by 112 amino acid (aa) (Fig. 1A) and  by three C-repeats 
denominated C1C2C3 with similar amino acid sequences1 (Fig. 1B). In order to characterize 
the albumin binding of ProtH ABD and determine the region responsible for human serum 
albumin binding, several constructions of C repeats (C1C2C3, C1C2, C2C3, C1, C2 and C3) 
were cloned into the pT7 vector with a leader peptide in N-terminus and histidine (His7) and 
HA tags in C-terminus (Fig. 1C).  
The proteins were expressed in E. coli BL21(DE3), purified by IMAC and SDS-PAGE 
analysis of the purified proteins showed a single protein band for all the constructs under 
reducing conditions (Fig 1D). The observed expression yield per liter of shake-flask culture 
without optimization was relatively high for all constructs (10-15 mg). Similar quantities of 
purified protein were observed for C1, C2 or C3 domains (10-12 mg per liter) and C1C2, 
C2C3 and C1C2C3 constructs presented the higher protein yields after purification (~15mg 
per liter). 
ProtH ABD thermal stability 
Melting temperatures of ProtH ABD and ProtH ABD C repeats was determined using a 
Real-Time PCR System and the Protein Thermal Shift software version 1.1. The Protein 
Thermal Shift software calculates the melting temperatures (Tm) from each fluorescence 
profile (Boltzmann method) and also the Tm of the dFluorescence (derivative method). The 
derivative Tm values are taken from the top of the peak in the derivative plot, while the 
Boltzmann Tm values are taken from the inflection point of the fluorescence plot. The results 
obtained (Table 1) indicate that ProtH ABD has a high thermal stability in the range of 58 to 
63 ºC. From C repeats, C1 possess the highest stability with a melting temperature of 74 ºC, 
comparing with C2, C3 and other combinations of these domains. 
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Binding of ProtH ABD to albumin 
In order to evaluate the albumin-binding activity of ProtH ABD, ELISA assays were 
performed at neutral pH and acidic pH. These conditions were tested to reproduce the same 
pH conditions existing inside endosomes, during the recycling mechanism of albumin 
mediated by neonatal Fc receptor (FcRn), responsible for the long half-life of albumin23,25. 
The human, rat and mouse serum albumin binding of ProtH ABD was similar in both pH 
conditions (Fig. 2A and 2B). Binding of ProtH ABD to albumin at pH 6.0 presented EC50 
values for HSA, RSA and MSA of 3.28 nM, 10.77 nM and 3.15 nM, respectively. At pH 7.4, 
EC50 for HSA and RSA were similar (EC50 = 9.77 nM and 10.92 nM, respectively), but EC50 
for MSA was a slightly lower (0.13 nM). Since the ProtH ABD presents three C repeats 
responsible for albumin binding, all the C repeats alone or in combinations were tested to 
characterize the albumin-binding. As shown is Figure 3, the highest binding is observed for 
the ProtH ABD (C1C2C3), nevertheless both the C1C2 construct and the C1 repeat also 
presented  also a high binding similar  to the values shown by the C1C2C3 full domain. In 
contrast, the other C repeats combinations or alone presented a much lower binding to human 
albumin (Fig. 3).  
To characterize the ProtH ABD:albumin interactions in more detail, SEC studies were also 
performed. As shown in Fig 4 and Table 2, SEC analysis also shows the interaction between 
ProtH ABD and human and mouse serum albumin in solution. ProtH ABD and albumins were 
incubated at 1:1, molar (corresponding to ~1:4, (w/w) ProtH:HSA) in PBS at room 
temperature. ProtH ABD eluted essentially as a monomer with an apparent molecular mass of 
12.3 kDa (RS 1.6 nm). HSA major peak (monomer) with an apparent molecular mass of 68.1 
kDa (RS 3.67 nm) and MSA monomer with an apparent mass of 64.3 kDa (RS 3.60 nm) were 
shifted after incubation with ProtH ABD to 83.2 kDa (RS 3.79 nm) and 89.2 kDa (RS 3.88 
nm), respectively.  
CD analysis 
Circular dichroism (CD) spectroscopy allowed the study of HSA, ProtH ABD and ProtH 
C1 structure and possible conformational changes after ProtH-HSA binding. HSA spectrum in 
buffer solution shows two negative bands near 208 and 222 nm and a positive band near 195 
nm, typical of α-helical conformation (Fig. 5A)26. ProtH C1 and ProtH ABD spectra are also 
typical of the helical conformation revealing both negative bands at ~208 and 222 nm (Fig. 
5B and C). The addition of ProtH ABD to a HSA protein solution revealed that the formed 
complex maintains the helical structure (Fig. 5D). 
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ProtH in silico predicted three-dimensional structures  
The amino acid sequence of ProtH H ABD was submitted to the I-TASSER server for 3D 
protein structure prediction. The in silico prediction of the three dimensional structure using 
the I-TASSER server from the University of Michigan resulted in a 3D model with an alpha-
helix conformation, represented by two pdb format pictures analyzed with Chimera software 
(Fig. 6A and B).  
 
DISCUSSION 
Streptococcal ABDs have been extensively studied and have become extremely important 
as therapeutic scaffolds and as promising approaches to extend the half-life of therapeutic 
proteins. In this study, we characterize the albumin-binding properties of ProtH ABD from 
protein H cell surface protein of Streptococcus pyogenes and evaluate the in silico prediction 
of ProtH domain conformation. Our data showed that ProtH ABD and ProtH ABD C repeats 
were stably expressed in E. coli, with high soluble yields of purified protein of several 
milligrams (10-15 mg) per liter of culture. Moreover, all the constructs exhibit high thermal 
stability, presenting melting temperatures of 58 to 63 ºC for the ProtH ABD (C1C2C3). From 
all C repeats constructs, C1 showed the highest stability with a melting temperature of 74 ºC, 
comparing with the lower melting temperatures of C2, C3 and the other combinations of these 
domains (Table 1).  
Our results of ProtH ABD binding to serum albumin were in the range of nanomolar, 
according with previous studies from other groups1,20-22. Thus, binding of ProtH to HSA, RSA 
and MSA at pH 6.0 present EC50 values of 3.28 nM, 10.77 nM and 3.15 nM, respectively. At 
neutral pH 7.4 EC50 values were similar HSA and RSA (EC50 = 9.77 nM and 10.92 nM, 
respectively), but slightly lower for MSA (0.13 nM) of the value obtained at pH 6.0. Frick and 
colleagues investigated the separate binding sites of protein H for IgG and albumin, and 
discovered that protein H binds serum albumin and IgG in different binding domains. The 
affinity constant for the reaction between albumin and protein H, calculated by Scatchard plot 
was 7.8 x 109 M-1, which was higher than the affinity for IgG (Ka = 1.6 x 109 M-1)1. Quite a 
few studies that evaluated the binding capacities between different bacterial ABDs are 
according to our data, showing results usually with affinities in the range of nanomolar 1,28,29. 
Furthermore, we determine the albumin binding ability of each unit of the C repeats (C1, C2 
and C3) and combinations of C repeats C1C2 and C2C3. Our results demonstrate that ProtH 
ABD containing the three C repeats (C1C2C3) has the highest binding to human albumin. 
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Moreover and importantly, these findings reveal that C1 repeat seems to perform a key role in 
the albumin binding of the ProtH ABD, showing a higher binding to albumin, similar to the 
values observed to the C1C2C3 and C1C2 domains. These cell wall-associated bacterial 
proteins usually contain tandemly repeated sequences, some with a single type of repeated 
motif, others with several distinct types of domains29. Hence, the C repeat units from the ABD 
of protein H have the same organization (C1C2C3) observed in the ABD from protein G1. 
The SEC results (Fig. 4) of ProtH ABD binding to human and mouse albumin also support 
the efficient binding of this ABD to serum albumin, showing the formation of complexes of 
ProtH/albumin with the increase in the of the Stokes radius.  
The CD experiments performed in our studies show that both ProtH C1 and ProtH ABD 
have an α-helical structure in buffer solution (Fig. 5B and C). The addition of ProtH ABD to a 
HSA solution in a 1:1 ratio reveals that the formed complex maintains the initial secondary 
structure while the increase in the negative bands signal reveal a higher helical content (Fig. 
5D), supporting efficient complex formation. A previous study presented similar results in the 
secondary structure analysis of protein H, using CD spectroscopy, and discovered that protein 
H is a predominantly α-helical protein at 4 ºC, with a α-helical content estimated to be 74%. 
In the presence of equimolar concentrations of albumin, the low-temperature conformation of 
protein H was stabilized, without affecting the α-helical conformation30. 
The ProtH ABD three dimensional in silico prediction is according with the CD 
experiments results, showing a possible α-helical structure conformation (Fig. 6). The server 
information also identifies ProtH ABD structural similarities in crystal structures of other 
bacterial proteins with anti-parallel coil-coil hairpin and helical-bundle conformations. 
Nilsson and co-workers analyzed the secondary structure of protein H and their results 
indicated that the extracellular part (sS, A, B and C regions) and part of the D region 
comprising amino acids 1-296 is predominantly (64%) α-helical. When the distribution of 
amino acids in the A, B and C domains of protein H and M1 protein, another M protein with 
C1C2C3 repeats, are analyzed, similarities with M proteins are evident and a high sequence 
similarity in both C repeats was observed. The analysis of M1 protein, reveals similar 
secondary structure profile, with the extracellular part of the molecule (amino-acids 1-404) 
consisting of 76% helical structure. The sequence of protein H was analyzed by a statistical 
method, showing a high probability for α-helical coiled-coil structure for almost the entire 
extracellular part (amino acids 49-302, including C repeats in amino acids 159-284). 
Furthermore, the evaluation of physicochemical properties of protein H determined that at a 
lower temperature (20 ºC) protein H is in a predominantly dimeric state, whereas at a higher 
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temperature (37 ºC) the molecule is found in a monomeric state. In both cases, the frictional 
ratio is indicative of a highly elongated structure. Interestingly, the frictional ratio 
representing the dimeric form is higher than the monomeric form, suggesting that the dimeric 
coil-coil state, observed at lower temperatures, is more elongated than the monomeric form 
and, at high temperatures conformation is considered to adopt a flexible conformation. Thus, 
at a physiological temperature protein H is considered to adopt a flexible conformation30.   
According with these findings and the 3D model structure predicted for ProtH ABD it will 
be expected that this ABD will adopt a flexible α-helical conformation. However, to evaluate 
this hypothesis it will be necessary more structural data, using NMR or X-ray crystallography 
to reach a three dimensional structure of ProtH ABD and to analyze the interactions of ProtH-
albumin.  
In summary, our albumin-binding studies and SEC results, confirm the formation of 
ProtH/albumin complexes in vitro and support the fact that surface protein H fusion with 
small therapeutic proteins can be an interesting strategy to improve the extension of the 
circulation time of these molecules, triggered by the FcRn-mediated recycling mechanism. 
Indeed, a comparative analysis of the half-life of an anti-TNFα nanobody in fusion with ProtH 
was currently performed in our laboratory, showing promising results of this ABD as a 
strategy for half-life extension of small-sized therapeutics. Moreover, the present study 
demonstrates that the C1 repeat alone presents a high binding to albumin, similar to full ProtH 
ABD, and this domain is also very stable. The advantage of a small size protein with the same 
features of albumin binding, that due to the small size, will be more stable and less 
immunogenic, and easier to engineer will be a promising approach to improve the half-life of 
therapeutic proteins and as a protein scaffold, for therapeutic applications. Exploring the 
physicochemical properties of this molecule and the ProtH-albumin interactions can also 
improve the properties of this ABD for therapeutic purposes. 
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FIGURE LEGENDS 
Fig. 1: Construction and production of ProtH ABD and C repeats. (A) Sequence of ProtH 
albumin-binding domain. (B) Sequence alignment of ProtH ABD C1, C2 and C3 repeats. (C) 
Schematic representation of the different ProtH ABD constructs under investigation in this 
study. Each ABD domain has an N-terminal leader peptide (LP) a C-terminal histidine (His7) 
and human influenza hemagglutinin protein tags (HA). (D) SDS-PAGE analysis of the ProtH 
ABD and ProtH ABD domains purified proteins (3 µg/lane) under reducing. Gel was stained 
with Coomassie brilliant blue.  
Fig. 2: Binding of ProtH ABD to human, rat and mouse albumin. Binding of ProtH ABD 
to serum albumin was evaluated in ELISA at neutral pH -  pH 7.4 (A); and acidic pH - pH 6.0 
(B). Bound proteins were detected using an HRP-conjugated anti-HA tag antibody. 
Fig. 3: Binding of ProtH domains to human serum albumin. Binding of ProtH ABD C1-
C3 repeats to HSA were evaluated by ELISA at 1000 nM and 100 nM concentrations. Control 
(-) PBS1x-soya milk 1%. Bound proteins were detected using an HRP-conjugated anti-HA 
tag antibody. 
Fig. 4: Size exclusion chromatography for ProtH/albumin complexes analysis. ProtH 
ABD (C1C2C3) (A), HSA (B), ProtH ABD + HSA (C), MSA (D) and ProtH ABD + MSA 
(E). ProtH ABD was incubated at equimolar concentrations with albumin in PBS at room 
temperature. Peak positions of marker proteins are indicated. 
Fig. 5: CD studies of ProtH and ProtH/HSA binding. Far UV-CD spectra of HSA (A), 
ProtH C1 and ProtH in the absence (C) and presence (D) of HSA.  HSA was kept at 4 µM (A) 
and ProtH C1 at 50 µM (B). ProtH protein was measured at 20 µM (C) and added to a HSA 
solution at 1:0.25, and 1:1 ratios (D, black curve, HSA; grey curve HSA:ProtH 1:0.25; grey 
dotted curve, HSA:ProtH 1:1). 
Fig. 6: In silico prediction of ProtH ABD (C1C2C3) structure. Three-dimensional 
structure models of ProtH ABD were predicted in silico prediction using the I-TASSER 
server. ProtH ABD predicted structure is represented  in two PDB pictures (A and B) with the 
C1 repeat represented in orange and red, C2 repeat represented in green and C3 repeat 
coloured in blue.  
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TABLES 
Table 1: Thermal stability of ProtH and ProtH C repeats. 
Protein Tm B - Mean ±SD (°C) 
Tm B – Median 
±SD (°C) 
Tm D - Mean 
±SD (°C) 
Tm D - Median 
±SD (°C) 
ProtH (C1C2C3) 58.28 ± 0.68 57.69 ± 0.68 62.91 ± 0.24 63.06 ± 0.24 
C1 74.00 ± 3.39 74.00 ± 3.39 74.09 ± 3.36 74.09 ± 3.36 
C2 58.58 ± 0.90 58.39 ± 0.90 57.10 ± 2.11 55.24 ± 2.11 
C3 58.87 ± 1.19 59.47 ± 1.19 58.86 ± 4.67 54.95 ± 4.67 
C1C2 54.89 ± 0.54 55.15 ± 0.54 55.05 ± 3.68 51.59 ± 3.68 
C2C3 59.57 ± 0.47 59.50 ± 0.47 45.64 ± 9.49 45.75 ± 9.49 
Tm B - Calculated Boltzamnn melting temperature; Tm D - Calculated Derivated melting temperature. 
 
Table 2: ProtH ABD/albumin complexes. 
Protein or 
complex Length 
Calculated 
Mra 
SEC apparent Mr 
Stokes’ 
radius (RS) 
 aa kDa kDa nm 
ProtH 148 16.7 12.3 1.6 
HSA 585 66.5 68.1 3.67 
MSA 584 65.9 64.3 3.60 
ProtH/HSA - 83.2 83.2 3.79 
ProtH/MSA - 82.6 89.2 3.88 
aCalculated based on the amino acid sequence. 
 
Table 3: Binding of ProtH to HSA, RSA and MSA. 
Protein EC50 for HSA (nM) EC50 for RSA (nM) EC50 for MSA (nM) 
ProtH pH 6.0 3.28 ± 0.03 10.77 ± 0.03 3.15 ± 0.02 
ProtH pH 7.4 9.77 ± 0.03 10.92 ± 0.02 0.13 ± 0.03 
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Figure 1  
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Figure 2 
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Figure 6  
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 CONCLUDING	REMARKS	AND	 
FUTURE	PERSPECTIVES	 
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The discovery and application of albumin-binding domains to improve the 
pharmacokinetics of small-sized therapeutics and as therapeutic protein scaffolds have 
demonstrated a great potential in biomedical research in the last years and opened new 
insights for biotechnological research, therapeutic and diagnosis applications.  The enormous 
potential of these proteins has been explored by several pharmaceutical and biotechnological 
companies, but there is still an urgent need in the art of new strategies to improve circulation 
half-life. New efforts need to be made to develop new small molecules or protein scaffolds 
that can be explored and engineering for therapeutic applications. Current strategies for half-
life extension of therapeutic proteins used by pharmaceutical industry are focused in 
PEGylation or in the chemical conjugation of other recombinant PEG mimetics. However, 
“PEGylation” technology has several drawbacks, e.g. clinical grade PEG derivates are 
expensive and their covalent coupling to a recombinant protein requires additional 
downstream process and purification steps, thus lowering yield and raising the costs. 
Moreover, PEG is not biodegradable, which can cause side effects such as vacuolation of 
kidney epithelium upon continuous treatment, and the chemical coupling step can lead to 
reduced binding and activity of the PEGylated protein (Gaberc-Porekar et al., 2008; Knop et 
al., 2010). Albumin-binding moieties are a good alternative to increase the circulation time of 
biodrugs. Current approaches using bacterial albumin-binding domains are based in the ABDs 
from proteins G and PAB, and the Ig-binding domain Z from staphylococcal protein A used 
as scaffold for the optimization of Affibody molecules. All these bacterial proteins have in 
common a three-α-helix structure and the natural binding to plasma proteins, which has been 
described to be involved in the escape of immune system surveillance, adding selective 
advantages to bacteria as a virulence factor.  This Thesis study was developed to explore the 
potential of two new streptococcal albumin-binding domains, the Zag ABD from S. 
zooepidemicus ZAG protein and the ProtH ABD from S. pyogenes protein H, as strategies to 
improve pharmacokinetic properties of therapeutic proteins. To validate our ABDs half-life 
strategy and as a proof-of-concept, the Zag and ProtH domains were fused with an anti-TNFα 
VHH single-domain antibody.  We aim to investigate the albumin-binding properties for half-
life extension or targeting, stability, and three-dimensional structures of these domains for 
future applications as fusion partners and protein scaffolds. Both albumin-binding proteins 
were described for the first time in the 90’s and there were not developed for therapeutic 
research. Therefore, this project represents a new challenge in protein-based drugs 
development and also provides an easy, fast, low cost, and reliable methodology to improve 
half-life of several therapeutic proteins, with special interest in the treatment of rheumatoid 
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arthritis and cancer, due to accumulation of albumin in tumours and arthritic joints. Moreover, 
with further investigation, these ABDs will be promising approaches for half-life extension of 
several therapeutic molecules and proteins, for the treatment of a wide number of diseases. 
All the Zag and ProtH constructions were successfully engineered and optimized for 
bacterial expression and IMAC purification with high yields of purified soluble protein, high 
degree of purity, without using several complicated and costly steps of purification. These 
protocols allow an inexpensive and easy protein production, using simple protein purification 
technology and, also allow a simple scale up process. After production, VHH-Zag and VHH-
ProtH fusion proteins showed a high thermal stability and a high affinity for human, rat and 
mouse in the range of nanomolar, which was described as well for other recombinant 
antibodies in fusion with ABD from protein G (Stork et al., 2007; Stork et al., 2009; Hopp et 
al., 2010). Binding to albumin was not reduced at low pH (pH 6.0), suggesting that the 
presence of ABD does not interfere with the pH-dependent binding of HSA to FcRn in vitro.  
The size exclusion chromatography results also confirm the HSA and MSA binding in 
solution, but with different stoichiometry for the Zag and ProtH fusion proteins. For instance, 
VHH-Zag presented a monomeric form alone and in complex with mouse and human 
albumins. However, VHH-ProtH alone in solution forms dimers and trimers, and the same 
stoichiometry is observed in complex with human albumin, but the VHH-ProtH/MSA 
complexes have an apparent monomeric form. One possible explanation for these results is 
that protein H could form temperature-dependent dimers with higher affinity for human 
albumin and IgG than the monomer (Åkerström et al., 1992; Frick et al., 1995). Nilson and 
colleagues findings showed that at lower temperature protein H is in a predominantly dimeric 
state, whereas at higher temperatures this protein is found in monomeric state (Nilsson et al., 
1995).  
ABDs have been successfully fused to a number of proteins, retaining the functional 
activity both of the albumin binding part and the fused part. VHH-ProtH and VHH-Zag fusion 
proteins maintained the TNFα binding (in the range of nanomolar) in the presence of albumin, 
and the blockade effect of the interaction of TNFα/TNFR from the therapeutic TNFα-
neutralizing VHH from Ablynx, for the treatment of rheumatoid arthritis. VHH, VHH-Zag 
and VHH-ProtH presented high serum stability, maintaining the antigen binding properties 
without suffer degradation in human serum during 24 days and in mouse serum until 4 days. 
Importantly, both Zag and ProtH substantially improved the circulation time of VHH in vivo, 
in approximately 39-fold for VHH-Zag (terminal half-life of 30.55 h) and in 26-fold for 
VHH-ProtH (terminal half-life of 20.54 h), respectively. As a half-life extension strategy, 
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fusion to Zag ABD resulted in a higher improvement of the circulation time of the VHH 
nanobody.  
In the past decades, the growth of nuclear medicine has been due mainly to the availability 
of technetium-99m (99mTc) radiopharmaceuticals. This isotope is a metastable nuclear isomer 
with a half-life of 6 h and is used in over 80% of all diagnostic procedures (Kratz and 
Elsadek, 2012). The organ biodistribution profiles of 99mTc-VHH-Zag and 99mTc-VHH-ProtH 
presented very different results in blood, kidneys and liver. The 99mTc-VHH-Zag exhibited a 
slow elimination from blood and an accumulation in irrigated organs such as liver. 99mTc-
VHH was rapidly cleared from the blood and presented a high accumulation in kidneys.  
Comparing with 99mTc-VHH-Zag, 99mTc-VHH-ProtH exhibited higher retention in kidneys 
and a reduced presence in blood, showing a distribution profile similar to 99mTc-VHH. 
However, the biodistribution profile of 99mTc-VHH-ProtH do not interfere with the long half-
life of the molecule, improved in 26-fold compared with the unmodified nanobody. 
Coppieters and collegues biodistribution studies with bispecific VHH against TNFα in 
fusion with a VHH targeting albumin (TR2-TR2-AR1), as a strategy for half-life 
improvement, showed similar results with a substantially extended half-life for the TR2-TR2-
AR1 of 2.2 days in BALB/c mice (versus 35 min and 54 min, for the monomeric and dimeric 
forms, respectively). The 99mTc-radiolabelled nanobodies, tested with a CIA preclinical 
model, also demonstrated an accumulation of radioactivity in the inflamed paws. The 
radioactivity was superior in the albumin targeting fusion proteins due to the accumulation of 
albumin in inflammation sites, with higher concentrations exhibited after 24 h after injection, 
and a higher uptake correlated with the higher clinical scores for the corresponding limbs 
(Coppieters et al., 2006).  
Furthermore, VHH and VHH-Zag recombinant antibodies biodistribution was evaluated in 
mice, using gallium 67 (67Ga)-citrate. 67Ga is a useful radiopharmaceutical for diagnostic in 
tumour detection, especially for patients with Hodgkin and non-Hodgkin lymphoma, lung 
cancer, malignant melanoma, breast carcinoma and Ewing’s sarcoma (Kratz and Elsadek, 
2012), and presents a decay half-life of 3.26 days. Since mouse serum presents a half-life of 
~1-2 days, we purposed to compare the biodistribution profile of the VHH and VHH-Zag 
proteins using a radionuclide with a decay half-life higher than MSA, with previous 
radiolabelling with 99mTc (decay half-life of approximately 6 h). Our results showed that the 
conjugation with p-SCN-Bn-NOTA and the radiolabelling with the radionuclide 67Ga (67GA-
NOTA) did not affect the albumin and TNFα binding. The profiles of biodistribution were 
similar with the study of biodistribution with 99mTc-VHH and 99mTc-VHH-Zag. Thus, 67Ga-
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NOTA-VHH-Zag uptake in blood and kidneys was superior, comparing with the 67Ga-
NOTA-VHH that also presented highest kidney retention and almost a total excretion at 24 h.  
The biodistribution profile of 67Ga-NOTA-VHH exhibited a rapid clearance from blood and 
most tissues. Instead, 67Ga-NOTA-VHH-Zag presented a slow washout from blood, muscle 
and bone, and an accumulation in highly irrigated organs such as liver, spleen and lung. 
This increased half-life most likely correlates with the half-life of serum albumin, which 
are 1.07-1.6 days for murine serum albumin and ~19 days for human serum albumin 
(Andersson et al., 1991; Peters, 1996; Stevens et al., 1992; Schmidt et al., 2013). 
Even though Zag and ProtH ABDs have shown substantial improvements in 
pharmacokinetic properties of the nanobody, concerns with the immunogenicity of these 
molecules for therapeutic applications may occur due to their bacterial origins. For instance, 
immunogenicity of the albumin-binding domain of protein G, in the amino acid sequence 
254-299, was detected in mice strains (Sjölander  et al., 1997). For therapeutic purposes, 
particularly in small proteins that require administration by repeated injections, it will be 
necessary reduce or ideally eliminate the immunogenicity. There are several de-immunization 
strategies that can be applied in future, to reduce the immunogenicity of these molecules (de 
Groot et al., 2005; Baker and Jones, 2007; Nagata and Pastan, 2009). Currently, we have 
already de-immunization studies ongoing for the Zag ABD. We have already identified and 
removed potential immunogenic epitopes by an in silico approach.  After de-immunization, 
the Zag ABD maintained the albumin-binding ability and half-life extension properties when 
fused with therapeutic proteins.  
In a future perspective it will be necessary to identify the immunogenic amino acids or 
regions in the sequence of the ProtH ABD and engineer the protein to eliminate the 
immunogenic epitopes.   
The Zag and ProtH ABDs fusion to the VHH, showed promising results for the 
improvement of pharmacokinetic properties of the therapeutic molecules without affecting the 
efficacy of the biodrug against the therapeutic target. After these findings, we proposed to 
characterize the albumin-binding properties of these ABDs and also study the structural 
conformations of both domains, in order to investigate their three-dimensional structures and 
understand the dynamic between ABD/albumin.  
Our data demonstrated that both unfused ABDs can be stably produced in E. coli and have 
albumin-binding in nanomolar range, according what is described in other studies (Frick et 
al., 1995, Linhult et al., 2002; Hopp et al., 2010; Kontermann, 2011, Kontermann, 2012). 
Though, Zag ABD is a G-related protein or GA module, with an amino acid sequence very 
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different from the ProtH ABD sequence. The Zag ABD is composed by 52 amino acids in one 
domain, and ProtH ABD exhibit a three C repeat organization (C1C2C3) with high homology 
between the three units. Like the GA modules, the C repeats comprise about 40 amino acid 
residues, but these HSA-binding units show no sequence homology with GA motifs (Frick et 
al., 1995). With a view to determine the albumin-binding of these units, several constructs 
were stably produced in bacteria, showing that the C1 repeat alone exhibit a high similar 
binding to the observed for the three repeats together (C1C2C3). These observations prove 
that C1 domain is the major responsible for the albumin binding of ProtH.  
It is generally observed that proteins with high sequence identities have similar three-
dimensional structures. It therefore appears likely that various GA modules, e.g. in protein G, 
will be found to have similar three-dimensional structures, due to the high sequence identities 
(around 60%) (Johansson et al., 1995). According with these observations, the NMR 
assignment shows a three-alpha helix structure in the Zag ABD. The in silico prediction of 
three-dimensional structure of ProtH also exhibited a helical conformation. Another 
interesting finding, demonstrated by CD measurements it is that the conformation of both 
ABDs is maintained in the presence of human albumin. However, it will be necessary more 
structural data, using NMR or X-ray crystallography to reach a three-dimensional structure of 
ProtH ABD and to analyze the interactions of ProtH/albumin. Currently, X-ray 
crystallography studies of Zag/HSA complexes are being developed to determine the binding 
sites of Zag to albumin, and to evaluate in more detail the ABD/albumin interactions.  
With more structural data to identify the region of albumin binding in both Zag and ProtH, 
and the binding site in albumin as well, it will be possible engineering these domains to 
improve their affinity to the target and stability. It will interesting to investigate if a higher 
affinity of these domains will increase the circulation time of fused therapeutic molecules. 
To investigate the impact of very high affinity binding to albumin, an affinity matured 
variant of ABD has been developed by Jonsson and co-workers (Jonsson et al., 2008). ABD3 
was used as a starting point to construct a library of domain variants. Fifteen of the 46 amino 
acids in the protein were subject to constrained randomization and displayed on bacteriophage 
for selection. A first set of binders showed improved binding affinities with KD in the low 
picomolar affinity range. Sequence features of individual variants were combined to create a 
second generation set of seven binders. One of the resulting binders, denoted ABD035, had 
relatively high Tm, excellent thermal refolding properties and an increased affinity for 
albumin. Initial SPR experiments suggested a very high affinity for human serum albumin 
with KD between 50–500 fM (Jonsson et al., 2008). The affinity was later measured in 
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solution, and a KD of 120 fM was obtained. The affinity was improved also for albumin of 
other species including rat, mouse and cynomolgus monkeys. When used as fusion partner for 
scDb constructs, the affinity matured binder increased the affinity of the trispecific fusion 
protein for HSA with a factor of 80 and for MSA with a factor of 12 (Fredj, 2012). 
Even if we improve the affinity of these motifs for half-life extension, with our data it will 
not be possible to realize what happen in the albumin when the nanobody reaches the 
therapeutic target is plasma circulation. In order to answer this question, it will be also 
important to investigate the albumin allosteric modifications the Zag and ProtH fusion 
proteins induce when the therapeutic protein is bound to albumin and catch up the therapeutic 
target in circulation. In a future perspective, it will be interesting to perform structural studies 
with VHH-Zag and VHH-ProtH in the presence of albumin and TNFα, using NMR or X-ray 
crystallography to study the dynamic of these protein-protein interactions.   
Furthermore, the C1 repeat from ProtH ABD alone demonstrated a high binding to serum 
albumin, very similar with the binding of the full ABD. Due to C1 repeat smaller size (41 aa 
and 4.7 kDa) it will be more stable and less immunogenic, and easier to engineering as a 
fusion partner in order to improve pharmacokinetics of therapeutic proteins. In the future, it 
will be interesting to compare the C1 ability of binding to albumin, and pharmacokinetic 
parameters, including organ biodistribution, using the same anti-TNFα VHH as proof-of-
concept. 
Another interesting approach it will be to use both Zag and ProtH ABDs as protein 
scaffolds for therapeutic purposes. Therefore, it will be interesting engineering these domains 
against clinical relevant therapeutic targets or as one therapeutic molecule targeting an antigen 
or receptor and albumin, for circulation time extension. For example, Nilvebrant and 
colleagues created a single-domain bispecific affinity protein targeting TNFα and serum 
albumin (Nilvebrant et al., 2011). For this purpose they have chosen an alkali-stabilized form 
of an ABD from protein G (Alm et al., 2010) as a scaffold, and selected by phage-display, 
mutations on helix one and three, that are not involved in HSA interaction. This strategy 
proposes to combine the advantages of a small size protein (e.g. efficient production in a 
bacterial host or by chemical synthesis, and specificity to the therapeutic target) with an 
intrinsic extended half-life, that may reduce the blood clearance with an increase in the 
circulation time typical for antibodies (Nilvebrant et al., 2011; Nilvebrant and Hober, 2013). 
Due to the accumulation of albumin in arthritic joints and tumours, the natural albumin-
binding ability of these ABDs will be an advantage for engineering the molecules as protein 
scaffolds for the treatment of cancer and rheumatoid arthritis. Affibody biotechnology 
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company is developing scaffolds, named affibody technology (Feldwisch and Tolmachev, 
2012; Löfblom et al., 2010). These scaffolds have characteristics and structural organization 
very similar with the Zag ABD, showing successful results in diagnostics and therapeutics of 
several diseases. Other biotechnology companies like Molecular Partners AG, which makes 
use of the DARPin technology (Boersma and Plückthun, 2011; Gebauer and Skerra, 2009; 
Stumpp et al., 2008), also explore and engineering α-helical scaffolds for therapeutic purposes 
with great results. 
Several protein therapeutics such as antibodies, often suffer from low efficacy, costly 
development, and sometimes toxic side effects. This means that these molecules perform at 
only a fraction of their potential, and are therefore not fulfilling their promise. Protein 
scaffolds can be selected to bind to any given target molecule, with unmatched affinity and 
specificity. These characteristics make them ideal agonistic, antagonistic or inhibitory drug 
candidates. Furthermore, these proteins can be rapidly developed and engineered candidates 
to include further enhancement of pharmacokinetic properties and adaptation to carry various 
effector functions, or multiple binding specificities can be combined enabling completely new 
drug formats. These formats are also advantageous because can be manufactured in low cost 
and high yield bacterial fermentation, and are easily formulated. 
In conclusion, in this project it was possible to achieve our goals, showing that both Zag 
and ProtH ABDs are promising strategies to improve the pharmacokinetics of therapeutic 
proteins, and also that both domains can be further engineered as therapeutic scaffolds. 
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